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Abstract 
H pylori infection is one of the most prevalent infectious diseases worldwide which affects 
nearly 40%-50% of the world population. Eradication of Helicobacter pylori (H. pylori) 
remains a worthwhile goal to treat the associated diseases, especially the peptic ulcer, and 
to reduce the lifetime risk of the infection, mainly the gastric cancer. 
The first line therapy for Helicobacter pylori infection and induced peptic ulcer is a ‗triple 
therapy‘ consisting of two antibiotics (amoxicillin or metronidazole with clarithromycin) 
and a proton pump inhibitor (i.e. omeprazole, esomeprazole, lansoprazole, etc.). Treatment 
of H. pylori with the conventional dosage forms may fail, due to the short time within 
which the antibiotics reside within the main site of the bacteria colonization in the stomach, 
since they may be emptied rapidly during gastric emptying event. Disadvantages of current 
treatments also include poor patient compliance due to the requirement of multiple dosing 
and the high prevalence of side effects. 
Improvement in the treatment of gastric ulcer requires providing alternative delivery 
systems that ensure the prolongation of the local availability of the antibiotics with a 
sustained and high concentration within the stomach (the site of infection), thus increasing 
the efficacy of the treatment, decreasing dosing frequency; hence increasing the patient 
compliance and decreasing side effects.  New gastroretentive drug delivery systems for the 
treatment of H. pylori have received great interest from researchers worldwide, since these 
systems may provide the aforementioned advantages. 
In this research, a novel dosage form is designed for the first-line triple therapy treatment 
(clarithromycin (CLA), metronidazole (MTZ) and esomeprazole (EZO)) of H. pylori 
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associated peptic ulcers. The design of the delivery system was based on single, bilayer 
gastroretentive tablet approach, with floating, swelling and sustained release (SR) 
properties. One layer included esomeprazole, which is a rapidly disintegrating layer that 
contained enteric coated pellets. The other layer is a floating-sustained release matrix of 
metronidazole and clarithromycin. 
Formulations were developed using hydroxypropylmethylcellulose (HPMC) with different 
viscosity grades (K-4M, K-15M and K-100M) and ethyl cellulose (EC) as the major 
swellable matrix-forming and rate-controlling polymeric excipients, while sodium 
bicarbonate (NaHCO3) and citric acid were used as the gas generating agents. Different 
manufacturing techniques were applied including, direct compression, wet granulation and 
dry granulation in order to choose the most suitable one.  The choice of the best formula 
was based on the requirements of short floating time, long floating duration and sustained- 
synchronous release of the two antibiotics. In the optimized formula, metronidazole was 
incorporated inside granules within the SR- layer, while clarithromycin was distributed 
within the matrix of the SR-layer itself which also included the gas generating agents 
NaHCO3 and citric acid in ratios 4:1. Esomeprazole pellets were incorporated within the 
rapidly dissolving layer to be separated from the tablet within two minutes. Physical 
properties of the tablets, namely, hardness, friability, weight variation, content assay and 
powder properties all meet the qualifications of the USP. 
The drug content (assay) and the release over time of both clarithromycin and 
metronidazole were determined simultaneously on a gradient high-performance liquid 
chromatography (HPLC) method that was developed and validated in this research. The 
developed HPLC method for the concurrent determination of CLA and MTZ was proved to 
be linear, accurate, precise and selective. 
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Single tablet of two layers, combining the first line therapy for treatment of  H. pylori 
induced ulcer was formulated. DG2 fotmula exhibited excellent floating properties and a 
synchronous sustained release of both antibiotics. The swelling index of the tablets, and the 
kinetics of the release were also elucidated. They indicated that the release mechanism of 
both antibiotics was mainly controlled by diffusion,  polymer relaxation and erosion. 
This final optimized formula was manufactured by dry granulation technique and 
contained (23%) HPMC-K100M, (17%) EC, (12%) NaHCO3 and (3%) citric acid within 
the SR-floating layer. In this formula the two layers separated with less than 20 seconds, 
the SR-layer has floating lag time (FLT) less than 30 seconds , and total floating time 
(TFT) more than 24 h. The drug release after 20 h was 85% of MTZ and 76% of CLA.  
These results applied to our goals of producing a delivery system that stays in the stomach 
for a long period while releasing the two antibiotics which will exert a local effect on the 
bacteria. As a result, this proposed formula of bilayer-triple therapy delivery system could 
be very promising in providing a better treatment of  H. pylori  induced ulcer than the 
existing ones. 
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Part one 
1. Introduction 
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1.1. Helicobacter Pylori 
1.1.1. Overview and epidemiology of H .pylori: 
Helicobacter pylori (H .pylori) infection is one of the most common bacterial infections in 
the world, it affects nearly half of the world‘s population and, thus, is one of the most 
frequent and persistent bacterial infections worldwide(1). It is a chronic infection and once 
acquired it remains life long, unless it is eradicated by suitable antibiotic treatments (2). 
 Globally, different strains of H. pylori exist & are associated with differences in virulence, 
and the resulting interplay with host factors and environmental factors leads to differences 
in the expression of disease. Age, ethnicity, gender, geography and socioeconomic status, 
are all factors that influence the incidence and prevalence of H. pylori infection. The 
overall prevalence is high in developing countries and lower in developed countries(3). 
In developing countries, the prevalence of infection is as high as 90%, whereas in 
developed countries the prevalence is below 40% (4). In asymptomatic patients, the  
prevalence of H. pylori infection varies from 31%-84%(2). 
Several studies reported data on the worldwide prevalence of H. pylori infection; these data 
are summarized in Table 1.1. (5).  
Other studies reported data on the Middle East prevalence which has a high  rate 
prevalence of   H. pylori infection , with percentages varies from ˃80% in Egypt, 60-70% 
in Saudi Arabia and ˂ 50 % in Palesine (6). 
 H. pylori were firstly discovered by Warren and Marshall in 1982, after they isolated it 
from patients with peptic ulcer. Then they published a research paper in 1984 that has 
firmly established H. pylori as an important etiologic agent in many diseases related to 
stomach(7). 
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Table1.1. Prevalence of H. pylori infection in adults reported by studies published in 
2013.(5)
 
 
 H. pylori is a gram-negative bacilli, microaerophilic bacteria, resides mainly in the  gastric 
mucosa, associated to the mucus layer, living both within and beneath it, and adhering to 
the gastric epithelial cells , mainly at the antral region of the human stomach, it can also be 
found on the epithelial cells of the duodenum (8) (Figure 1.1). 
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The organism is catalase positive, oxidase positive and urease positive. As a result, urea is 
broken down into bicarbonate and ammonia, which protects the bacterium in the acid 
medium of stomach and causes gastric epithelial injury(9). 
                     
                    Figure1.1.  H. pylori location in the stomach(10) 
 
1.1.2. Proposed mechanisms of pathogenesis of H. pylori  (11) (12), (13). 
By direct contact of H. pylori with the gastric mucosa, elaboration of different enzymes 
and cytotoxins by H. pylori occur, this can directly cause gastric cells injury and, therefore 
is responsible for the most of gastric diseases associated with gastric cells damage, this 
process of pathogenesis can be mediated by (Figure 1.2) 
 Bacterial Adherence: This process is mediated by specialized adhesion molecules that 
allow H. pylori to maintain themselves within their habitat. This adhesion prevents 
bacteria from being removed by the host-defense mechanisms (e.g. peristalsis, ciliary 
activity, and turnover the mucous layer).  
 Ureases: H. pylori produces large amounts of urease enzyme (localized inside and 
outside of the bacterium).Urease breaks down urea (which is normally secreted into the 
stomach) to carbon dioxide and ammonia which is converted to ammonium by 
accepting a proton (H+), this will neutralizes surrounding media and enable the 
survival of H. pylori in the acidic stomach. The ammonia is toxic to the epithelial cells, 
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and beside other products of H. pylori including proteases and certain phospholipases, 
damages gastric cells. 
 Lipase and Protease: H. pylori proteases activity leads to disintegration of the 
polymeric structure of mucin, whereas elaborated lipases and phospholipase act on the 
lipids degradation in the mucous layer and the gastric epithelial cell membranes, so 
bacterial colonies damage the mucous linings and undermine the gastric mucosal 
cytoprotection. 
 Bacterial Virulence factors: the two most important virulence factors of H. pylori are 
Cytotoxin-associated gene A (cagA) and vacuolating cytotoxin gene A (vacA). 
cagA is related to peptic ulcer and gastric malignancy in certain populations ,vacA can 
induce host cell vacuolation and eventually cell death. 
 
Figure 1.2: H. pylori pathogenesis factors  
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1.1.3. Symptoms of H. pylori infection: 
 H. pylori infection generally is asymptomatic and most people with H. pylori don‘t have 
any symptoms. Although number of symptoms may be associated with H. pylori infection, 
including: Gnawing pain, Nausea, Vomiting, Loss of appetite, Bloating, Burping, Weight 
loss, Bleeding (14) (15). 
1.1.4.  Diagnosis of H. pylori infection (16),(17), (18): 
 Serological test: 1.1.4.1.
It is a blood test to find out antibodies against H pylori and especially against its most 
specific antigen CagA. If antibodies to H. pylori present in the blood, it means the patient 
either currently infected or has been infected in the past.  Its sensitivity is 92% but only a 
specificity of 83%. 
 Urea breath test (UBT):  1.1.4.2.
The C13 or C14 urea breath test (UBT) has been recognized as an excellent test because of 
its accuracy as well as of its robustness is easy to perform. 
Its sensitivity is 88- 95% and specificity 95%-100%. 
 Stool antigen test: 1.1.4.3.
 A stool antigen test is used to see if antigens that trigger the immune response & produced 
by H. pylori (CagA & VagA) are present in the feces (stool). This test is considered as a 
valuable noninvasive alternative to diagnose H. pylori when UBT is not available.  
It has a sensitivity of 94% and a specificity of 92%. 
 Stomach biopsy: 1.1.4.4.
 This test is invasive because a small sample (biopsy) is taken from the lining of the 
stomach and small intestine during an endoscopy procedure.  
  
7 
This test is important to perform susceptibility testing to antimicrobial agents in a regions 
of high clarithromycin resistance before prescription of the first-line treatment(19), and 
after a second line therapy failure, it should be performed in all cases(18). 
1.1.5. Transmission of H. pylori (20), (5):  
H. pylori transmission occurs via several routes including: 
1.  Oral-oral (e.g. mothers could transmit the infection via mouth secretions when tasting 
the Child‘s food). 
2. Fecal-oral (e.g. contaminated ground-water and plants with feces, lack of personal 
hygiene).  
3.  Gastro-oral (iatrogenic spread with inadvertent use of unsterile endoscopes). 
1.1.6. Risk factors related to H. pylori infection: 
1. Low socioeconomic conditions are the most important risk factors for H. pylori 
infection(7). 
2.  living in a rural area(21). 
3.  Living in crowded homes(22). 
4. Having contaminated sources of drinking water(23). 
1.1.7. Diseases associated with H. pylori. 
 Possible diseases caused from H. pylori infection. 1.1.7.1.
Occurrence of many diseases can be caused by H. pylori infection, those are: 
 Gastritis, non-ulcer dyspepsia (NUD),  peptic ulcer diseases (PUD) including duodenal 
ulcer and gastric ulcer, gastric atrophy, gastric carcinoma, gastric lymphoma of mucosa 
associated lymphoid tissue (MALT) and even coronary heart diseases(24). It was found 
from a number of studies to that H. pylori may play a role in iron deficiency anemia (25). 
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It has been approved that H .pylori is the cause of almost all peptic ulcer diseases (i.e. 
duodenal ulcers (DU) and gastric ulcers (GU) ) that are not related to nonsteroidal anti-
inflammatory drugs (NSAID)(26). 
 H. pylori appears to be associated with 95% of the gastritis cases, 90-95% of DU cases 
and 70-90%  of GU cases (27), (28).  
 H. pylori-positive patients have at least a six-fold greater risk of developing gastric  
adenocarcinoma than do those without infection(29). 
 
 Peptic ulcer disease: 1.1.7.2.
  Overview: 1.1.7.2.1.
Peptic ulcer disease (PUD) represents a serious medical problem affects about 5% and 10% 
of adults globally, with a 4 million new cases every year (30). 
It affects the stomach & the upper part of the duodenum, consisting of a distinct breach 
(open sore) in the gastrointestinal mucosa of the stomach or the duodenum, causing 
burning sensation or pain in the area between the chest and umbilicus, this pain becomes 
more intense when the stomach is empty. It lasts from few minutes to several hours.  A 
2%-14% of the these ulcers will perforate, and severe complications  that  cause mortality 
rates varies from 10%-40%(31). 
 Duodenal ulcers are rarely malignant but gastric ulcers are more commonly associated 
with malignancy. People can have both gastric and duodenal ulcers at the same time. They 
also can develop peptic ulcers more than once in their lifetime. 
The majority of peptic ulcers are caused by infection with H. pylori. Globally, different 
strains of H. pylori exist & are associated with differences in virulence, and the resulting 
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interplay with host factors and environmental factors leads to differences in the expression 
of disease. Age, ethnicity, gender, geography and socioeconomic status, are all factors that 
influence the incidence and prevalence of H. pylori infection. The overall prevalence is 
high in developing countries and lower in developed countries(3). 
 Most H. pylori induced ulcers can be cured with proper treatment that consists usually of a 
combination of drugs, including antibiotics and a proton pump inhibitor. 
  Pathophysiological & etiological factors of peptic ulcer: 1.1.7.2.2.
 The majority of duodenal and gastric ulcers are caused by Helicobacter infection, 95% 
of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. 
Eradication of H pylori reduces the relapse rate of ulcers but the magnitude of this 
effect is uncertain(32). 
 Acid secretion: auto-digestion of the gastro-duodenal mucosa by acid secretion. In 
variety of diseases known to cause peptic ulcer, including Zollinger-Ellison syndrome 
(ZES /gastrinoma), antral G-cell hyper function. 
 Abnormalities of normal mucosal defense mechanisms(33), and reflux of duodenal 
contents into the stomach or delayed gastric emptying may also be involved 
 Drugs ( mainly  NSAIDs, corticosteroids) .Taking NSAIDs causes 15 to 20 % annual 
incidence of peptic ulcer (34). It is reported that there is a synergism between 
Helicobacter infection and NSAID use for the development of peptic ulcer as well as 
ulcer bleeding(35). 
 Cigarette smoking:  smokers are approximately twice as likely to develop peptic ulcer 
disease as non -smokers (36).Smoking increases gastric acid secretion and 
duodenogastric reflux. Smoking decreases gastro-duodenal prostaglandin production. 
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  Drinking alcohol. 
 Stress( both physiological and psychological stress play a role in the development of 
peptic ulcer in some patients ) (37). 
 Complications of peptic ulcer associated with H. pylori (14):       1.1.7.2.3.
1. Bleeding:  when a peptic ulcer breaks through the blood vessels. 
2. Obstruction: ulcer progression may block the pyloric region and prevents food from 
leaving the stomach. 
3. Perforation, can happen when an ulcer breaks through the stomach wall. 
4. Peritonitis: infection of the peritoneum, or the lining of the abdominal cavity 
 
1.1.8. Treatment of H. pylori induced Peptic Ulcer Disease:       
 Background and General Considerations: 1.1.8.1.
The main goals of peptic ulcer treatment are:  
 Relief of symptoms. 
 Healing of ulcer. 
 Preventing ulcer recurrences. 
 Reducing ulcer related complications. 
 Reducing the morbidity and mortality rates.  
Primarily, before the bacterium was found, it was believed that stomach ulcers occur when 
excess acid damage the gastric mucosa so the treatment was based on reduction or 
neutralization of that acid(38). Patients were treated with H2-blockers and, more recently, 
proton pump inhibitors, these drugs include: 
 H2-receptor antagonists (i.e. ranitidine, cimetidine, famotidine). 
 PPI (i.e. omeprazole, pantoprazole, esomeprazole). 
 Cyto-protective agents (i.e. sucralfate) 
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 Prostaglandin agonists (i.e. misoprostol) 
 Antacids (aluminum hydroxide, magnesium hydroxide, calcium carbonate, sodium 
carbonate). 
This kind of treatment could certainly relieve ulcer-related symptoms, but has a high 
recurrence rate(39).   
The identification of H. pylori and understanding of H. pylori associated peptic ulcer 
disease (GU and DU) have greatly changed therapeutic regimens covering peptic ulcer 
disease. Eradication of H. pylori is now recognized to be the most correct approach in the 
treatment of the disease(40). 
H pylori eradication is highly recommended for both DUs and GUs, as it has been proved 
that H. pylori eradication effectively heals the ulcer rates of >90%(41). 
The presence of H. pylori should usually be confirmed before starting the eradication 
therapy,  ―test-and-treat strategy‖ which is highly recommended by international 
communities (42). 
 Although most antibiotics have very low in-vitro minimum inhibitory concentrations 
(MIC) against H. pylori (43), no single antibiotics has been able to eradicate this organism 
effectively, and effective eradication rate need a combination of different antibiotics(44), 
since the cross-resistance present within each family of antibiotics but no cross-resistance 
between different families of antibiotics which have different resistance mechanisms(29). 
Prerequisite for clinically effective H. pylori eradication regimens is at least 80-90 % 
eradication rate, without induction of major side effects nor bacterial resistance (45). 
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 Regimens available for treatment of H. pylori induced ulcers:  1.1.8.2.
1.1.8.2.1. First line therapy: 
The triple treatment including Proton pump inhibitor (PPI)-clarithromycin and amoxicillin 
or metronidazole proposed at the first Maastricht conference1 to treat H pylori infection 
has become universally the 1
st
 line therapy since it was recommended by all the consensus 
conferences held around the world (42) (46),(47). 
Table 1.2: First- line seven day triple therapy regimen(46) 
 
 After completion of triple therapy, the proton pump inhibitor has been recommended to 
be continued once daily for a total of 4–6 weeks to ensure complete ulcer healing(42) 
 In regions with high resistance to clarithromycin, PPI-clarithromycin-containing triple 
therapy should be abandoned without prior susceptibility testing(42). 
How to improve the 1
st
 line therapy? 
1- Increase the length of treatment. 
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Eradication rate for 7days is  70-85% (47), while increasing the duration of the treatment to 
10-days, improves the eradication rate by 4%,  and a 14-days treatment improves the 
eradication rate by 5-6%, in comparison to a 7-day treatment(48),  (42). 
2- Increase the  dose of PPI: 
Using twice-a-day PPI was better than a single daily dose in triple therapy and increases 
the efficacy of the triple therapy(49), also increases the cure rate by 6-10% (50). 
3- Use metronidazole instead of amoxicillin as the second antibiotic. 
PPI-clarithromycin-metronidazole (PCM) and PPI-clarithromycin-amoxicillin (PCA) 
regimens are equivalent but PCM is less expensive & has less side effects than PCA as 
Amoxicillin sometimes is associated with allergic reactions (42)  
Pooled data for PAC regimens show eradication rates of 79.8% with clarithromycin 250 
mg compared with 89.6% with clarithromycin 500 mg, while in PCM regimens, doubling 
the dose of clarithromycin had no statistically significant effect: eradication rates were 
87.4% for clarithromycin 250 mg and 88.9% for clarithromycin 500 mg(51), this is 
beneficial as the lower dose is also better tolerated and less costly  
What are the reasons for the decreased efficacy of the standard triple therapy? 
The low patient compliance, the high gastric acidity, the high bacterial load, the type of H. 
pylori strains and the most important is the increase in H pylori resistance to 
clarithromycin are the main reasons for the decreased efficacy of the standard therapy(42). 
In addition, in high BMI persons, especially the obese people, the distribution volume of 
the drugs being higher, which means that the concentration at the drug in the gastric 
mucosa will be lower and the risk of treatment failure is higher(52).  
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In case of  1
st
 line therapy failure or in case of high resistance to clarithromycin ( ˃ 15-
20%) the 2
nd
 line therapy is recommended (42). 
1.1.8.2.2. Second line therapy: 
 (Bismuth 120mg qds + tetracycline 500mg qds+ metronidazole 400mg tds+ PPI OD) : 
(Bismuth based therapy) for 7days. (eradication rate 70-85%) (47) 
                                                               OR 
(PPI-levofloxacin 500mg OD- amoxicillin 1G BID) for 10-day is the other alternative 
second-line treatment based on the results obtained in recent years(53). (eradication rate 
75-90%)(47). 
 In regions of low clarithromycin resistance: 
After the failure of the 1
st
 line triple therapy, one of the two regimens, either bismuth based 
therapy or levofloxacin quadruple therapy can be used as a second line therapy (42). 
 In regions of high clarithromycin resistance: 
 Bismuth-containing quadruple therapies are the first choice (the 1
st
 line therapy). After 
failure of bismuth containing quadruple therapy, levofloxacin containing triple therapy is 
recommended as the 2
nd
 line therapy(42). 
 Also Bismuth-containing quadruple therapy could be used as alternative first choice 
therapy regardless resistance to clarithromycin (18) , (54). 
 Rising rates of levofloxacin resistance should be taken into account before taking 
levofloxacin triple therapy, and it is recommended to test levofloxacin susceptibility 
before prescribing it (55). Also it is strongly advised not to use levofloxacin in a patient 
with chronic infections who may have received fluoroquinolones (42). 
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1.1.8.2.3. Third line therapy: 
 No standard third-line therapy exists. After failure of second-line therapy, European 
guidelines recommend that treatment  should be based on the antibiotic sensitivity 
(56),(42).  
 Usually, after two treatment failures, it is recommendable to prescribe antibiotics not 
previously used , but whenever possible it is better to obtain gastric biopsy and perform 
susceptibility testing(57). 
 Different combinations have been prescribed after the failure of the 2nd line therapy, 
examples of  these combinations are: (3) 
•  PPI + amoxicillin + rifabutin for 10 d.  
•  PPI + furazolidone + levofloxacin for 7–10 d. 
1.1.8.2.4. Alternative therapies: 
1.1.8.2.1.1. Sequential therapy: 
 It is considered as an alternative therapy for the standard 1st line therapy in case of 
clarithromycin resistance.  
 It involves treatment with: PPI and amoxicillin for 5 d, followed by the PPI and  a 
nitroimidazole antibacterial (metronidazole or tinidazole) and clarithromycin for a 
further 5 days, is more effective than a standard 7 or 10 d triple therapy regimen in 
treatment naïve-patients(58, 59). 
 This therapy showed excellent eradication rates 90-94%(60). 
 Sequential therapy is effective despite clarithromycin resistance, due to the cell wall 
disruption by amoxicillin preventing the development of clarithromycin efflux 
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channels& due to the larger number of antibiotics to which the microorganism is 
exposed (61). 
1.1.8.2.1.2.  Concomitant therapy: 
 A novel alternative regimen for first line therapy in case of clarithromycin 
resistance(62). 
 A 4-drug regimen contains a PPI, clarithromycin ,amoxicillin and metronidazole (63). 
 Both the sequential therapy and the concomitant therapy showed that they were 
equivalent in eradication rates, but the concomitant therapy is less complex as it does 
not involve changing drugs halfway through(64). 
1.1.8.2.1.3.  Hybrid (dual therapy): 
 A recent hybrid (dual-concomitant) therapy has been reported, consisting of a dual 
therapy; starting on a PPI (standard dose, b.i.d.) and amoxicillin (1 g, b.i.d.) for 7 d 
followed by a concomitant quadruple therapy with a PPI , amoxicillin , clarithromycin 
and metronidazole for 7 d (65). 
 This therapy provided excellent eradication rates of 97% -99%. Also it is noticed that 
the new therapy has a high efficacy in the treatment of H. pylori strains harboring dual 
resistance to clarithromycin and metronidazole on the contrary to the sequential therapy 
(66). 
 Future therapeutic strategies: 1.1.8.3.
 Vaccination 1.1.8.3.1.
The host response plays an important role during H. pylori colonization. Thus 
immunization against H. pylori may be considered as a strategy to potentiate the host 
immune response to be capable of attenuating or eliminating H. pylori and its associated 
gastric inflammatory sequelae(67).So vaccination is expected be very effective for 
elimination of H. pylori infection and would be cost-effective strategy(68). 
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 H pylori is vaccine is feasible in animal models, but requires further research, and efforts 
to be applied  against H pylori in humans (69). 
 Genome-based drug discovery: 1.1.8.3.2.
The principle of genome based drug development is identifying the essential proteins 
which are specific to H. pylori, and then to isolate, identify and synthesize a small 
molecule chemical which inhibits the essential activity of such proteins(70). 
  Novel drug delivery approaches: 1.1.8.3.3.
One of the reasons for the failure in eradication of H .pylori is the short residence time of 
the antimicrobial agents in stomach, so the effective antimicrobial concentration cannot be 
achieved in the mucus layer or epithelial cell surfaces where H. pylori colonizes(71), (72). 
To overcome the problem, a new site specific drug delivery system (DDS) has been 
proposed based on increasing the residence time in stomach; this DDS is known as 
―gastroretentive drug delivery systems (GRDDS)‖(73) 
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Table1.3: Summary of the recommended regimens for Helicobacter pylori therapy(63). 
 
 
1.1.9. Risk of Recurrent Helicobacter pylori Infection: 
 The long-term effectiveness of H. pylori eradication programs will depend on 
recurrence risk after 12 months of eradication. Recurrence of H. pylori infection is the 
result of recrudescence (due to ineffective treatment regimen), reinfection, individual 
factors and community factors. Recrudescence is considered to be more likely 
responsible for most of cases than reinfection(14).  
 Annual recurrence rates per patient-year of follow-up have been reported to vary across 
countries(74).The percentage of H pylori annual recurrence was 2.67% and 13.00% in 
developed and developing countries respectively, this confirming that low 
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socioeconomic development areas are more likely to have higher rates of H. pylori 
infection recurrence. (75), (76).  
 Risk of Recurrent H. pylori Infection 1 Year after Initial Eradication Therapy in 7 Latin 
American Communities was studied in 2013; recurrence occurred in 11.5% of 
participants who had negative post treatment UBT results. Recurrence reasons were, 
non-adherence,  demographics, and the most important  was the non- specific antibiotic 
regimen(77). 
1.2. Anatomy and physiology of the stomach:(78) ,(79),(80)  
 
The stomach is an important part of the digestive system. It is a muscular, hollow, sac-like, 
dilated organ located in the left upper part of the abdominal cavity just below the 
diaphragm and liver. The volume of empty stomach is 20–25 ml, which can get expanded 
up to 1.5 L after meal consumption. The stomach locates between the esophagus and to the 
small intestine.  
1.2.1. Parts of the stomach:     
 The stomach is divided into 5 regions, as shown in Figure 1.3: 
1. The cardia: A small area in the upper portion of the stomach where the esophagus and 
stomach join (in gastroesophageal (GE) junction).This region includes the cardiac 
sphincter, which acts as a valve that prevents the stomach contents from going back up into 
the esophagus. 
2. The fundus: Is the area below the cardia, but it balloons out above it and serves as a 
temporary storage area for food. 
3. The body: Is the main part of the stomach where the food becomes mixed and broken 
down. 
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4. The antrum:  Is the lower part of the stomach which holds the broken down food, until it is 
ready to be released into the small intestine. 
5. The pylorus:  Is the narrow, bottom part of the stomach near the small intestine it includes 
the pyloric sphincter that acts as a valve to control the emptying of stomach contents into 
the small intestine. 
                             
                                                  Figure 1.3:  Stomach regions 
1.2.2. Functions of stomach: 
There are three major functions of stomach: 
 Physical digestion (churning function). 
  Chemical digestion. 
  Limited absorption (some water, alcohol, certain drugs). 
1.2.3. Anatomical structure of stomach:  
The stomach is made up of several layers of tissue that facilitate its functions(see 
Figure 1.4):  
1. The mucosa (mucous membrane) is the inner lining of the stomach. It has many glands 
that produce mucus , hydrochloric acid and .digestive enzymes 
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2. The submucosa is a layer of connective tissue that has large blood vessels, lymph 
glands, nerve cells and fibers, and glands that secrete digestive hormones. 
3.  The muscularis propria (or muscularis externa) is the next layer. It is the main muscle 
of the stomach, and is made up of 3 layers of muscle which help in breaking up the 
food by churning action resulting in milky white liquid chime. 
4. The serosa is the fibrous membrane covering the outside of the stomach, consisting of 
layers of connective tissue continuous with the peritoneum. 
               
               Figure 1.4:  Layers of the stomach   
1.2.4. Gastric motility and gastric emptying time:(81),(82),(83) 
The emptying process of the stomach is caused by tonic contraction of the stomach and 
peristaltic waves moving over the gastric region. Two types of GI motility and secretion 
exist, including the fasted and the fed states. As a result, the bioavailability (BA) and the 
efficacy of orally administered drugs vary depending on the state of feeding. The gastric 
motility associated with various cyclic events, known as the migrating motor complex 
(MMC), which regulates its motility. The MMC is divided into four phases. 
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i. Phase I (basal phase) is a quiescent period with virtually no contractions, 
characterized by lack of secretory, electrical, and contractile activity, lasts for 
30–60 min. 
ii. Phase II (pre-burst phase) lasts for 20-40 min with intermittent, irregular low 
amplitude contractions. Bile secretion occurs during this phase, and mucus 
discharge occurs during the latter part of Phase II and throughout Phase III. 
iii. Phase III (burst phase) consists of intense, large, and regular contractions 
known as (house-keeper waves) in which all the undigested material is swept 
out of the stomach to the small intestine. This phase lasts for 10-20 min. 
iv. Phase IV is a short transition period between phases III and I of two 
consecutive cycles and lasts for 0–5 min with very little or no contractions. 
This cycle of electrical events is repeated every 2-3 hours in the fasted state. In the fed state 
a continuous pattern of spike potentials and contractions called postprandial motility occur.  
The larger the ingested amount of food, the longer the period of feeding activity, with usual 
duration of 2–6 hours. 
The performance of the peroral DDS generally and the GRDDS specifically is affected by 
the state and the phase during which it is administered. When the DDS is administered in 
the fasted state, the phase of the MMC can significantly influence the gastric residence 
time (GRT) and transit time in the gastro intestinal tract (GIT). This will have greater effect 
on the drugs with narrow absorption window in the upper GIT; the lesser time spent in that 
region, the lower degree of absorption. Therefore, the design of GRDDS should take into 
consideration the resistance of the dosage form to gastric emptying during Phase III of the 
MMC in the fasted state and to continuous gastric emptying through the pyloric sphincter 
in the fed state. Therefore, the GRDDS must be functional quickly and able to resist the 
aggressive gastric physiological events for enough time. 
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1.3. Gastroretentive Drug Delivery Systems (GRDDS): 
1.3.1. Overview: 
Oral route remains the most desired, convenient and preferred drug delivery system (DDS), 
due to its ease of administration, low cost, patient compliance  and flexibility in 
formulation and manufacturing that gives it more attention in the pharmaceutical field(84). 
About 50% of the drug delivery systems available in the market are oral systems(85). 
Optimal DDS ensures the presence of the drug in its active form at the site of action within 
its therapeutic range (concentration above the minimum effective concentration (MEC) and 
below the minimum toxic concentration (MTC))for the correct time an duration(86).  
It is necessary to take the drug several times a day to maintain its concentration within the 
therapeutic range, which could result in significant fluctuation in plasma drug 
concentration(87). 
This has led to the development of sustained releases (SR) dosage forms, where the dosage 
form is designed to control the drug release such that its plasma profile is maintained 
within the therapeutic range for prolonged time(88). 
Sustained release dosage forms are DDS that provide the drug release over extent period of 
time after administration, thereby extending the dosing interval (decreasing the dosing 
frequency) and reducing fluctuations in the drug plasma concentration (Figure 1.5). 
This can be achieved by using of suitable polymers which are used as reservoir systems 
(coating of granules or tablets) or matrix systems (in which drug is dispersed).(86)     
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Figure 1.5:  Drug plasma concentration and dosing intervals from sustained release and 
immediate release systems.(86)   
                                              
Oral sustained release delivery system has been developed due to its therapeutic 
advantages, mainly for drugs that have short half-lives and are easily absorbed throughout 
the GIT (89). A common property of conventional sustained release dosage forms is that a 
large amount of the drug loaded in it is released in the colon where it stays for a relatively 
long time compared to other parts of the GIT. So while this DDS is suitable for many 
drugs, it is inappropriate for drugs that are poorly absorbed from the lower part of the GI 
tract, drugs with narrow absorption window or drugs having local effect in the upper GIT 
part(90).  
This approach has many difficulties; The inability to restrain and locate within this desired 
region of the GIT  due to variable gastric emptying and motility and the relatively short 
gastric emptying time (GET) result in incomplete absorption of the drug from the drug 
delivery system(89). Also the extent of drug absorption from duodenum and jejunum is 
limited despite their high absorption properties as the passage through them is rapid. After 
crossing this absorption window, the released drug goes to waste with low absorption. This 
phenomenon significantly decreases the time available for drug absorption and limits the 
success of the delivery system (90). 
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In order to increase the bioavailability and the efficacy of such drugs (drugs characterized 
by a narrow absorption window or local effects in the upper part of GIT, the residence time 
of the drug delivery system (DDS) in the upper GIT needs to be prolonged; this will offer 
better option for drug therapy. This can be achieved by the development of a unique oral 
sustained or controlled release dosage form, that can withstand the vigorous gastric 
motility and gastric emptying and exhibits extended release of the drug in the gastric 
environment, this system is called ―gastroretentive drug delivery system‖.(91) 
1.3.2. Definition of GRDDS: 
Orally administered, site-specific, controlled release drug delivery systems that could 
potentially prolong the gastric residence time of the drug at the gastric region (stomach) 
and can withstand the barriers that affect their residence in the stomach. 
Gastroretentive drug delivery systems control/sustain the release of a drug over a long 
period, thereby it could be supplied continuously to its target site in the stomach and the 
upper part of small intestine, this could potentially improve its bioavailability and its 
therapeutic effect; as a result the drug necessary dose can be reduced, and its side effects 
will be minimized.(92) 
A gastroretentive delivery system must be stable in the acidic environment of the stomach 
for prolonged time and should have good absorption in the upper GIT (93). 
1.3.3. Drug candidate for GRDDS: 
Many processes occur in the GIT to the drug after its release from a dosage form, 
including: degradation (chemical, enzymatic or bacterial), absorption (passive and/or 
active), precipitation, efflux by P-glycoprotein pump, and metabolism by Cyp450 
enzymes. As a result this will affect the pharmacokinetics (PK) and the pharmacodynamics 
(PD) of the drug depending on its delivery site(94). 
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Taking into considerations the above mentioned processes, the best PK and PD properties 
would be achieved for the following drug candidates when formulated as GRDDS: 
 Drugs that have narrow absorption window in the upper part of GIT (mainly the 
duodenum). 
E.g. L-DOPA, Furosemide, Riboflavin, Para-aminobenzoic acid, Cyclosporine, 
Atenolol, Theophylline, Dilitazem, Risedronate.(95),(96). 
 Drugs those are locally active in the stomach. 
E.g. Antacids and Misoprostol.(97) 
 Drugs that are used for eradication of H. pylori in the stomach. 
E.g. Clarithromycin, Metronidazole, Amoxicillin(97). 
 Drugs that are substrates for Pg-p (which have highest levels in the colon).  
E.g. Digoxin(98). 
 Drugs those are unstable and undergo degradation at the intestinal or colonic 
environment (high pH). 
E.g. Captopril, Ranitidine-HCl, Metronidazole.(96),(99)  
 Drugs with high solubility at low pH values. 
E.g. Chlordiazepoxide, Cinnarizine, Diazepam, Verapamil, Cefpodoxime-proxetil, 
Rosiglitazone maleate.(100) 
 Drugs that are mainly absorbed from the stomach. 
E.g. amoxicillin(97), alendronate(98). 
 
1.3.4. Advantages of GRDDS: 
1. Appropriate dosage forms for the drugs that are primarily absorbed through the 
stomach and the duodenum, for drugs with local effect in the stomach, for gastric H.  
pylori medications, and for drugs which are unstable in intestinal pH .(101) 
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2. Enhance the absorption and the bioavailability of drugs which are absorbed or 
solubilized only in the upper part of GIT compared to the administration of non-
gastroretentive drug delivery. i.e. the bioavailability of riboflavin CR-GRDF was 
significantly enhanced compared  to the administration of non-GRDF CR 
formula.(102) 
3. Reduce fluctuations of drug concentration by the continuous input of the drug from this 
sustained release dosage form. When fluctuations are minimized, the concentration 
dependent adverse effects associated with peak concentrations can be decreased. (103) 
4.  Improved selectivity in receptor activation as a result of minimizing fluctuations in 
drug concentration, this is especially for drugs that activate different types of receptors 
at different concentrations(103). 
5. Enhance the pharmacological effects and improves the clinical outcomes of drugs that 
have non-concentration dependent pharmacodynamics, such as some antibiotics, for 
which their response is not associated with peak concentration, but rather with the 
duration of time over a critical therapeutic concentration.(91) 
6. Improve the patient compliance by decreasing dosing frequency and thereby improves 
the therapy .(101) 
7. Enhance the therapeutic effect of the drugs with short half-life(101). 
8. Avoid gastric irritation because of the sustained and uniform release of the drug from 
this delivery system.(101) 
9. Minimize the adverse activity at the colon by decreasing the amount of drug that 
reaches to it. Thus, undesirable side effects of the drug in colon would be reduced.(91) 
10. Site-specific gastroretentive dosage forms provide sufficient local action at the target 
site, and minimizing the systemic exposure of drugs, thus will increase the local 
activity and reduce undesirable side effects. So they are useful in the treatment of 
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disorders related to stomach and small intestine (e.g. eradication of Helicobacter pylori) 
(95). 
11. In case of abnormal intestinal movement and a short intestinal transit time such as in 
case of diarrhea, poor absorption is expected. In this case it may be advantageous to 
retain the drug in the stomach to get a relatively better response; based on type of drug 
(101). 
1.3.5. Disadvantages of GRDDS: 
1. They require continuous food intake for extension of gastric emptying time and high 
levels of fluid to achieve buoyancy in the stomach.(104) 
2. GRDDS are affected by many factors such as motility and pH of the stomach, the 
age, gender and posture of the patient….etc (104). 
3. They are not suitable for the following drug candidates:(105) 
 Drugs with stability problems in the stomach, e.g. Erythromycin. 
 Drugs which undergo extensive first pass metabolism. 
 Drugs with irritant effect to the stomach, e.g. NSAIDS. 
 Drugs experience high first pass metabolism, e.g. Nifedipine 
 Drugs that have good absorption throughout the different GIT regions.  
 Drugs with poor solubility at acidic pH of the gastric region, e.g. Phenytoin. 
 Drugs intended for selective release in the colon, e.g. 5- amino salicylic acid and 
corticosteroids. 
4. Poor in-vitro and in-vivo correlation.(106) 
5. Higher cost formulations (106). 
6. Difficult Retrieval of drug in case of overdose or poisoning (106). 
7. Large size of the tablets due to many excipients  have to be used in their 
formulation. 
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1.3.6. Factors affecting gastric retention of dosage forms: 
1. Age and gender : 
People over 70 years usually have a longer gastric residence time than younger 
peoples. The mean gastric residence time differs between males and females; in males 
it is (3.4±0.6 h) while in female counterparts (4.6±1.2 h) (107). 
2. Fed or fast state and frequency of feeding: 
Under the fast state, the GI motility is characterized by MMC which act to remove the 
undigested food from the stomach. The retention time of the dosage form is very short 
if its administration coincides with that of the housekeeper waves of the MMC. 
GRT increases in the presence of food. Successive meals can increase the gastric 
retention time by 6–7 h. The presence of food in the stomach maintains the FDDS 
away from the gastro-duodenal junction, which prevents the early emptying during the 
digestive phases(108). 
3. Nature of food: 
The nature of food and the caloric content affect the GRT of the dosage form. GRT 
increases by 4–10 h after high fats and proteins meal (109). 
4. Subject posture (standing or supine): 
In the upright (standing) position, the floating systems floated to the top of the gastric 
contents and are protected from postprandial emptying, showing prolonged GRT than 
non-floating units. However, in supine position, the floating units are emptied faster 
than non-floating units of similar size(110). 
5. Concomitant drug administration : 
 Concomitant administration of anticholinergics like atropine and propentheline , 
opiates like codeine and prokinetic agents like metoclopramide, can prolong gastric 
retention time(111). 
  
30 
6. Density of the dosage form: 
Dosage forms having a density lower than that of gastric fluid experience floating 
behavior and hence good gastric retention time. A density of <1.0 gm/cm3 is required 
to exhibit floating property. However, sometimes the bulk density of a dry dosage form 
is not an appropriate parameter for describing the buoyancy due to the floating force 
kinetics of these dosage forms which can be estimated from the resultant-weight  
measuring versus time(112). 
7. Size of the dosage form: 
The dosage forms which are less than 10mm in size can get emptied faster from the 
stomach than larger dosage form(113). 
1.3.7. Approaches for GRDDS: 
―The first pioneering GRDDS  was suggested as far as back in 1957‖(93). Over the last 2–
3 decades, numerous gastroretentive dosage forms have been designed to prolong the 
gastric residence time (93), those included in  Figure 1.6: 
(1) High-density systems 
(2) Swelling and expandable systems 
(3) Mucoadhesive or bioadhesive systems 
(4) Superporus hydrogels 
(5) Magnetic systems 
(6) Floating systems 
(7) Raft forming systems 
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           Figure 1.6: Different approaches of GRDDS. 
  High-density systems: 1.3.7.1.
The density of gastric content is about (˂1.004 g/cm3), whereas the density of these 
systems is about (3 g/cm
3
). So these systems retained in the bottom of the stomach due to 
their high density, they withstand the gastric motility and gastric emptying and hence 
increase their gastric residence time (113),(114). 
The major drawback of these systems is the difficulty of their manufacturing with high 
drug capacity, because when the drug is released from the matrix, its weight decreases 
progressively and this will decrease its density and accordingly affect its residence time 
(115). 
Some studies declared that high-density systems did not extend the gastric residence time 
significantly(116).Till date, these systems are not available in the market(93). 
  Swelling and expandable systems: 1.3.7.2.
The size of these systems increases significantly and rapidly when they reach the stomach 
and come in contact with its contents and this will prevent premature emptying through the 
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pyloric sphincter. The initial size of these systems should enable their oral swallowing, and 
the size of these systems needs to decrease after completing the drug release to enable their 
evacuation from the stomach(117). 
The stomach must be filled with fluids for these systems because their swelling and 
expansion is due to the fluid uptake. The expansion can be achieved by swelling or 
unfolding of the system in the stomach(118). 
The expandable systems should not interfere with gastric motility or cause any local 
damage to the gastric mucosa. They should be biodegradable because their long retention 
time in the stomach may cause bowel obstruction (119). 
The major drawbacks of these systems are the stability problems in their integrity and their 
mechanical shape during storage due to the presence of hydrolysable, biodegradable 
polymers. Also their manufacturing is costly and not easy(93). 
  Mucoadhesive or bioadhesive systems: 1.3.7.3.
Another approach to increase the retention time of the dosage form in the stomach or upper 
small intestine is the adhesion of the dosage forms to the mucosal membrane of the 
stomach(120) . These formulations incorporate bioadhesive materials which enable the 
system to adhere to the gastric mucosal wall by forming strong non-covalent bonds with 
the mucin-epithelial cells surface of the GIT. The bioadhesion of polymers to the mucus 
membrane is achieved by the formation of electrostatic and hydrogen bonding at the 
mucus-polymer boundary(121). 
The main drawback of these systems is their unpredictable adherence to the gastric mucosa  
that controls the gastric residence time of the dosage form, this is due to the continuous 
renewal of mucus on the walls of the stomach (122).Another drawback of the 
mucoadhesive delivery systems is their local side effects due to their direct contact with the  
gastric mucosa for long time(123). 
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   Super-porous hydrogels: 1.3.7.4.
Hydrogels are cross-linked network of hydrophilic polymers that are insoluble in water, but 
they have the ability to swell by absorbing water(124). 
The conventional hydrogels are not suitable for GRDDS as their rate of swelling is very 
slow, and hence, premature evacuation of the dosage form through the pyloric sphincter 
can take place, while super-porous hydrogels (pore size ˃100 µm) swell very fast due to 
rapid water uptake, and hence, they can be used in the development of gastroretentive 
delivery systems (125). 
  Magnetic systems: 1.3.7.5.
These  systems contain small amount of iron powder within their matrix as an internal 
magnet, and an external magnet piece placed on the abdomen over the position of the 
stomach to control the gastrointestinal position and transit of these systems(126). 
These systems have prolonged residence time in the stomach, and this was proved 
clinically in healthy volunteers by magnetic resonance imaging (127). 
The major drawback of these systems is that their efficacy depends on the position of the 
external magnet, which should be fixed on the abdomen at one position accurately; over 
the stomach, during the treatment period and this will limit the free movement of the 
patient and lead to poor compliance(127). 
  Floating systems: 1.3.7.6.
These systems have a density less than that of the stomach fluids, which cause their 
floating over its contents for prolonged time and increase their gastric residence time(128). 
Floating of these systems can be achieved by different techniques (discussed in details 
under the section ‗floating drug delivery systems‘: 
1. Effervescent systems. 
2. Non-effervescent systems. 
  
34 
3. Raft forming systems. 
The major drawbacks of these systems are their need for high level of fluids and frequent 
feed, also their  residence in the stomach is dependent on the floating lag-time, if it was too 
long the system can be eliminated rapidly from the gastric region(93). 
   Dual working systems: 1.3.7.7.
These systems combine both mucoadhesion and floating technologies. So they have more 
potential to improve the in vivo performance of the gastroretentive dosage forms. The 
combination of mucoadhesion and floating technologies aims to increase the gastric 
residence time of the system by ameliorate the major drawbacks of  both 
systems(129),(130). 
In last few years, many studies for these systems on the animals have been reported. These 
studies proved that these systems have prolonged gastric residence time(131). 
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Table.1.4.. Marketed gastroretentive drug delivery systems available in the international 
market(93). 
 
1.4. Floating Drug Delivery Systems (FDDS): 
1.4.1. Background of FDDS: 
In 1968 Davis firstly described the concept of floating drug delivery system to solve 
gagging or choking problems in some persons while swallowing medicinal tablets. He 
formulated pills having density less than water density (1gm/ml), so that the pills will float 
on the water surface and could be administered easily in the bowed position. Since then 
several approaches have been proposed for ideal floating delivery devices(132). 
FDDS should have a bulk density less than gastric fluids to remain buoyant in the stomach 
for a prolonged period. But this bulk density of the dry dosage form is not the most 
appropriate parameter for determining of the floating capacity, because  during the floating 
time of the system a minimal level of floating force (F) is required to keep the dosage form 
buoyant, this force could be estimated from the total vertical forces affecting the immersed 
system(112) (Figure 1.7). To measure the floating force (resultant weight), a novel 
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apparatus has been designed(133) .The principle of this apparatus based on measuring 
continuously the force equivalent to F (as a function of time) that is required to maintain 
the system floating. The object floats better if F is on the higher positive side, whereas it 
will sink if  the value of F is in minus(112).  
                                            F = F buoyancy - F gravity………(85) 
                                               = Df .g . V – Ds .g. V 
                                                = (Df - Ds) g.V 
        Where, F = total vertical force,  Df = fluid density, Ds = system density,  V = 
volume    
                    and  g = acceleration due to gravity. 
  
Figure 1.7 Measuring of the floating force.    
 
1.4.2. Technologies of FGRDDS: 
Different technologies have been utilized in the development of FDDS, based on the 
buoyancy mechanism:  
   Non-effervescent systems: 1.4.2.1.
These systems are developed using a high level of one or more gel-forming, highly 
swellable polymers (i.e. hydroxypropylmethyl cellulose (HPMC), hydroxethyl cellulose 
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(HEC), hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (Na-CMC), 
polyacrylate, polystyrene, agar, carrageenans and alginic acid) that swell to a great extent 
by hydration when come in contact with the gastric fluid; the entrapment of air within the 
swollen polymer framework maintains a bulk density for these systems of less than one, 
and provides buoyancy to the dosage form(134). 
These systems can be divided into many subtypes: 
 Hydrodynamically balanced systems (HBS): 1.4.2.1.1.
Sheth and Tossounian were the first designators of the ‗hydrodynamically balanced 
systems(135).These systems are single-unit dosage forms. Their incorporation of swellable 
gelatinous polymer enables the gel barrier formation on the outer surface that maintains 
good system integrity and low apparent density less than the gastric fluid to remain 
buoyant on the stomach content for longer periods. The drug is released by diffusion and 
erosion from this gel barrier (Figure 1.8). Incorporating of fatty excipients gives low-
density to the system and reducing its erosion (135), (136).  
 
 
 
Figure1.8. Hydrodynamically balanced systems (HBS). 
 
 Microporous compartment systems: 1.4.2.1.2.
These systems consist of floating chamber attached to microporous compartment which 
encapsulates a drug reservoir (Figure 1.9). The floating occurs due to the presence of the 
floatation chamber, which may be filled with a vacuum or filled with air or a harmless gas. 
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The microporous compartment contains pores along its top and bottom walls, these 
micropores enable the entry of the gastric fluid to the drug reservoir to dissolve the drug, 
while the peripheral walls of the drug reservoir compartment are completely sealed to 
prevent direct contact with the undissolved drug(137). 
 
Figure1.9: Microporous compartment system 
 
 Alginate Beads: 1.4.2.1.3.
Multi units floating dosage forms that are developed from freeze dried calcium alginate. 
They are spherical shape beads with diameter of about 2.5 mm. 
 These beads can be prepared by dropping sodium alginate solution into aqueous solution 
of calcium chloride causing precipitation of calcium alginate beads; these beads are then 
separated, frozen in liquid nitrogen, and finally freeze-dried at -40ºC for 24 hours, this 
process leads to the formation of porous beads, which have longer residence time (about5.5 
h), compared to the solid beads which have shorter floating time (1 h)(138),(139). 
 Hollow microspheres/ Microballons: 1.4.2.1.4.
These are multiple-units systems that load the drug in their outer polymer shelf. 
They are prepared by emulsion solvent diffusion method to create a hollow in their inner 
core; this hole will prolong the GRT of the system. The most common used polymers in 
these systems are: polycarbonate, cellulose acetate, agar, Eudragit S, etc. The polymer is 
dispersed/ dissolved in the organic solvent and the drug is dissolved/ dispersed in the 
polymer solution. The resultant solution emulsified into an aqueous phase containing 
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polymers to form oil-in-water emulsion. Then the organic solvent is evaporated leading 
cavity formation, and thus, hollow microspheres are formulated (Figure 1.10). These 
microballoons can float over the surface of an acidic media for 12h(140). 
 
Figure 1.10: Example on hollow microsphere system. 
  Effervescent systems: 1.4.2.2.
The matrix of these systems contains two main components; swellable polymers (i.e. 
methocel, polysaccharides (e.g., chitosan) etc.) and effervescent components (i.e. sodium 
bicarbonate, calcium carbonate, citric acid or tartaric acid, etc.), these systems generate 
carbon dioxide when they come in contact with stomach fluids, causing the system to float 
over the stomach contents  (141). 
Another technology is the incorporation of  liquid which produce gas that evaporates at 
body temperature (142). 
 
 These systems further divided into two main types: 
 Volatile liquid containing systems: 1.4.2.2.1.
These systems incorporate inflatable chamber which contains a liquid that gasifies at body 
temperature (e.g. ether, cyclopentane) and cause the inflation of the chamber in the 
stomach and floatation for the system. The system may also consist of bioerodible 
materials that dissolve gradually causing the inflatable chamber to collapse after a 
predetermined time to permit its evacuation from the stomach(143). 
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 Gas-generating Systems: 1.4.2.2.2.
These systems are composed of:  gas (usually CO2) generating components, the drug and 
the matrix that contains hydrophilic swellable polymers. The floating of these systems 
depends on the reaction between the gas generating components and the  gastric acids or 
the acids incorporated within the system to liberate  a gas in this system, which gets 
entrapped in the gelled hydrocolloid layer formed by the hydrophilic swellable polymer; 
thus decreasing its density lower than the density of the gastric content and enables its 
floatation over these contents for prolonged time that gives the desired sustained drug 
release from the system. These systems have to be biodegradable after completion of the 
drug release, and they could be: 
 Single layer tablet (Intragastric floating tablet). 
This system contains the drug, the CO2 generating components and the hydrocolloidal 
polymer in one sustained release layer (Figure 1.11) (144). 
                            
                           
 
 
 
Figure1.11: Intragastric floating tablet   
 Bilayer tablet (Intra gastric floating bilayer tablet). 
This system consists of two layers; one layer for SR contains the CO2 generating agents 
with the drug and the hydrocolloid polymer, while the other layer is for immediate release  
(Figure 1.12)  (145). 
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                        Figure 1.12: Intra gastric floating bilayer tablet. 
 Multiple-unit type of floating pills. 
This system consists of multiple units (pills) which all have tha ability to generate CO2 and 
float(146). 
  Raft systems. 1.4.2.2.3.
These systems are gel forming solutions (e.g. sodium alginate solution containing 
carbonate) that swell and forms a viscous gel containing entrapped CO2 bubbles that are 
formed by contact with gastric fluid .This viscous, continuous, floating layer of cohesive 
gel above the gastric contents (called raft). The floated raft on the gastric fluids will not 
only increases the gastric residence time of the system, but also will act as a barrier 
between the stomach and the esophagus and prevents the reflux of the gastric contents into 
the esophagus(147, 148), so they can be also used for treatment of gastroesophageal 
reflux(149) 
1.4.3. The major requirements for floating drug delivery system (150): 
 It must be convenient for intake to enhance patient compliance. 
 It should maintain an overall density lower than that of gastric contents (1.004 – 1.01 
g/cm
3
). 
 It should form a swellable and cohesive gel barrier. 
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 It should act as reservoir, that dissolves slowly and release the drug in a controlled 
manner.  
1.4.4. Formulation aspects of FDDS (104, 151-153): 
Specific polymers and suitable excipients should be utilized in the formulation of floating 
drug delivery systems to give the major requirements of these systems, these are: 
 Hydrocolloidal polymers. 
These polymers have the ability to be hydrated when come in contact with water, forming 
swellable, cohesive gel barriers in the floating systems, to retard drug release, entrap gases 
within the systems to decrease their densities.  
Examples:  Acacia, Pectin, agar, alginates, gelatin, casein, veegum, methylcellulose, 
hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), 
hydroxyethylcellulose (HEC) and carboxymethylcellulose sodium (CMC-Na). 
 Inert fatty materials. 
Nontoxic, edible inert fatty material that have a specific gravity less than one can be 
incorporated within these systems to decrease their hydrophilic property and their 
density, and hence increase their floatation. 
 Examples: Purified grades of beeswax, fatty acids, glycerides, and mineral oils. 
 Effervescent agents. 
These are the gas generating component (produce CO2 after their reaction), the 
entrapment of the gas bubbles within the system caused decrease in its density and so 
enable its buoyancy. 
 Examples: Calcium and Sodium bicarbonate, calcium carbonate, tartaric acid, citric acid,  
Di-Sodium Glycine Carbonate. 
 Release rate accelerants.  
These agents can increase the release rate of the drug from its delivery system. 
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They can be used up to 60% of the system weight. 
Examples: lactose and mannitol. 
 Release rate retardants. 
These are insoluble substances that decrease the solubility of the system and hence retard 
the release of drug from it. 
Examples:  dicalcium phosphate, ethyl cellulose (EC), talc and magnesium Stearate. 
 Buoyancy increasing agents. 
These agents have bulk density less than one, so when added to the system they decrease 
its density and enhance its buoyancy. Can be used up to 80 % weight by weight. 
Example: ethyl cellulose (EC). 
 Miscellaneous. 
Other pharmaceutical excipients could be used, like diluents, preservatives, emulsifiers, 
and lubricants can be incorporates in the system as needed. They shouldn‘t adversely affect 
the floatation of the systems. 
1.4.5.  Advantages of floating systems over other systems: 
Floating systems are the most preferable GRDDS; this is due to the following specific 
advantages they have: 
1. Have all the advantages of GRDDS (section 1.3.5.). 
2. Have simple procedures and conventional equipment for manufacturing(154). 
3. They are advantageous over other GRDDS as many drawbacks of other systems can be 
avoided with FDDS, example (155):  
 Have higher drug loading capacity than high density systems. 
 Avoid chocking problems caused by the increased size, and the economical 
manufacturing economical difficulties of the expandable systems, and have lower 
storage problems  
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 Don`t cause gastric mucosa is irritation as mucoadhesion systems. 
 No compliance problems as magnetic systems 
4. Can be used specifically and effectively for the treatment of upper gastrointestinal 
disorders such as gastro-esophageal reflux (156). 
1.4.6. Disadvantages of floating systems: 
1. The gastric retention time of these systems is influenced by many factors such as:  
floating lag-time, pH and gastric motility. These factors are not constant and hence the 
floating time cannot be predicted(157). 
2. The ability of the system to remain in the stomach depends on the patient`s posture, 
which need to be positioned upright(153). 
3. They need high level of fluids and continuous feeding to remain afloat over the    
stomach contents(158). 
1.4.7. Different manufacturing processes of FDDS (153): 
  Direct compression: 1.4.7.1.
This procedure involves the compressing of tablets directly from the mixture of the 
components in the powder form. The vehicles that form the matrix must have good flow 
and compressibility properties. Direct compression is the most preferable technology due 
to the minimal number of manufacturing steps it requires, thus offering advantage in terms 
of speedy production.  
 Wet granulation: 1.4.7.2.
Wet granulation process involves wetting of the formula powders, granulating, drying and 
compression. Granules are formed by binding the powders together by addition of solution 
or suspension containing the binder or adding the binder to the dry powder mixture and the 
liquid then added by itself. The result mass should be moist rather than wet or pasty, and 
solvent that is used should have a limited quantity. Once the granulating liquid has been 
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added mixing continues until a uniform dispersion is attained and all the binder has been 
activated. Then the wet mass is granulated by sieving. The wet granules undergo drying, 
after completion of the drying; lubricant is blended (in case of tablets) with dried granules 
and finally compressed. 
  Dry granulation: 1.4.7.3.
This process is used to form granules without using a liquid solution in case that the drug 
granulated may be sensitive to moisture and heat. This process requires compacting of the 
powders as one bulk under high pressure instead of wetting, then dry granulation with no 
need for drying.  
  Melt granulation. 1.4.7.4.
This process involves the agglomeration of the formula powders within melt-able material 
when it is in the molten state. Then cooling of the resultant agglomerate takes place with 
granulation process. Both the agglomeration and granulation accomplished in high shear 
mixer equipment supplied with a jacketed bowl. The process is less time consuming and 
uses less energy. 
 Spray drying: 1.4.7.5.
It involves dispersing of the formula components in a liquefied coating material, then 
spraying this mixture into a drying chamber and mixing it with a heated gas to rapidly 
evaporate the solvent from the coating material and cause solidification to the mixture.  
Spray drying process has good control on the resultant powder properties such as density, 
particle size, flow properties and moisture content. 
 Ionotropic gelation technique: 1.4.7.6.
Ionotropic gelation is based on the ability of polyelectrolytes to cross link in the presence 
of counter ions to form hydrogel beads (gelispheres). Gelispheres are spherical crosslinked 
hydrophilic polymeric entity capable of extensive gelation and swelling in simulated 
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biological fluids and the release of drug through it controlled by polymer relaxation. The 
hydrogel beads are produced by dropping a drug-loaded polymeric solution into the 
aqueous solution of polyvalent cations. The cations diffuses into the drug-loaded polymeric 
drops, forming a three dimensional lattice of ionically crosslinked moiety. Biomolecules 
can also be loaded into these gelispheres under mild conditions to retain their three 
dimensional structure(159). 
1.5. Quality control of floating gastroretentive tablets: 
In-vitro evaluation of physical and chemical properties is important in controlling the 
quality of any dosage form. The most important parameters for evaluation of floating 
gastroretentive tablets that has to be tested are described in details in methodology, section 
5.2.  
1.6. Kinetic mathematical models of drug dissolution/release: 
1.6.1. Overview  
Drug release/dissolution from a solid dosage forms is necessary to ensure that drug 
dissolution occurs in an appropriate manner and in vitro dissolution has been recognized as 
an important element in drug development. Recently both the industry and the health 
authorities focus on drug dissolution studies which could be used as a surrogate for the 
Bio- equivalence studies. The quantitative analysis of the values obtained in the 
dissolution/release tests is easier when using mathematical models that express the 
dissolution results as characteristic functions of some of the dosage forms. Hence, the use 
of mathematical models is useful in the prediction of release kinetics and enables the 
measurement of some important physical parameters, such as the type of drug diffusion 
and resorting to model fitting on experimental release data. The principle for evaluation of 
the kinetics of drug release was offered by Noyes and Whitney in 1897  (160).  Nowadays 
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there are several kinetic models describing the drug release from solid dosage forms in 
which the dissolved amount of drug (Q) is a function of the test time (t) or Q = f(t) 
The quantitative interpretation of the values obtained in the dissolution assay is facilitated 
by the usage of generic equations that mathematically translates the dissolution curve in 
function of some parameters related with the pharmaceutical dosage forms(161). 
The drug polymorphic form, crystalinity, particle size, solubility and its amount in the 
pharmaceutical dosage form can inﬂuence the kinetics of the release(162). A water-soluble 
drug incorporated in a matrix is mainly released by diffusion, while for a low water-soluble 
drug the self-erosion of the matrix will be the principal release mechanism. To compare 
dissolution proﬁles between two drug products model dependent (curve ﬁtting), statistical 
analysis and model independent methods can be used(161). 
Mathematical models have been used extensively for the parametric representation of drug 
release kinetics from formulations. Models that have been used include the zero order, first 
order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell (161). 
1.6.2. Objectives of kinetic of mathematical modeling (161), (160) 
The major objectives of mathematical modeling are  listed below:  
1.  Designing the new drug delivery system based on general release expression.  
2.  Prediction of the exact drug release rates and drug release behavior through the matrix, 
thus avoid excessive experimentation.  
3.  Optimization of the drug formulations. 
4.  Elucidation of the physical mechanism of drug transport by simply comparing the 
release data to mathematical models. 
5. Compare the release profiles between two drugs. 
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1.6.3. Kinetic of mathematical models for slow release dosage forms. 
  Zero order model 1.6.3.1.
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and release 
the drug slowly (assuming that area does not change and no equilibrium conditions are 
obtained) can be represented by the following equation:  
                                          Qt = Q0 + K0 t  
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution and K is the zero order release constant(163).  
Application: This model can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms. (E.g. transdermal systems, matrix tablets 
with low soluble drugs in coated forms, osmotic systems, etc.) (164). 
  First order model 1.6.3.2.
This model was first proposed by Gibald & Feldman (1967) later by Wagner (1969). The 
pharmaceutical dosage forms containing water-soluble drugs in porous matrices follow 
first order release kinetics, and can be expressed by the equation: 
                                                     Qt = Q0      
Where Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the 
solution and k is the 1st order release constant. The above equation in decimal logarithm 
will take the form, 
                                             ln Qt = ln Q0 + kt   
This equation implies that a graphic of the decimal logarithm of the amount of drug versus 
time will be linear. The dosage forms that follow this dissolution profile release the drug in 
a way that is proportional to the amount remaining in the interior of the dosage form, in 
such a way that the amount of drug released by unit of time diminishes. Thus any system 
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obeying this model releases the drug in such a way that the remaining amount in the 
system governs the rate of release of drugs (161). 
Application: This relationship can be used to describe the drug dissolution in 
pharmaceutical dosage forms such as those containing water-soluble drugs in porous 
matrices(165). 
  Higuchi Model. 1.6.3.3.
In 1961 Higuchi introduced the most famous and often used mathematical equation to 
describe the release rate of drugs from matrix system initially; it was valid only for planar 
systems(166). It was later modified and extended to consider different Geometries and 
matrix characteristics including porous structure (167). Higuchi developed an equation for 
the release of a drug from an ointment base and later applied it to diffusion of solid drugs 
dispersed in homogeneous and granular matrix dosage system. In this model, it is assumed 
that solid drug dissolves from the surface layer of the device first; when this layer becomes 
exhausted of drug, the next layer begins to be depleted by dissolution through the matrix to 
the external solution. In this way the interface between the regions containing dissolved 
drug and that containing dispersed drug moves into the interior as a front(161).  In a 
general way it is possible to resume the Higuchi model to the following expression 
(generally known as the simpliﬁed Higuchi model): 
                                             Qt = KHt
0.5
 
 
Where, KH is the Higuchi dissolution constant. Higuchi describes drug release as a 
diffusion process based on the Fick‘s law, square root time dependent. 
Application: This relationship can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems and matrix tablets with water soluble drugs(166). 
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 Korsmeyer- Peppas Model (The Power Law) 1.6.3.4.
Power law equation is more comprehensive very simple and semi-empirical equation 
developed by Korsmeyer- Peppas which can be used to analyze data of drug release from 
polymers. The equation implies that; the fractional release of drug is exponentially related 
to release time(162). 
                                                          
Where, Mt & M∞ are the absolute cumulative amounts of drug released at time t and 
infinity respectively, k is a constant incorporating structural and geometrical characteristics 
of the device, the k value is experimentally determined, and n is the exponent, indicative of 
the mechanism of drug release. The numerical value of the release exponent, n, is 
characteristic of the mechanism of diffusion release from delivery system. Peppas used the 
n value to characterize different release mechanisms from polymeric systems, and the data 
are summarized in Table (1.5).  
A value of n = 1,however, means that the drug release is independent of time, regardless of 
the geometry. Thus, zero-order release can exist for any geometry; only for slabs does this 
release coincidered with Case-II transport. 
Table 1.5:  Exponent (n) of the power law and drug release mechanism from polymeric 
controlled delivery systems of cylindrical and spherical geometry(168).  
Exponent, n 
Thin Film                Cylinder                         Sphere                              Drug Release 
Mechanism 
0.5                            0.45                                0.43                                 Fickian diffusion 
0.5<n<1.0                0.45<n<0.89                  0.43<n<0.85                   Anomalous transport 
1.0                                0.89                                0.85                             Case II transport                             
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When the release mechanism is not well known or when more than one type of release 
phenomena could be involved, this model can be used to analyze the release of poly-metric 
dosage form. This equation was later modified to accommodate the lag time (L) in the 
beginning of the drug release from the pharmaceutical dosage form(169): 
                                                  
And when there is possibility of burst effect(170) (b), 
                                               
Whenever there is absence of lag time and burst effect L and b value would be zero and 
only Kt
n
 is used. This mathematical model has been frequently used to describe the drug 
release from different modified release dosage forms(161). 
 Hixson-Crowell model 1.6.3.5.
Hixson and Crowell (1931) recognized that the release of drug from particles with regular 
area is proportional to the cube root of its volume. They derived the equation:  
                              
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the 
remaining amount of drug in the pharmaceutical dosage form at time t and κ (kappa) is a 
constant incorporating the surface-volume relation. The equation describes the release from 
systems where there is a change in surface area and diameter of particles or tablets(171). 
Application: This model applies to pharmaceutical dosage form such as tablets, where the 
dissolution occurs in planes that are parallel to the drug surface if the tablet dimensions 
  
52 
diminish proportionally, in such a manner that the initial geometrical form keeps constant 
all the time(172). 
1.6.4. Selection of the Best Model 
The selection of the appropriate model in the drug release studies is critical to ensure the 
effectiveness of the study.  There are various criteria for the selection of the mathematical 
models which are based on the statistical treatments. The most widely used method 
employs the coefficient of determination, R
2
, to assess the fit of the model equation. This 
method can be used when the parameters of the model equations are similar. But when the 
parameters of the comparing equations increased; a modification is incorporated in this 
technique where an adjusted coefficient of determination (R
2
 adjusted) given by:   
                                   
Where (n) is the number of dissolution data points and (p) is the number of parameters in 
the model. Hence, the best model is the one with the highest adjusted coefficient of 
determination. A value for R
2
 adjusted > 0.950 is considered acceptable for the purposes of 
comparison of modeling dissolution profiles generated(161). 
Similarly other statistical tools like correlation coefficient (R), Analysis of Variance 
(ANOVA) and Multivariate analysis of variance (MANOVA) are used for the comparison 
and selection of the models(161). 
1.7. Background Information for the drugs of choice: 
1.7.1. Clarithromycin (CLA): 
  Description (173): 1.7.1.1.
 Molecular formula: C38H69NO13  
 Molecular weight: 747.95 
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 CAS: 81103-11-9 
 Chemical structure:  
 
 IUPAC Name: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{(2S,3R,4S,6R)-4-
(dimethylamino)-3-hydroxy-6-methyloxan-2-yl}oxy-14-ethyl-12,13-dihydroxy-4-
{(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl}oxy-7-methoxy-
3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione. 
 
 Content: Clarithromycin contains NLT 96.0% and NMT 102.0% of clarithromycin 
(C38H69NO13), calculated on the anhydrous basis.  
 General properties: 1.7.1.2.
 Appearance: White to off-white, crystalline powder(173). 
 Solubility: Soluble in acetone; slightly soluble in dehydrated alcohol, in methanol, and 
in acetonitrile, and in phosphate buffer at pH values of 2 to 5; practically insoluble in 
water (0.33 mg/L) (173). 
 log P:  3.16 (14)                
  pKa: 8.99     at 25 oC (14)       
 Stability :Clarithromycin is stable in aqueous solutions of pH (5.0-8.0) (174). 
  Pharmacodynamics  (175),(176),(177). 1.7.1.3.
 Pharmacological-therapeutical group: ATC code J01F A09  
 Clarithromycin is a macrolide antibiotic, semi-synthetic derivative of erythromycin.  
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 Mechanism of action:  
Clarithromycin binds to the 50s ribosomal sub-unit of susceptible bacteria and 
suppresses protein synthesis. It is highly potent against a wide variety of aerobic and 
anaerobic gram-positive and gram-negative organisms. The 14-hydroxy metabolite of 
clarithromycin also has antimicrobial activity, its MICs equal or two-fold higher than 
the MICs of the parent compound. 
  Pharmacokinetic (175),(176),(177): 1.7.1.4.
 Clarithromycin is rapidly absorbed from the gastrointestinal tract, mainly in the 
jejunum. 
 The bioavailability of the parent drug is about 55%. 
  Peak plasma concentration occurs 2 to 3 hours after an oral dose. 
 The extent of absorption is relatively unaffected by the presence of food. 
 Clarithromycin distribution levels in the tissues are several times higher than the 
circulating drug levels since it has good penetration into different compartments. 
Clarithromycin is 80 % bound to plasma proteins at therapeutic levels. 
 Clarithromycin is rapidly and extensively metabolized in the liver.  
 Elimination half-life is 3 to 4 hours for 250mg and 5-6 hours for 500mg dose. 
 Clarithromycin PK is non-linear. 
 Clinical uses and indications,(175),(176),(177). 1.7.1.5.
 Acute bacterial exacerbation of chronic bronchitis. 
  Mild to moderate community acquired pneumonia.  
  Acute bacterial sinusitis. 
 Bacterial pharyngitis. 
 Skin infections and soft tissue infections of mild to moderate severity.  
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 Clarithromycin used in appropriate combination with antibacterial therapeutic regimens 
and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in 
patients with Helicobacter pylori associated ulcers. 
  Special considerations 1.7.1.6.
 Clarithromycin can  penetrate the gastric mucus(175). 
 In gastric juice samples of pH 2.0, clarithromycin degradation half-live is1.0 +/- 0.04 h. 
The co-administration of omeprazole with clarithromycin is likely to increase its 
chemical stability in gastric juice (174). 
 The eradication of H. pylori needs a high concentration of clarithromycin in the 
stomach to  ensure effective localized treatment for the pathogen (100) 
 Clarithromycin was the most commonly used single potent antibiotic in anti-
helicobacter treatment and penetration through gastric mucus at a 9-folds higher than 
amoxicillin and 48-folds higher rate than tetracycline(178). 
1.7.2. Metronidazole (MTZ): 
  Description (173): 1.7.2.1.
 Molecular formula: C6H9N3O3   
 Molecular weight: 171.15  
 CAS : 443-48-1 
 Chemical structure:  
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 IUPAC Name: 1H -Imidazole-1-ethanol, 2-methyl-5-nitro-;   
                         2-Methyl-5-nitroimidazole-1-ethanol    
                        2-(2-methyl-5-nitroimidazol-1-yl) ethanol 
 Content: Metronidazole contains NLT 99.0% and NMT 101.0% of metronidazole 
(C6H9N3O3), calculated on the dried basis. 
 
 General properties: 1.7.2.2.
 Appearance: White to pale yellow, odorless crystals or crystalline powder (173). 
 Solubility: Soluble in dilute hydrochloric acid (1 in 2); sparingly soluble in water and 
in alcohol; slightly soluble in ether and in chloroform.  (173). 
Solubility g/100 ml at 20 °C: 1.0 in water, 0.5 in ethanol, less than 0.05 in ether, 
chloroform; soluble in dilute acids; sparingly soluble in dimethylformamide (14). 
 pH : of saturated aqueous  solution is 5.8 (14). 
 PKa: 2.38  (14). 
 log P : - 0.02 (14). 
 Stability: Is stable in air, but darkens on exposure to light(173). 
              It is stable in aqueous solutions of pH 2.0-7.0 
  Pharmacodynamics  (175),(176),(177). 1.7.2.3.
 Pharmacological-therapeutical group: J01XD01. 
 Metronidazole is a 5-nitroimidazole derivative with has activity against both anaerobic 
bacteria and protozoa 
 Mechanism of action:  
Its mechanism of action is thought to involve interference with DNA by a metabolite in 
which the nitro group of metronidazole has been reduced. 
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  Pharmacokinetic (175),(176),(177). 1.7.2.4.
 Metronidazole is readily and almost completely absorbed (>80%) after oral doses. 
  Peak plasma concentration occurs 1 to 2 hours after an oral dose. 
 The absorption is relatively unaffected by the presence of food. 
 Less than 20% of the circulating metronidazole is bound to plasma proteins. 
Metronidazole appears in cerebrospinal fluid, saliva, and human milk in concentrations 
similar to those found in plasma. 
 The major route of elimination of metronidazole and its metabolites is via the urine (60 
to 80% of the dose). 
 Elimination half-life is 8.5 ± 2.9 hours. 
  Clinical uses and indications,(175),(176),(177). 1.7.2.5.
 The prevention and treatment of post-operative infections due to anaerobic bacteria, 
(i.e. septicaemia, bacteraemia, peritonitis, etc.). 
 Urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. 
 All forms of amoebiasis. 
 Giardiasis. 
 Acute ulcerative gingivitis. 
 Acute dental infections (e.g. acute pericoronitis and acute apical infections). 
 Eradicate of Helicobacter pylori in peptic ulcer disease (with other antimicrobials, and 
either bismuth compounds or proton pump inhibitors). 
 Special considerations. 1.7.2.6.
Metronidazole is bactericidal at low concentrations (0.78–6.25 µg/ml) for most 
anaerobes(179). 
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1.7.3. Esomeprazole (EZO):  
  Description (173): 1.7.3.1.
 Molecular formula:  C34H36MgN6O6S2  (anhydrous). 
                                 C34H36MgN6O6S2 · 3H2O (trihydrate). 
 Molecular weight: 713.12  g/mole (anhydrous) 
                              767.17 g/mole (trihydrate) 
 CAS : 217087-09-7 
 Chemical structure:             
 
                  
 IUPAC Name: 1H -Benzimidazole,5-methoxy-2-{(S)-{(4-methoxy-3,5-dimethyl-2-
pyridinyl)methy}lsulfinyl}, magnesium salt (2:1), trihydrate;      
5-Methoxy-2-{(S)-{(4-methoxy-3,5-dimethyl-2-
pyridyl)methyl}sulfinyl}benzimidazole, magnesium salt (2:1), trihydrate .     
 Content: Esomeprazole Magnesium contains NLT 98.0% and NMT 102.0% of 
C34H36MgN6O6S2 , calculated on the anhydrous basis 
  General properties: 1.7.3.2.
 Appearance: White to slightly colored powder. (173). 
 Solubility:  Soluble in methanol;  very slightly soluble in water; practically insoluble in 
heptane.(173).  
 It is a weak base. 
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 log P: 0.6 (14). 
 Stability: It is light sensitive, should be protected from light(173).Also it is acid 
labile(175). 
  Pharmacodynamics  (175),(176),(177). 1.7.3.3.
 Pharmacological-therapeutical group: (ATC code: A02B C05) 
It is a proton pump inhibitors (S-isomer of omeprazole). 
 Mechanism of action: Esomeprazole specifically inhibits the proton pump (H+ /K+ -
ATPase) in the gastric parietal cells, and thus inhibits acid secretion and decreases both 
basal and stimulated acid secretion. 
  Pharmacokinetic (175),(176),(177): 1.7.3.4.
 Esomeprazole is rapidly absorbed after oral doses. 
(Food delays and decreases its absorption, but this does not significantly change its 
therapeutic effect). 
  The peak plasma levels occur after 1 to 2 hours. 
 The absolute bioavailability is 64% after a single dose of 40 mg and 50% for 20 mg 
and it increases with repeated doses. 
 With repeated dosage, there is a decrease in first-pass metabolism and systemic 
clearance.  
 Esomeprazole is 97 % plasma protein bound. 
 Esomeprazole is completely metabolized in the liver (mainly by CYP2C19). 
 Elimination half-life is about 1.3 hours.  
 The mean steady state AUC and Cmax of both esomeprazole & clarithromycin increase 
in case of co-administration. 
 The PK of esomeprazole is dose-dependent (non-linear). 
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 Clinical uses and indications,(175),(176),(177). 1.7.3.5.
 Gastroesophageal Reflux Disease (GORD) 
 In combination with appropriate antibacterial therapeutic regimens for the eradication 
of Helicobacter pylori and healing of Helicobacter pylori associated duodenal ulcer and 
prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated 
ulcers. 
 Patients requiring continued NSAID therapy (for prevention of gastric and duodenal 
ulcers associated with NSAID therapy, in patients at risk). 
 Treatment of Zollinger Ellison Syndrome. 
 Special considerations 1.7.3.6.
 The chemical stability of the clarithromycin and amoxicillin has been approved to be 
increased when co-administered with PPI, thus their degradation half-lives will 
increased and will maintain them within the effective antibacterial concentration in the 
stomach(180), this could be justified by the median gastric pH which is maintained ˃4 
(4±0.8 ) for 14 h after treatment with 40mg daily of EZO(181).  
 After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within 
one hour(175). 
 Esomeprazole is the (S)-isomer of the proton pump inhibitor (PPI) omeprazole. 
esomeprazole and omeprazole have the same mechanism of action and are subjected to 
the same metabolic transformations with less first pass metabolism for esomeprazole 
resulting in a higher area under the concentration-time curve (AUC) after 
administration of the same dose(182). Esomeprazole has been clinically studied versus 
omeprazole for a variety of acid-related conditions, showing that the compound is as 
well tolerated and more effective with regard to healing and symptom relief than the 
recommended treatment with omeprazole(183). Esomeprazole provided better control 
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of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted 
in patients with gastro-oesophageal reflux disease (GORD) or healthy volunteers(184). 
these reasons let us chose esomeprazole instead of omeprazole in our research as a 
component of the 1
st
 line therapy for the treatment of H.pylori induced ulcers. 
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 After more than30 years of discovering H. pylori, clinicians and researchers are still 
exploring the ideal treatment with the ideal dosage form for eradication of this pathogen. 
Recent researches have focused on the gastroretentive drug delivery systems as novel 
approaches to increase the eradication of H. pylori which colonize the stomach, in order to 
release drugs as long as possible in the ecological niche of the bacterium and hence 
increasing eradication (100). 
 Recently, GRDDS for treating H. pylori infection and H. pylori associated peptic ulcer 
have shown special importance and interest, as the prolongation of the local availability of 
the antibacterial agents within the stomach has been reported to be an important factor in 
increasing the eradication of H. pylori(185). Here we will focus on the works done on the 
first line therapy drugs:  
 1994-Dettmar and Lloyd-Jones(186) 
A patent raft-forming formulation using triclosan was developed. The drug was mixed with 
alginic acid, sodium bicarbonate, calcium carbonate and mannitol. The mixture was 
granulated, citric acid added, and then packed into sachets or compressed to tablets. In 
contact with the stomach acidic media, CO2   bubbles were produced, within the raft 
structure formed by the alginates, causing it to float. 
 1998- Libo Yanga, Jamshid Eshraghib, Reza Fassihia (187). 
Developed an intragastric delivery system based on a swellable asymmetric triple layer 
tablet, incorporating the triple drug therapy (tetracycline, metronidazole and bismuth 
salt). The first layer contained the gas generating material, the second layer contained 
both antibiotics in a SR-matrix (main polymers were Hydroxypropylmethylcellulose-K4 
and polyethylene oxide) and the third layer was rapid dissolving contained the bismuth 
salt. This system was manufactured by ―direct compression technique‖. 
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The in-vitro results showed that, the lag floating time was in the range of 17–28 min, the 
rapidly dissolving layer disappeared after 30 min during dissolution, and both drugs 
were able to be delivered at constant rates up to 90% of the total loading dose within 8 
h.  
 Main drawback of this system is the long floating lag time. 
            
 2007-Rania A.H. Ishak, Gehanne A.S. Awad, Nahed D. Mortada, Samia A.K. 
Nour(185). 
 Developed metronidazole-loaded alginate beads, chitosan- alginate based beads (with 
different polymers, methyl cellulose, carbopol 934P and κ-carrageenan incorporated) 
using ―the ionotropic gelation technique” in the manufacturing process. 
The in vitro studied showed that the beads have immediate floating, good entrapment 
efficiency (about 89%) and acceptable release and good SR of the drug (100% drug 
release after 4 h). 
The in vivo H. pylori eradication tests showed that MTZ floating beads with a dose of 
15 mg/kg provided 100% eradication rate whereas the MTZ oral suspension with a dose 
of 20 mg/kg gave only 33.33% eradication rate. 
 Main drawback of this system is the rapid release time. 
 
 2008-Muralidhar Nama, Chandra Sekhar Rao Gonugunta, and Prabhakar Reddy 
Veerareddy(188) 
A hydrodynamically balanced system of Clarithromycin (CLA) was developed, using 
―Wet granulation technique‖.  Different polymers were used in the SR matrix 
(Carbopol 934P, HPMC K4M, Xanthan gum, HPC-LF and sodium alginate), but 
desired properties achieved for with the formula having 12% HPMC K4M polymer and 
8% sodium bicarbonate. The floating lag time was less than 3 min with a floating time 
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of 12 h, and an in vitro release profile very near to the desired release (100% within 
12h).. 
 
 2011- Juárez-Soberanez ,Villafuerte-Robles,(189) 
Metronidazole‐Gelucire 39/01 (wax matrix) granules and tablets were prepared by 
―melt granulation technique‖, alone and after addition of HPMC-K15M or sodium 
cross‐linked carboxymethylcellulose (Carmacel). Addition of Carmacel and HPMC-K4 
enhances the drug release but Carmacel formulations have no floating. The single‐unit 
systems (tablets) gave more gradual drug release than granules (both give 100% within 
3h), and the total floating time was 6h for the tablets while was 3h only for the 
granules. Gelucire 39/01, can be used as a matrix for floating drug delivery systems 
only when mixed with dissolution enhancers to increase the permeability of the 
impermeable wax matrix. 
 2013- ANILKUMAR (Ph. D Thesis) (190). 
He developed floating Chitosan microparticles containing Clarithromycin by a ―capillary 
extrusion procedure” and Eudragit coated Pantoprazole alginate beads by ―ionotropic 
gelation method”. Other polymers used (Pectin (low methoxy). 
The in vitro studies conducted on the clarithromycin loaded chitosan formulations proved 
that it has a potential as a floating delivery system. The best floating of clarithromycin 
formulation in-vitro was that 55.6% of the beads floated for 8 hours. This has been proved 
in situ where 45.40 % of the floating beads retained in the stomach at the end of 4 h. 
 The in vivo and in situ animal studies have shown an enhanced gastric mucosal and 
plasma concentration of clarithromycin in the presence of enteric coated pantoprazole 
formulations. 
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 2014-Porntip Pan-Ina, Wijit Banlunarab, Nuntaree Chaichanawongsarojc, Supason 
Wanichwecharungruang(191). 
Clarithromycin-loaded EC nanoparticles were developed using ―anti-solvent particle 
induction method” that gave submicron-sized semi-spherical particles (223 ± 50 nm) with 
EE (entrapment efficiency) of 86 ± 0.5%and the clarithromycin loading of the particles was 
22.3 ± 0.17% weight by weight. In vivo studies showed that the efficiency of these 
particles on   H. pylori clearance in C57BL/6 mice infected with these bacteria was 
significantly improved although their MIC was greater than the free CLA. 
 
 2015- Nancy Abou Youssef , Abeer Kassem , Magda EL-Massik a, Nabila 
Boraie(192) 
Gastroretentive floating raft system of metronidazole was developed, using ion-sensitive, 
in-situ gel forming polymers and gas generating agents (i.e. sodium alginate, gellan gum, 
sodium citrate and calcium carbonate, glyceryl mono stearate).  The final system is a liquid 
dispersion with in situ gelling and floating properties. 
The best formula exhibited short gelation lag time (3 s), long duration (>24 h), floating lag 
time 1 min and duration >24 h, and sustained drug release with mean dissolution time of ˜6 
h. 
 2015-Alessandra Rossi, Chiara Conti, Gaia Colombo, Luca Castrati, Carmelo 
Scarpignato, Pedro Barata, G. Sandri, Carla Caramella, Bettini, Francesca Buttini 
& Paolo Colombo(193). 
Floating modular drug delivery systems of two antibiotics together (Amoxicillin and 
Clarithromycin) has been developed. The final dosage form consisted of three modules of 
clarithromycin and two of amoxicillin (each has100mg of the antibiotic). Clarithromycin 
modules were prepared by wet granulation technique with HPMC-K15 as a matrix, while 
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Amoxicillin modules were prepared by direct compression technique. The modules were 
compressed in different geometrical shapes and then manually attached to each other to 
form one system. The assembled system floated immediately in vitro for more than 5 h. 
The floating mechanism is determined by the internal void of the assembly system. 
The drugs release profiles from individual modules and assembled systems exhibited 
quasi-linear release rate (erosive release mechanism) during buoyancy and about 80% of 
drugs were released within 4-6h. The predicted simulated drug Intra-gastric concentrations 
over time were higher than the MIC values of both antibiotics. An experiment in dogs 
showed prolonged plasma concentrations of clarithromycin and amoxicillin.  
 Main drawback: The high doses of antibiotics required in therapy, restricted the 
formulation design, due to its limited drug loading capacity. 
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Part three 
3. Problem statement
69 
 The objective an optimal H. pylori treatment is the complete eradication of the bacteria
from its colonization site. It is well known that the ecological niche of H. pylori is the 
human stomach, where it colonizes for long periods within the gastric mucosa. Hence, for 
effective H. pylori eradication, therapeutic agents have to penetrate the gastric mucus layer 
to disrupt and inhibit the mechanism of colonization (10). 
 Until today, the available DDS for H. pylori infection have many problems, and the
major problem associated with the first line therapy for treatment of H. pylori is the 
incomplete eradication achieved from the conventional dosage forms available (42). 
 Conventional drug delivery systems including immediate release (IR) and sustained
release (SR) do not remain in the stomach for prolonged periods; they are unable to deliver 
the antibiotics to the site of infection in effective concentrations and in fully active forms. 
It was proved that the absorption of antibiotics into the epithelial cells through the mucus 
layer (from the gastric lumen) is believed to be more effective for H. pylori eradication 
than absorption through the basolateral membrane, i.e. from blood(194, 195). 
 The conventional (IR) dosage forms of the therapies available for H. pylori eradication,
typically, possess several disadvantages that lead to incomplete eradication (196),(197), 
(198): 
 Poor patient compliance due to the large doses needed to be administered multiple
times daily. 
 Incomplete and non-uniform drug absorption profiles at the site of infection.
 The residence time of antimicrobial agents in the stomach is so short that effective
antimicrobial concentrations cannot be maintained for prolonged time in the gastric 
mucous layer or epithelial cell surfaces where H. pylori exists 
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 Large amounts of excipients incorporated with the large daily doses will increase
their associated side effects. 
 Sustained release (SR) dosage forms have no remarkable benefit in efficacy over the
conventional immediate release dosage forms due to the following reasons(199),(197) : 
 Their variable and short gastric residence time at site of infection.
 Incomplete drug release at the targeted site.
 They extend the time for the drug release along GIT and thus increase the absorption
to the  plasma of some antibiotics, while the absorption of antibiotics into the mucus 
through the mucus layer (from the gastric lumen) is approved to be more effective for 
H. pylori eradication than absorption through the basolateral membrane (i.e. from 
blood). 
 As a result, eradication of H. pylori with conventional systems (IR, SR and CR) may
fail due to their systemic effect all over the gastro intestinal tract and not focusing in the  
gastric region (200). So a logical way to improve the effectiveness of these therapies was 
to develop a dosage forms that maintains in the stomach for a sufficient time and deliver 
and sustain a continuous effective dose of the drug over an extended period of time in the 
ecological niche of the bacterium, and thus enhance a successful treatment for H. pylori 
infection, such systems have been known as gastro-retentive drug delivery systems (93), 
(100). 
 Since two decades, lot of work has been done targeting H. pylori therapeutic agents
based on gastro-retentive mechanism , to minimize the drawbacks associated with the 
existing conventional dosage forms, and to optimize the therapy efficacy and enhance the 
patient compliance (201), (201), different gastroretentive techniques have been applied and 
developed, different manufacturing procedures were used, single and combination of drugs 
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were incorporated ,  but: Until today NO work has been done that combines a full 
regimen`s drugs for H. pylori eradication in one single dosage form. 
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Part Four. 
4. Objectives
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4.1. General objectives: 
  Develop a single dosage form (tablet-FDDS) that combines the first line triple therapy`s 
drugs for H. pylori eradication and treatment of associated peptic ulcer (Esomeprazole, 
Metronidazole and Clarithromycin). 
 To retain the tablet in the gastric region for longer time based on buoyancy principle. 
 Enhance the chemical stability of CLA by decreasing the degradation in the acidic 
environment by concomitant administration with the PPI which will increase the pH . 
 Increase the local eradication of H. pylori by increasing the residence time of the active-
stable antibiotics within their site of action (the colonization site of bacteria), thus the 
antibiotic concentrations in the stomach maintained for long time higher than their 
minimum inhibitory concentrations (MIC), (i.e. it has been approved that  60-70%  of the 
oral dose in the gastric region was found to be distributed in the mucosal layer, mainly in 
the mucous layer and in surface epithelial cells following oral administration(202). Thus 
increasing the residence time in the stomach will increase the conc. At the site of action 
and improve eradication). 
 Decrease the number of tablets to be administered each time, by incorporation the 
different drugs in one tablet. 
 Increase the dosing interval (decrease the frequency of dosing) by the sustained release 
of these dosage forms. 
 Minimizing the daily intake of the antibiotics and hence, decreasing their associated side 
effects. 
 Enhance the patient compliance. 
 Decrease the cost of manufacturing of the triple therapy on industrial scales. 
 Decrease the cost of the treatment on the patient.            
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4.2. Specific Objective 
1) To develop a method for concurrent analysis of both antibiotics in the SR-layer 
(Metronidazole and Clarithromycin) by HPLC for assay and dissolution. 
  Note: follow the USP-36 method of analysis for the assay and dissolution of 
Esomeprazole. 
2) To validate the new method of analysis according to International Conference of 
Harmonization (ICH) guidelines for Validation Q2 (R1). 
3) To develop/formulate a floating bilayer tablet (contains: 300mg Metronidazole, 
250mg Clarithromycin and 20 mg Esomeprazole), with different release mechanism 
layers (rapidly dissolving layer (RDL) of Esomeprazole and sustained release layer 
of Metronidazole and Clarithromycin) and acceptable size for oral administration. 
4) To optimize the amounts of excipients and different types and grades of polymers to 
achieve the desired properties (Quick separation of layers, good floating properties, 
good  matrix of the SR layer with sustained-synchronous release of both antibiotics. 
5) To choose appropriate dissolution media. 
6) To perform quality control testing for the tablets (physical & chemical tests). 
7) To analyze the drug release data and test the kinetics of drug release using the 
kinetic mathematical models for slow release dosage forms using DDSOLVER. 
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Part Five 
 
5. Methodology 
(Experimental part) 
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5.1.  Materials and reagents: 
5.1.1. Materials and reagents used in the analytical parts: 
(All were supplied by Central Public Health Laboratory- Palestinian MOH). 
Clarithromycin reference standard (CLA-RS), Metronidazole reference standard (MTZ-
RS), Potassium di-Hydrogen Phosphate, Phosphoric Acid, Distilled water (HPLC-grade 
water), Methanol (HPLC Grade), Hydrochloric acid (concentrate), Sodium hydroxide, 
Acetonitrile (HPLC-grade), Sodium acetate anhydrous, Glacial acetic acid, Phosphoric 
Acid, Mono Potassium Phosphate, Dibasic sodium phosphate, Tribasic sodium phosphate 
dodecahydrate, Omeprazole reference standard, 
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5.1.2. Materials used in the formulations: 
    Table 5.1: Materials used in the formulations: 
Item Manufacturer Donated by 
Metronidazole (MTZ) Alembic, India Bir Zeit Pharm. Co 
Clarithromycin (CLA) Arti Drugs Limited, India 
Bir Zeit Pharm. Co 
Pharmacare Pharm. Co 
Esomeprazole enteric coated pellets 
Glukem Pharmaceuticals 
Ltd, India 
Bir Zeit Pharm. Co 
       Pharmacare Pharm. Co 
Ethyl Cellulose (EC) Ashland, Japan Bir Zeit Pharm. Co 
Avicel PH102 FMC Biopolymer, Irland Bir Zeit Pharm. Co 
Sodium bicarbonate (NaHCO3), Merck Milpore, Germany Bir Zeit Pharm. Co 
Citric Acid TTCA Ltd. China  Bir Zeit Pharm. Co 
Aerosil (silicone dioxide) Evonik Industries, Germany Bir Zeit Pharm. Co 
Lactose DFE Pharma. Germany Bir Zeit Pharm. Co 
Polyvinylpyrrolidone K 30 
Jiaozou Zhongwei special 
peoducts Pharm. Co Ltd, 
china 
Bir Zeit Pharm. Co 
Magnesium stearate (Mg-stearate) Magnesia, Germany Bir Zeit Pharm. Co 
Hydroxypropylmethyl cellulose-K4M 
(HPMC-K4M) 
Orison Chemicals Limited, 
China 
Bir Zeit Pharm. Co 
Hydroxypropylmethyl cellulose-K15M 
(HPMC-K15M) 
Orison Chemicals Limited, 
China 
Bir Zeit Pharm. Co 
Hydroxypropylmethyl cellulose (HPMC-
K100). 
Shin-etsu, Japan Bir Zeit Pharm. Co 
 
      
5.1.3. Tools, instruments and equipments used in the analytical parts: 
     (All were supplied by Central Public Health Laboratory-Palestinian MOH). 
1) Disposables: Syringes, HPLC-vials, filters (Nylon membrane -0.45µm and Cellulose 
ester filters- 0.45 µm), pipettes, plastic cups.  
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2) Glassware: Volumetric flasks, volumetric pipettes, graduated measuring Cylinders, 
beakers.  
3) Machinery: Analytical balance, Vortex (IKA Genius 3), Glass electrode pH meter, 
Sonicator, Hot-plate (710 R), UV double beam spectrophotmeter with scanner, HPLC-
Waters (e2695-Separation Module) equipped with photodiode array and UV detectors, 
Stationary phase: XBridge, C18 column-5µm (4.6*150mm) (It was supplied by Dr. 
Saleh Abu-Lafi), Hardness tester (Pharma Test-PTB), Friability tester (Pharma Test-
PH138), Dissolution apparatus (ERWEKA-DT700), Dissolution auto-sampler (Pharma 
Test-DT70).  
5.1.4. Tools, Instruments and equipment used in the formulation part:  
      (All were available in Al-Quds University labs). 
1) Disposables: plastic droppers, syringes, weighing papers, plastic cups, aluminum foil. 
2) Glassware: graduated cylinders, beakers. 
3) Others: pH-meter, Magnetic stirrors and sieves with different mesh numbers. 
4) Machinery: Oven (Reichenbacher-KOM 119676), MIXER (ERWEKA -AR402),  
IR-Disc compression machine (RERKIN ELMER), Slugging machine ( in Jerusalem 
pharmaceutical company). 
5.2. Development of analytical procedure for concurrent determination of CLA and 
MTZ (for assay and dissolution): 
5.2.1. Selection of suitable HPLC conditions and reagents: 
 Prior to optimizing the HPLC conditions, a suggested method based on the single 
USP-monographs of CLA and MTZ were primarily used, it was as follow: 
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 Buffer preparation: 
In order to prepare 1 Liter of 0.067 M   KH2PO4 buffer: 
 Dissolve 9.1 g of KH2PO4 in 1L of purified water. 
 Filter the buffer using 0.45 µm filters. 
 Degas the buffer using the Sonicator. 
 Three standards were prepared for analysis as described in each step below: 
 CLA-RS solution. 
 MTZ-RS solution. 
 Mixture of CLA and MTZ solution. 
 Selection of suitable wave-length for detection of both CLA and MTZ: 5.2.1.1.
 In this trial we aim to: 
 Select a single wavelength (λ) for detecting of both CLA and MTZ in single run of 
HPLC, this λ should have maximum absorbance of both two substances (C LA and 
MTZ). 
  Procedure: 
 Prepare two solutions, one of CLA by dissolving 27.8mg in 100ml mobile phase, and  
Mode LC 
Detector UV 
 
UV wavelength, nm 
210  and 
254 
Flow rate, ml/min 1.0 
Injection Volume 
(L) 
20 
Temperature 40 C1 
Mobile phase 
Methanol : Buffer 
 
60 : 40 
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another of MTZ by dissolving 33.3mg in 100ml mobile phase. 
 Prepare mixture solution of both of CLA and MTZ with the same previous 
concentrations. 
 Take 1ml of each solution and dilute to 25ml with the mobile phase. 
 Measure the absorbance using UV-spectrophotmeter. 
 Selection of HPLC-column: 5.2.1.2.
The selection of the column depends on the nature and the chemical structure of the 
substances to be analyzed. 
 Selection of suitable mobile phase (components and percentages), column 5.2.1.3.
temperature and flow-rate: 
Different mobile phases (components, percentages and programs), different column`s 
temperature and different flow-rates were applied in order to obtain peaks of both CLA and 
MTZ with the following properties: 
 Good shape (sharp peaks, symmetrical peaks). 
 Well separated from each other (avoid overlapping problem). 
 Away from the solvent peaks as much as possible.  
 Well defined retention times. 
Procedure: 
The following HPLC-settings were applied during development of the analytical method: 
 Isocratic mobile phase trials: 5.2.1.3.1.
Different conditions were applied by changing one variable each time,  using the isocratic 
mode, these trials were summarized in  Table 5.2. 
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 Gradient mobile phase trials: 5.2.1.3.2.
Different conditions were applied by changing one variable each time,  using the gradient 
mobile phase mode, these trials were summarized in  Table 5.3. 
Table 5.2: Modifications of isocratic program during HPLC-method development 
 
Trial 
No. 
     Mobile phase  
Buffer (KH2PO4) 
conc. (M) 
 
       
Injection V. 
       (µl) 
                  
Column Temp. 
      (ºC) 
 
Flow rate. 
(ml/min) 
 
Methanol % 
 
Buffer 
% 
1 80 20 0.067 20 40 1 
2 60 40 0.067 20 40 1 
3 60 40 0.067 (pH 4) 20 50 1 
4 60 40 0.067 (pH 4) 10 50 1 
 
Table 5.3: Modifications of gradient program during HPLC-method development 
 
Trial 
No. 
                                Mobile phase  
Buffer 
 conc.      
   (M) 
 
 
Injec. 
V. 
(µl) 
                  
Column 
Temp. 
  (ºC) 
 
Flow    
rate 
ml/min 
 
Methanol  
     % 
 
Buffer 
     % 
 
Acetonitrile 
    % 
 
Time intervals 
1 40»40»7
0»40 
60»60»30»60 ------- 0»2»6»7»10 0.02 10 50 1 
2 20»20»8
0»80»20
»20 
80»80»20»20»
80»80 
--------- 0»3»6»8»9»11 0.02 20 50 1 
3 20»20»8
0»80»20
»20 
80»80»20»20»
80»80 
------- 0»3»9»12»14»16 0.02 20 50 1 
4 20»20»6
0»60»20
»20 
80»80»40»40»
80»80 
------- 0»3»6»8»9»11 0.02 20 50 1 
5 20»20»8
0»80»20
»20 
80»80»20»20»
80»80 
------- 0»3»6»8»9»11 0.017 20 50 1 
6 20»20»8
0»80»20
»20 
80»80»20»20»
80»80 
------- 0»3»6»8»9»11 0.014 20 50 1 
7 20»20»8
0»80»20
»20 
80»80»20»20»
80»80 
------- 0»3»6»8»9»11 0.018 20 50 1 
8 10»10»7
0»70»10
»10 
90»90»30»30»
90»90 
-------- 0»3»6»8»9»12 0.017 20 50 1 
9 -------- 90»90»35»35»
90»90 
10»10»65»65»
10»10 
0»3»10»11»12»1
5 
0.017 20 50 1 
10 ------- 90»90»35»35»
90»90 
10»10»65»65»
10»10 
0»3»17»18»19»2
0 
0.017 20 50 1 
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5.2.2. Selection of suitable dissolution media: 
As recommended by USP-NF 36; 
Physical and chemical data for the drug substance and dosage unit need to be determined 
before selecting the dissolution medium. Two key properties of the drug are the solubility 
and solution state stability of the drug as a function of the pH value. When selecting the 
composition of the medium, the influence of buffers, pH value, and surfactants on the 
solubility and stability of the drug need to be evaluated. The dissolution characteristics of 
an oral formulation should be evaluated at different physiologic pH range. During method 
development, it may be useful to measure the pH before and after a run to discover whether 
the pH changes during the test. Selection of the most appropriate conditions for routine 
testing is then based on relevance to in vivo performance, where possible. 
Volume of dissolution media: 
Normally, for basket and paddle apparatus, the volume of the dissolution medium is 500 
mL to 1000 mL, with 900 mL as the most common volume.  
Procedure:  
1. To test the stability of CLA and MTZ in the dissolution media: 
Fresh standards solutions of both active ingredients were prepared, then the maximum dose 
of these drugs were dissolved in 900ml of the following different dissolution media at 
37ºC, left for at least for 3 hours, then samples were withdrawn and analyzed. The resultant 
peak response of each sample was compared to its freshly prepared standards. 
The following dissolution media were tested: 
 0.1 N HCl (pH=1.2). 
 0.1 N HCl (Adjust the pH with 1N NaOH to pH=4) 
 0.01 N HCl (adjust the pH by NaOH solution to pH=5). 
  0.1M sodium acetate media (adjusted the pH with glacial acetic acid to pH=4). 
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 0.1M sodium acetate media (adjust the pH with glacial acetic acid to pH=5). 
2. To test the solubility of the drugs in the selected media: 
 Dissolve the maximum amount of the drugs present in the dosage form (250mg CLA, 
300mg MTZ) in 200ml of the selected dissolution media in the previous step (1), use 
sonication and mechanical shaking to facilitate dissolution. 
Take 10mlof the stock solution and complete the volume to 50ml, then filter a portion 
and analyze using HPLC. 
 Prepare standard solution by dissolving 25mg CLA and 30mg MTZ in 100ml 
dissolution media. Filter portion and analyze. 
 Compare the peak response of both. 
5.3. Validation of analytical procedures (assay and dissolution)   (203),(173). 
5.3.1. Introduction: 
Validation of an analytical procedure is the process by which it is established, by 
experimental studies, that the performance characteristics of the analytical procedure meet 
the requirements and hence the analytical method is suitable for its intended purposes. 
Typical analytical performance characteristics that should be considered in the validation 
procedure according to the ICH-guidelines and USP-NF are: Accuracy, precision, 
selectivity/specificity, linearity, range, limit of quantitation (LOQ) and limit of detection 
(LOD) and robustness. 
5.3.2. HPLC conditions: 
The most suitable conditions were selected based on trials in section 5.1 and are listed in 
the results and discussion chapter under section 6.1.1. 
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5.3.3. Procedure: 
This validation procedure was applied to the method of analysis that was selected in 
section 5.1, as directed by ICH-Q2 (R1) and USP-36 (Chapter 1225) to ensure its 
suitability and accurate analysis of the assay and dissolution of both CLA and MTZ in our 
novel formula. 
  Linearity 5.3.3.1.
Linearity is the ability of the method to elicit test results that are directly proportional to 
analyte concentration within a given range. Linearity is generally calculated by using 
appropriate lest-squares regression programs. 
ICH recommends that, for the establishment of linearity, a minimum of five concentrations 
normally be used. It is also recommended that the following minimum specified ranges 
should be considered: 
 For assay, the minimum specified range is from 80-120% of the target concentration. 
 For content uniformity testing, the minimum range is from 70-130% of the test or target 
concentration. 
 For Dissolution Testing: ±20% over the specified range (e.g., if the acceptance criteria 
for a controlled-release product cover a region from 30%, after 1 hour, and up to 90%, 
after 24 hours, the validated range would be 10% to 110% of the label claim). 
Acceptance Criteria:  
The correlation coefficient (R
2
) is not less than (NLT) 0.999 for the least squares method 
of assay analysis, and NLT 0.98 for dissolution. 
Procedure: 
 Prepare standard stock solution with concentrations of 1.665 mg/ml Metronidazole and 
1.385 mg/ml Clarithromycin.  Transfer 166.5mg Metronidazole-RS and 138.5mg 
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Clarithromycin-RS to a 100 volumetric flask. Add 50ml diluent (sodium acetate pH=5) and 
sonicate for 5min, complete to volume with the diluent. Then 7 standard solutions with 
different concentrations are prepared by diluting proportions from the stock solution with 
the diluent according to the table 5.4.  
The standards then will be analyzed in according to the selected HPLC analytical method. 
 Data Analysis: 
The response of each concentration was plot versus standard concentrations prepared for 
linearity and Range. The least squares linear regression analysis, the slope, and Y-intercept 
of the data were performed.  
Table 5.4: Standard solutions preparation for linearity determination 
Solution 
No. 
Conc. 
% 
Conc. MTZ 
(µg/ml) 
Conc. CLA 
(µg/ml) 
Volume Pipetted from 
Stock St Solution (ml) 
Final Volume 
(ml) 
1 160 532.8 443.2 8 25 
2 120 399.6 332.4 6 25 
3 100 333 277 5 25 
4 80 266.4 221.6 4 25 
5 50 166.5 138.5 5 50 
6 25 83.25 69.25 5 100 
7 10 33.3 27.7 2 100 
 
  Accuracy:  5.3.3.2.
The accuracy of an analytical procedure measures the closeness of agreement between the 
value, which is accepted either as a conventional true value or an accepted reference value 
and value found. Accuracy is evaluated by analyzing synthetic mixtures spiked with known 
quantities of active pharmaceutical ingredient. 
Accuracy should be assessed using a minimum of 9 determinations over a minimum of 3 
concentration levels covering the specified range (e.g.3 concentrations /3 replicates each ). 
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Accuracy should be reported as percent recovery by the assay of known added amount of 
analyte in the sample or as the difference between the mean and the accepted true value. 
Acceptance Criteria:  
 The mean recovery of the assay should be within 100±2.0% at each concentration over 
the range of 80 – 120% of nominal concentration. 
 The mean recovery of the dissolution should be within 100±5.0% at each 
concentration. 
Procedure:  
Prepare placebo mixture, by mixing excipients used in the formulation procedure. 
Prepare spiked sample (stock solution) by spiking (addition) of known concentration of 
both MTZ and CLA to a portion of placebo sample. Try to get concentrations of 
CLA1.665mg/ml MTZ and 1.385mg/ml CLA by dissolving 333mg MTZ and 277mg CLA 
with portion of placebo powder in 200-ml volumetric flask, dissolve with 50ml methanol 
and 50ml of the diluent and sonicate for 10min, the volume is then completed to 200ml 
with the diluent, then five samples with different concentrations are prepared in triplicates, 
by diluting proportions from the stock solution by the diluent according to Table 5.5, 
analyze the samples according to the HPLC analytical method. 
      Table 5.5: Accuracy determination sample solutions:  
Conc. 
(%) 
Concentration of 
MTZ (µg/ml) 
Concentration 
of CLA (µg/ml) 
Pipetted 
Volume of 
sample (ml) 
Flask 
Volume 
(ml) 
160 532.8 443.2 8 25 
100 333 277 5 25 
50 166.5 138.5 5 50 
25 83.25 69.25 5 100 
10 33.3 27.7 2 100 
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 Data Analysis:  
The actual concentrations of the stock -spiked sample prepared were 1.55mg/ml MTZ and 
1.33mg/ml CLA, so the concentrations of the prepared samples were slightly different 
from the theoretical ones, and hence the recovery will be calculated according to the 
following equation: 
 Calculate the recovery data for each determination; calculate the average of recovery 
data and the relative standard deviation (RSD) for each level. 
                               Peak area sample                            Conc. standard  
 % Recovery=   ------------------------------- X        --------------------- 
                              Peak area standard                           Conc. sample (actual)          
Conc. : concentration 
 Precision: 5.3.3.3.
The precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. Precision may be considered at 
three levels: repeatability, intermediate precision and reproducibility. Precision should be 
investigated using homogeneous, authentic samples. However, if it is not possible to obtain 
a homogeneous sample it may be investigated using artificially prepared samples or a 
sample solution.  
The precision of an analytical procedure is usually expressed as the variance, standard 
deviation or coefficient of variation of a series of measurements. 
Procedure: for Repeatability. 
Repeatability expresses the precision under the same operating conditions over a short 
interval of time. Repeatability is also termed intra-assay precision. Repeatability is 
assessed using 9 injections covering the specified range for the procedure (3 concentrations 
/ 3 replicates each), it can be assessed using the data of samples from the accuracy test. 
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Acceptance Criteria: Relative Standard Deviation between the data of the same 
concentration shall not be greater than 2%. 
 Range 5.3.3.4.
The range is the interval between the upper and lower concentrations of analyte in the 
sample that have been demonstrated to have a suitable level of precision, accuracy, and 
linearity. The specified range is normally derived from linearity studies and depends on the 
intended application of the procedure. It is established by confirming that the analytical 
procedure provides an acceptable degree of linearity, accuracy and precision when applied 
to samples containing amounts of analyte within or at the extremes of the specified range 
of the analytical procedure.  
The following minimum specified ranges should be considered:  
 For the assay of an active substance or a finished product: normally from 80 to 120 
percent of the test concentration.  
 For content uniformity testing, the minimum range is from 70-130% of the test or target 
concentration. 
 For dissolution testing, from below the lowest expected concentration to above the 
highest concentration during release. 
  Selectivity: 5.3.3.5.
Specificity is the ability to assess unequivocally the analyte in the presence of components  
which are expected to be present. Typically these might include excipients, degradants, 
impurities, diluents, etc.  
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Procedure: 
A. No interference from excipients:  
This test is conducted by preparing a placebo sample (mixture of the product excipients 
without the active ingredients), then prepare a 100% sample solution from this placebo 
same as sample preparation under accuracy test, and analyze under the same conditions. 
B. No interference from the diluent: 
Inject a blank sample (only contains the diluent) to the HPLC under the same conditions of 
analysis. 
5.4. Formulations development: 
5.4.1. Selection of the excipients: 
1. Excipients selection for our formulations was mainly dependent on the  selection of the 
essential components of the floating gastro retentive systems (i.e. hydrophilic swellable 
polymers, release retardants, gas generators, density decreasing materials) and other 
components of tablets (i.e. binders, glidants and lubricants) (151, 204), (205).  
2. The excipients should be of pharmaceutical grades,  for internal use and biodegradable. 
5.4.2. Selection of the manufacturing process:  
Different manufacturing procedures were applied in order to achieve a formula with the 
desired properties, these procedures included: Direct Compression, Wet Granulation and 
Dry Granulation. 
5.4.3. Formulations and Manufacturing procedures: 
 Different formulations were generated based on using different grades of hydrophilic 
polymers (i.e. HPMC K-100M, K-15M and K-4M) and hydrophobic polymers (i.e. ethyl 
cellulose) as SR-matrix modifiers. Sodium bicarbonate and anhydrous citric acid were used 
as gas generating agents. Other excipients were used such as glidants, binders, diluents, 
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and lubricants in order to attain the objective of designing a new floating system with 
acceptable floating and sustained release properties. 
 During manufacturing process the amount of MTZ had been decreased from 400mg/tab 
to 300mg/tab, due to the large size of the tablet and based on previous studies which had 
shown that the efficacy of floating system of MTZ against H. pylori was nearly threefold 
that of the classical MTZ system(206)  
 In the immediate dissolving layer, the esomeprazole enteric coated pellets were 
compressed directly using microcrystalline cellulose (Avicel) as the pressure absorbing 
matrix to prevent the destruction of the coat that protect EZO from degradation in the 
acidic media (207). 
 The primary parameters to evaluate formulations were: the separation time of the two 
layers (the rapidly dissolving EZO-layer and the SR layer of CLA and MTZ), and the in-
vitro buoyancy testing which includes the floating lag time and the total floating time. 
The two layers should be separated immediately upon contact with the dissolution media 
before floating(187). The tablets should show floating lag time less than two minutes(188) 
and total floating time not less 24 hrs(208). 
 After passing these tests, further in-vitro dissolution testing will be applied, the 
dissolution profile showing SR or CR manner of both CLA and MTZ will be accepted. If a 
synchronous SR of both API`s could be achieved this would be a superior result. 
 The quantities listed are per single unit and the % is for materials in each layer. 
 Direct compression Formulations: 5.4.3.1.
 Summary of formulations manufactured by direct compression technique: 5.4.3.1.1.
The different formulations prepared by direct compression were summarized in Table 5.6.  
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Table 5.6: Direct compression formulations. 
Layer Component 
Function in the 
formula 
 
D1 
 
 
D2 
D3 
 
 
Mg % mg % Mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole Active Ingredient 300 24.5 300 24.5 300 23.1 
Clarithromycin Active Ingredient 250 20.5 250 20.5 250 19.1 
 
HPMC-K4 
SR-matrix & 
swelling agent 
(hydrophilic) 
250 20.5 ----- ----- ----- ----- 
 
HPMC-K100 
SR-matrix & 
swelling agent 
(hydrophilic) 
----- ----- 250 20.5 250 19.1 
Ethyl cellulose 
(EC) 
SR-matrix 
(hydrophobic) 
250 20.5 250 20.5 250 19.1 
NaHCO3 Gas generating agents 160 12.8 160 12.8 160 12.3 
Citric acid Gas generating agent ----- ----- ----- ---- 80 6.16 
Aerosil Glidant 10 0.8 10 0.8 10 0.76 
Mg-stearate Lubricant 5 0.4 5 0.4 5 0.38 
1
st
Layer Wt.**  1225  1225  1305  
2
nd
 layer 
Esomeprazole pellets 
(22.5%) 
Active Ingredient 100 49.5 100 49.5 100 49.5 
Avicel PH102 
( MCC) 
Diluent and binder 100 49.5 100 49.5 100 49.5 
Mg-stearate Lubricant 2 1 2 1 2 1 
2
nd
 Layer Wt.  202  202  202  
 Tablet Wt.  1427  1427  1507  
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Table 5.6: Continued… 
   
Component 
    
        D4 
 
     D5 
 
      D6 
 
    
    
     D7 
 
 
mg % mg % mg % Mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole 300 24.5 300 22.5 300 23.7 300 24.7 
Clarithromycin 250 20.4 250 19 250 19.8 250 20.6 
 
HPMC-K4 
----- ----- ----- ----- ---- ----- ----- ----- 
 
HPMC-K100 
210 17.1 210 15.8 200 15.8 250 20.6 
Ethyl cellulose 
      (EC) 
250 20.4 250 19 300 23.7 200 16.5 
NaHCO3 160 13.1 220 16.6 160 12.7 160 13.1 
Citric acid 40 3.3 40 6 40 3.2 40 3.25 
  Aerosil 10 0.8 10 0.76 10 0.79 10 0.83 
Mg-stearate 5 0.4 5 0.34 5 0.39 5 0.42 
1
st
 Layer Wt.  1225  1325  1265  1215  
2
nd
 layer Esomeprazole pellets 
(22.5%) 
100 49.5 100 49.5 100 49.5 100 49.5 
Avicel PH102 
  ( MCC) 
100 49.5 100 49.5 100 49.5 100 49.5 
Mg-stearate 2 1 2 2 2 1 2 1 
2
nd
 Layer Wt. 202  202  202  202  
 Tablet Wt. 1427  1487  1467  1417  
 
**: Wt (weight). 
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 Manufacturing steps of direct compression procedure: 5.4.3.1.2.
The following steps describe the general manufacturing procedure, mentioning all the 
ingredients were used during different formulation trials; so one can only consider the 
ingredients those were present in each formula as listed in the table of ―Direct 
Compression Formulations‖. 
1
st
-layer 
1. Pass EC and citric acid through sieve mesh # 20. 
2. Pass MTZ, HPMC-K4, HPMC-K100, NaHCO3, and Avicel PH102 through sieve  
mesh#40. 
3. Mix ingredients in steps 1 and 2 for 5minutes (min)*.  
4. Pass talc, aerosil via sieve mesh# 20. 
5. Mix ingredients in steps 3 and 4 for 5min*. 
6. Add Magnesium stearate to the mixture in step 5and mix for additional 10 min*. 
*:  mixing was done using ERWEKA-Mixer. 
2
nd
-layer: 
1. Pass Avicel PH-102 through sieve mesh #40. 
2. Mix the esomeprazole pellets with Avicel PH-102 manually using polyethylene bag for 
5 min. 
3. Add 1% magnesium stearate and mix for additional 5minutes manually using the 
polyethylene bag. 
Tablet compression:  
1. Fill the IR-disc hopper manually with accurate weight of the first layer and compress at 
low pressure 0.5 ton. 
2.  Then add the accurate weight of the second layer above first layer, and compress at 
high pressure 2.5 tons. 
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 Wet-Granulation Formulations: 5.4.3.2.
 Summary of formulations manufactured by wet-granulation technique: 5.4.3.2.1.
The different formulations prepared by wet-granulation were summarized in Table 5.7. 
Table 5.7: Wet granulation formulations. 
 
Layer 
 
 
Component 
 
Function 
in the 
Formula. 
(W1) 
1 
 
(W2)
 1 
 
 
 
(W3)
1 
 
 
 
(W4)
2 
 
mg % mg % mg % mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole Active Ingredient 400 39.5 400 38.5 400 39 400 36.3 
Clarithromycin Active Ingredient 250 24.5 250 24 250 24.3 250 22.7 
 
HPMC-K4 
SR-matrix & 
swelling agent 
(hydrophilic) 
122 12 122 11.7 110 10.6 122 11.1 
HPMC-K15 
SR-matrix & 
swelling agent 
(hydrophilic 
----- ----- ----- ----- ----- ----- ----- ----- 
 
HPMC-K100 
SR-matrix & 
swelling agent 
(hydrophilic) 
----- ---- ----- ----- ----- ----- ----- ----- 
Ethyl cellulose 
(EC) 
SR-matrix 
(hydrophobic) 
----- ----- ----- ----- ----- ----- ----- ----- 
NaHCO3 
Gas generating 
agents 
90 9 120 11.5 120 11.7 150 13.6 
Citric acid 
Gas generating 
agent 
----- ----- ----- ----- ----- ----- 30 2.7 
Avicel PH102 
(MCC) 
Diluent and binder 126 12.5 126 12.2 126 12.3 126 11.5 
Aerosil Glidant 10 1 10 0.95 10 0.96 10 0.9 
PVP K-30 
(2%solution)
 Binder 9 0.9 7 0.7 7 0.67 8 0.75 
Mg-stearate Lubricant 5 0.5 5 0.45 5 0.47 5 0.45 
1
st
 Layer Wt.  1012  1040  1028  1101  
2
nd
 layer 
Esomeprazole 
pellets (22.5%) 
Active Ingredient 100 49.5 100 49.5 100 49.5 100 49.5 
Avicel PH102 
( MCC) 
Diluent and binder 100 49.5 100 49.5 100 49.5 100 49.5 
Mg-stearate Lubricant 2 1 2 1 2 1 2 1 
2
nd
 Layer Wt.  202  202  202  202  
 
Tablet Wt. 
 
 1214  1242  1230  1303  
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Table 5.7: Continued. 
 
Layer 
 
 
Component 
        (W5)
3 
 
(W6)
4 
 
 
       (W7)
4 
 
(W8)
4 
 
 
 
(W9)
4 
 
 
mg % mg % Mg % mg % mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole 300 24.5 300 23.5 300 23 300 22.6 300 22.6 
Clarithromycin 250 20.5 250 19.5 250 19.2 250 19 250 19 
 
HPMC-K4 
----- ----- ----- ----- ----- ---- ----- ----- ----- ------ 
 
HPMC-K15 
----- ----- ----- ----- ----- ----- ----- ----- ----- ----- 
 
HPMC-K100 
250 20.5 300 23.5 330 22.4 300 22.6 225 17 
Ethyl cellulose 
(Fine powder) 
200
 
16.3 200
 
15.5 200 15.4 230 17.3 230 17.3 
Lactose ----- ----- ----- ----- ----- ----- ----- ----- 75 5.6 
NaHCO3 160 13.1 160 12.5 160 12.3 180 13.5 180 13.6 
Citric acid 40 3.25 40 4 40 3.1 45 3.4 4.5 3.3 
Avicel PH102 
(MCC) 
----- ----- ----- ---- ----- ---- ----- ----- ----- ---- 
Aerosil 10 0.81 10 0.75 10 0.78 10 0.75 10 0.8 
PVP K-30 
(2%solution)
 7 0.57 6 0.5 6 0.46 6 0.45 5 0.4 
Mg-stearate 5 0.41 5 0.36 5 0.38 5 0.38 5 0.4 
1
st
 Layer Wt. 1222  1271  1301  1326  1325  
2
nd
 layer 
Esomeprazole 
pellets (22.5%) 
100 49.5 100 49.5 100 49.5 100 49.5 100 49.5 
Avicel PH102 
( MCC) 
100 49.5 100 49.5 100 49.5 100 49.5 100 49.5 
Mg-stearate 2 1 2 1 2 1 2 1 2 1 
2
nd
 Layer Wt. 202  202  202  202  202  
 
Tablet Wt. 
 
1424  1473  1503  1528  1527  
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Table 5.7: Continued 
 
 
    
Layer 
 
 
Component 
 
  (W10)
4 
 
     (W11)
5 
    
 
 
     (W12)
4 
 
      (W13)
4 
 
    
mg % mg % Mg % mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole 300 22.6 300 22.6 300 23 300 23 
Clarithromycin 250 18.9 250 18.8 250 19 250 19 
HPMC-K4 ----- ----- ---- ---- 50 3.82 50 3.8 
HPMC-K15 ----- ----- 150 11.3 ----- ----- ----- ----- 
 
HPMC-K100 
280 21.1 150 11.3 250 19 250 19 
Ethyl cellulose 
  (Fine powder) 
230 17.3 230 17.4 230 17.6 230 17.7 
  Lactose 20 1.5 ----- ----- ----- ------ ---- ----- 
NaHCO3 180 13.6 180 13.7 170 13 160 12.4 
Citric acid 45 3.4 45 3.4 40 3.04 40 3.2 
Avicel PH102 
   (MCC) 
---- ----- ----- ----- ----- ---- ----- ----- 
  Aerosil 10 0.8 10 0.74 10 0.76 13 1 
  PVP K-30  
(2%solution)
 
6 0.4 5 0.38 5 0.39 5 0.4 
Mg-stearate 5 0.4 5 0.38 5 0.39 6.5 0.5 
1
st
 Layer Wt. 1326  1325  1310  1304  
2
nd
 layer Esomeprazole pellets 
(22.5%) 
100 49.5 100 49.5 100 49.5 100 49.5 
Avicel PH102 
  ( MCC) 
100 49.5 100 49.5 100 49.5 100 49.5 
Mg-stearate 2 1 2 1 2 1 2 1 
2
nd
 Layer Wt. 202  202  202  202  
 Tablet Wt. 
 
1528  1527  1512  1506  
 
1, 2, 3, 4 and 5: 
Indicate the composition of the granules, listed in Table 5.8.  
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 Manufacturing steps of wet-granulation procedure: 5.4.3.2.2.
1
st
-layer 
1. Prepare 100ml of 2% PVP solution as follow: 
 Dissolve 2g of PVP-K30 in 100ml isopropanol using the magnetic stirrer. 
2. Sieve the following materials by passing through sieve mesh #40 independently from 
each other: MTZ, CLA, HPMC-K4, HPMC-K15, HPMC-K100 lactose, Avicel PH102 and 
NaHCO3. 
And sieve the following material by passing via sieve mesh # 20: citric acid and aerosil. 
3. Grind EC pellets into fine powder then pass through sieve mesh #40. 
4. Mix the components of granules (the existed ones in each formula) listed in the Table 
5.7  below very well before granulation. 
5. Granulate mixture in step 4 using PVP solution.  
 Wet the mixture with suitable quantity of the solution till reaching suitable end point. 
 Pass the wet mass via sieve #20 to get granules. 
 Dry the wet granules in oven at 50ºC for 30min. 
 Sieve the dried granules again using sieve mesh #20. 
6. Mix the remaining ingredients (those not included in granules in step 4) except 
magnesium stearate for 5min. 
7.   Mix ingredients in steps 5 (dry granules) and 6 together for 10min using ERWEKA 
mixer. 
8. Add Magnesium stearate to the above mixture in step 7 and mix for additional 
10minutes using ERWEKA mixer. 
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2
nd
-layer:  
1. Pass Avicel PH-102 via sieve mesh #40. 
2. Mix the esomeprazole pellets with Avicel PH-102 for 5 minutes. 
3. Add 1% magnesium stearate and mix for additional 5minutes. 
Tablet compression:  
1. Fill the IR-disc hopper manually with accurate weight of the first layer and compress at 
low pressure 0.5 ton. 
2. Then add the accurate weight of the second layer above the first layer & compress at 
high pressure (2.5tons). 
Table 5.8: Granules composition in the wet granulation 
Method   number                  Components of the granules. 
1 MTZ, CLA, HPMC-K4, NaHCO3, Avicel PH 102.  
2 MTZ, CLA, HPMC-K4, ½ (NaHCO3), Avicel PH 102. 
3 MTZ, CLA, ½ (HPMC-K100), ½(NaCO3), ½ (EC), Citric acid.  
4 MTZ, ½ (HPMC-K100), ½ (HPMC-K4), ½ Lactose. 
5 MTZ, HPMC-K15 
. 
 Dry-granulation method: 5.4.3.3.
 Summary of formulations manufactured by dry-granulation technique: 5.4.3.3.1.
The different formulations prepared by dry granulation were summarized in Table 5.9. 
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Table 5.9: Dry-Granulation Formulations. 
 
 
    
Layer 
 
 
 
Component 
 
Function in the     
       formula 
 
    
        DG1 
 
     DG2 
    
 
 
     DG3 
mg % mg % mg % 
 
 
 
 
 
 
 
1
st
-layer 
Metronidazole Active Ingredient 300 23.44 300 23.35 300 23.35 
Clarithromycin Active Ingredient 250 19.53 250 19.45 250 19.45 
 
HPMC-K100 
SR-matrix & 
swelling agent 
(hydrophilic) 
300 23.44 300 23.35 300 23.35 
Ethyl cellulose 
      (EC) 
SR-matrix  
(hydrophobic) 
215* 16.8 215* 16.73 215 16.73 
NaHCO3 Gas generating agents 160 12.5 160 12.45 160 12.45 
Citric acid Gas generating agent 40 3.12 40 3.11 40 3.11 
  Aerosil Glidant 10 0.78 10 0.78 10 0.78 
Mg-stearate Lubricant 5 0.39 10 0.78 10 0.78 
1
st
 Layer Wt.   1280  1285  1285  
2
nd
 
layer 
Esomeprazole 
pellets (22.5%) 
Active Ingredient 100 49.5 100 49.5 100 49.5 
Avicel PH102 
  ( MCC) 
Diluent and binder 100 49.5 100 49.5 100 49.5 
Mg-stearate Lubricant 2 1 2 1 2 1 
2
nd
 Layer Wt.  202  202  202  
 Tablet Wt.  1482  1487  1487  
 
*: Ethyl Cellulose fine powder. 
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  Manufacturing steps of dry-granulation procedure:  5.4.3.3.2.
1
st
-layer: 
 
1. Sieve half of HPMC-K100 and MTZ via sieve mesh #40. 
2. Mix ingredients in step 1 for 5 min. 
3. Compress the mixture in step 2 into a slug using a pilot press machine. 
4. Mill the slug resulted in step 3. 
5. Pass the milled material in step 4 through sieve mesh # 20 to form granules. 
6. Sieve the following ingredients through mesh # 40: CLA, the remaining HPMC-K100, 
NaHCO3 and EC. And Sieve citric acid and aerosil through sieve mesh # 20. 
7. Mix ingredients in step 6 for 5 min. 
8. Mix ingredients in steps 7 and 5 using double-cone ERWEKA mixer for 15 min.  
9. Add Magnesium stearate to mixture in step 8 and mix for additional 10 min. 
2
nd
-layer: 
1. Sieve Avicel PH-102 using sieve mesh #40. 
2. Mix the esomeprazole pellets with Avicel PH-102 for 5 min. 
3. Add 1% magnesium stearate to mixture in step 2 and mix for additional 5min. 
Tablet compression:  
 
1. Fill the IR-disc hopper manually with accurate weight of the first layer and compress at 
low pressure. 
2. Then add the accurate weight of the second layer above the first layer & compress at 
high pressure (2.5tons). 
5.5. Quality control tests of the selected formula. 
In-vitro evaluation of physical and chemical parameters is very important in controlling the 
quality of any dosage form. The floating tests were applied to all formulas. Those which 
passed the floating test will be further undergoing In-vitro dissolution testing. And the 
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selected formula (formula of choice) based on dissolution results will undergo all the tests 
described below. 
5.5.1. Pre-compression tests / In process control (IPC) (209): 
 Angle of repose (Ѳ): 5.5.1.1.
The frictional forces and hence the flowability of powders and granules can be detected by   
measuring this angle. 
 Procedure: It is measured by putting 20 g of the powder as a single heap on a flat 
surface (a glass surface 30 cm X 30 cm), then raising the surface to the point at which the 
powder heap starts to fall apart (powder starts to flow). At this point the angle made 
between the flat surface and ground surface is measured as the angle of repose(210).  
 Then the flowability of the powder is then evaluated as follow (Table 5.10). 
        Table 5.10 : The relationship between angle of repose and powder flowability(211). 
                        
  Carr’s index( Compressibility Index): 5.5.1.2.
The compressibility is the ability of powder to decrease in volume under pressure. Carr`s 
index is frequently used in pharmaceutics as an indication of the flowability of a powder. 
 Procedure: 20 g of the selected formula blend are poured gently through a glass funnel 
into a granulated cylinder and the volume of unstirred granules is measured. Then, the 
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cylinder will be tapped100 times from a height of 2.0cm and the volume of granules after 
stirring is measured. 
 Calculations: 
Compressibility index is calculated using the formula: 
                  Compressibility Index = (ρt – ρ0) /ρt × 100% 
 Where,    ρt = Tapped density      and        ρo = Bulk density 
 And the flow property of the powder/granules is evaluated as follow (Table 5.11): 
      Table 5.11: The relationship between Carr`s index and powder   flowability(211). 
                                      
5.5.2. Post-compression tests: 
  Description of the tablet: 5.5.2.1.
The color, odor & taste of the tablet have to be described briefly, they can be evaluated 
organoleptically. 
Thickness and diameter are measured using a calibrated varniear caliper.  
  Hardness (212). 5.5.2.2.
The hardness indicates the ability of a tablet to withstand mechanical shocks. 
Procedure: measure the hardness of 10 tablets using a Hardness tester ―Pharma Test-PTB 
311E‖. 
Mean and standard deviation will be computed and reported. It is expressed in kilopascal 
(kp) or neuton (N). 
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  Weight (mass) variation test (BP 2013) (213). 5.5.2.3.
This test indicates the uniformity of weight for the tablets. 
 Procedure: Twenty tablets selected at random and are weighed individually and then 
the average weight is determined. 
 Acceptance criteria: Not more than 2 of the individual weights deviate from the 
average weight by more than the percentage deviation shown in (Table 5.12) and none 
deviates by more than twice that percentage. 
 Table 5.12: Acceptance criteria for weight variation test. 
 
  Friability test (173). 5.5.2.4.
This test applied to compressed, uncoated tablets. Measurement of tablet friability 
supplements other physical strength measurements, such as tablet breaking force. 
 Procedure: The tablet is performed on 10 tablets. The tablets should be dedusted prior 
testing, and then they are accurately weighed (Wo) and then placed on the drum of the 
friability tester. Rotate the drum 100 times, and remove the tablets. Remove any dust on 
the tablets and accurately weigh again (W). 
 Calculation: The percent of friability is calculated as described in the following 
equation: 
              % Friability = (Wo-W)/ Wo X 100% 
 Acceptance criteria: A maximum mean weight loss from the samples (% 
friability) doesn`t exceed 1.0%. 
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   Assay test  5.5.2.5.
This test is carried out to measure the content of the drug substance in the dosage form 
units (drug product). In this test two solutions are prepared; standard solution that contains 
a known concentration of the drug substance alone, and sample solution prepared by taking 
10 tablets and grinding them into fine powder, then a known weight of this powder is taken 
and dissolved in suitable diluent (usually from the mobile phase), small portion of this 
sample solution is taken and diluted to have a known concentration of the drug substance. 
Then both of these solutions are analyzed using a suitable method and peak response is 
considered (173). 
 Assay of CLA and MTZ: 5.5.2.5.1.
 Procedure: By HPLC Validated Method (In-House). 
Chromatographic conditions: 
Mode: LC 
Detector: UV; λ=210nm. 
Column: C18, 4.6-mm * 15-cm; particle size 5µm. 
 Flow rate:  1 ml/ min (1000µl/min). 
Injection volume:  20µl. 
Diluent:  sodium acetate buffer (pH=5), 5% methanol can be used in dissolving the sample. 
Temperature: 50ºC 
Mobile phase: (Acetonitrile and Buffer*)  
Program: gradient. 
Time Acetonitrile Buffer 
Zero 10 90 
3 10 90 
17 65 35 
18 65 35 
19 10 90 
20 10 90 
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* Buffer 0.017M KH2PO4, Adjust the pH to 4 by phosphoric acid. 
Standard solution. 
Dissolve 166.5 mg of Metronidazole and 138.5 mg of Clarithromycin RS in the 50ml of 
the diluent (dissolution media), sonicate for 10minutes and then complete the volume to 
100 ml with diluent (Standard Stock solution).  Transfer 10.0 mL of this stock solution to a 
50-mL volumetric flask, dilute with diluent to volume, and mix. Pass through a filter 
having a 0.45-µm or finer porosity, and use the filtrate as the Standard preparation. (CS 
CLA= 277µg/ml, and CS MTZ= 333µg/ml). 
Sample Solution:   
Weigh and powder not less than 10 tablets, transfer accurately weighed portion of powder 
equivalent to 277 mg CLA and 333 mg MTZ to 200ml volumetric flask, add 20 ml of 
methanol and 50 ml diluent  and sonicate for 15 minutes. Dilute with diluent to volume, 
mix, and allow any insoluble matter to settle. Transfer 10 ml of the supernatant liquid to 
50ml volumetric flask, dilute with diluent to volume, and mix. Filter a portion of this 
solution through a filter having a porosity of 0.45µm or finer and use the filtrate as the 
assay preparation. (CU CLA= 277µg/ml, and CU MTZ= 333µg/ml). 
 Calculations: Calculate the percentage of the labeled amount of CLA and MTZ in the 
tablets as follow: 
                             Assay = (RU /RS) × (CS /CU) × 100%                  
Where; 
RU = peak response from the Sample solution   
RS = peak response from the Standard solution   
CS = concentration of drug substance in the Standard solution (µg/mL)  
CU =nominal concentration of the drug substance in the Sample solution (µg/mL) 
 Acceptance criteria: 90.0% -110.0% (for both CLA and MTZ) (173). 
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 Assay of Esomeprazole (EZO) (173). 5.5.2.5.2.
 Procedure: By HPLC Method (USP-NF 36) 
Buffer:  Prepare a pH 7.3 phosphate buffer by mixing 10.5 mL of 1.0 M monobasic 
sodium phosphate buffer and 60 mL of 0.5 M dibasic sodium phosphate buffer, and 
diluting with water to 1000 ml.  
Diluent: Prepare a pH 11.0 diluent as follows. Dissolve 5.24 g of tribasic sodium 
phosphate dodecahydrate in water. Add 110 mL of 0.5 M dibasic sodium phosphate 
solution, and dilute with water to 1000 ml.  
Mobile phase:  Mix 350 mL of acetonitrile and 500 mL of the Buffer. Dilute with water to 
1000 ml.  
Standard solution:  Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, 
and dissolve in about 10 mL of methanol. Add 40 mL of Diluent, and dilute with water to 
volume. This solution contains 0.04 mg/mL of USP Omeprazole RS.  
Sample stock solution:  grind the contents of NLT 10 tablets. Transfer a portion of the 
powder, equivalent to 20 mg of esomeprazole, to a 100-mL volumetric flask, add 60 mL of 
Diluent, and shake for 20 min to dissolve the pellets. Sonicate for a few min, if needed, to 
completely dissolve. Add 20 mL of alcohol, and sonicate for a few min. Cool, and dilute 
with Diluent to volume. Pass a portion of the solution through a filter of 1-µm pore size.  
Sample solution:  0.04 mg/mL of esomeprazole from the Sample stock solution in water. 
Store this solution protected from light.  
Chromatographic system   
Mode:  LC  
Detector:  UV 302 nm  
Column:  4.6-mm × 15-cm; 5-µm packing L1  
Flow rate:  1 mL/min  
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 Injection size:  20 µL 
 Calculations: Calculate the percentage of the labeled amount of  EZO in the tablets as 
follow: 
                            Assay = (RU /RS) × (CS /CU) × 100%                  
Where; 
RU = peak response from the Sample solution   
RS = peak response from the Standard solution   
CS = concentration of drug substance in the Standard solution (mg/mL)  
CU =nominal concentration of the drug substance in the Sample solution (mg/mL) 
 Acceptance criteria: 90.0% -110.0%. 
  In-vitro dissolution test:  5.5.2.6.
Dissolution test is performed to determine the compliance of drug release from the dosage 
with its requirements for such dosage form.  In this test the percent of the drug released 
from the dosage form is calculated versus time. This is usually carried out in suitable 
dissolution media, maintained at 37 °C, using the USP dissolution apparatus II (paddle). 
Samples are withdrawn periodically from the dissolution medium with replacement to their 
size with fresh dissolution media and then their content of the drug substance is analyze 
using  developed HPLC method. (173),(214). 
 Dissolution test for MTZ and CLA: 5.5.2.6.1.
 Procedure: By HPLC Validated Method (In-House). 
Test Conditions.  
Media:  0.1M sodium acetate buffer, pH 5. 
Apparatus: apparatus II (Paddle). 
Volume: 900 ml. 
Rotational Speed: 50 RPM. 
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Dissolution media preparation. 
o Prepare 0.1M dissolution media by dissolving 8.2 of sodium acetate anhydrous in each 
1L of distilled water. (M.Wt of sodium acetate anhydrous = 82g/mole). 
o Adjust the pH to 5 by addition of glacial acetic acid. 
Blank Solution:  
Take a sample of the freshly prepared dissolution media, filter then inject to the HPLC. 
Standard Solution preparation. 
Dissolve 27.7mg of clarithromycin W.S and 33.3mg of Metronidazole W.S in 100ml 
dissolution media. 
Sample preparation. 
Place the stated volume of the dissolution medium (900mL±1%) in each vessel of the 
apparatus, assemble the apparatus, equilibrate the dissolution medium temperature at 
(37
o
C± 0.5
o
), and the rotational speed. Place one tablet in each vessel in the apparatus, wait 
till the tablet floats and then immediately operate the apparatus. At specified time intervals 
withdraw a specimen of 5ml from each vessel and replace with fresh dissolution media. 
Filter the sample through 0.45µm filter, fill in HPLC-vial and then inject to the HPLC.  
 Calculations: Calculate the percentage of CLA and MTZ released from each tablet 
using the same equation used to calculate the assay. 
 Acceptance criteria:  
Sustained, synchronous release of both MTZ and CLA is required. 
 Dissolution of Esomeprazole (173): 5.5.2.6.2.
 Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system:  
Proceed as directed in the Assay. 
 Method: HPLC method according to USP-NF36 
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Medium:  0.1 N hydrochloric acid; 300 ml. After 2 h, continue with a pH 6.8 phosphate 
buffer as follows. To the vessel, add 700 ml of 0.086 M dibasic sodium phosphate, and 
adjust with 2N hydrochloric acid or 2N sodium hydroxide, if necessary, to a pH of 6.8 ± 
0.05.  
Apparatus 2:  100 rpm  
Time:  2 h in 0.1N HCl, and 30 min in a pH 6.8 phosphate buffer  
Standard solution:  Prepare a solution containing 2 mg/mL of USP Omeprazole RS in 
alcohol. Dilute this solution with pH 6.8 phosphate buffer to obtain a solution containing 
(L/1000) mg/mL, where L is the label claim, in mg/tablet (0.02mg/ml). Immediately add 
2.0 mL of 0.25 M sodium hydroxide to 10.0 mL of this solution, and mix. {Note— Do not 
allow the solution to stand before adding the sodium hydroxide solution}  
Sample solution:  After 30 min in pH 6.8 phosphate buffer, pass a portion of the solution 
under test through a suitable filter. Transfer 5.0 mL of the filtrate to a suitable glassware 
containing 1.0 mL of 0.25 M sodium hydroxide. Mix well. Protect from light.  
 Calculations:  
Samples:  Standard solution and Sample solution  
Calculate the percentage of esomeprazole (C17H19N3O3S) dissolved:  
Result = (R U / R S) × (CS /L) × V × 100 
RU = peak response from the Sample solution   
R S = peak response from the Standard solution   
CS = concentration of the Standard solution (mg/mL)  
L= label claim (mg/tablet)  
V= volume of Medium, 1000 mL  
 Acceptance criteria:  NLT 75% of the labeled amount of esomeprazole 
(C17H19N3O3S) is dissolved. 
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   In-vitro floating testing:(208) 5.5.2.7.
 Floating lag-time: 5.5.2.7.1.
 The time between the introduction of the tablet into the dissolution medium and its 
floating on the surface of the dissolution medium is termed as floating lag time. 
 Procedure: introduce one tablet into the dissolution media and estimate the time needed 
for the tablet to float. 
 Acceptance limit: NMT 2 min (215). 
 Total floating time: 5.5.2.7.2.
The entire time during which the tablet remains afloat on the surface of the dissolution 
media is termed as the floating time. 
 Procedure: The test is usually performed by immersing the tablet in 900ml of the 
dissolution media maintained at 37 °C, using USP dissolution apparatus II (paddle). Then 
estimate the time since the tablet floats until it sinks in the dissolution media. 
 Acceptance limit: NLT 24 h (216) 
  Swelling-index test (water uptake) (105): 5.5.2.8.
Swelling test or water uptake (WU) test is important for evaluating the swelling behavior 
of the swollen polymer in the floating dosage form, and so dissolution behavior could be 
explained.  
 Procedure: The test is done by immersing the tablets in 900 ml dissolution media at 37 
°C, and determining the weight change at regular time intervals until 24h.   
 Calculations: WU (swelling index) at each time interval is measured in the terms of 
percentage of weight gain, as given by the following equation:      
                 % WU = (Wt –Wo) /Wo X 100 % 
in which: (Wo) is the initial weight of the tablet. 
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    (Wt) is the average weight of the dosage form at time t.      
5.6. Kinetic modeling of the selected formula. 
To determine the mechanism by which CLA and MTZ are released from the matrix of the 
floating sustained release layer of our novel bilayer tablet, dissolution data are fitted to 
different  mathematical models (refer to section 1.6) using DDSOLVER program, the best 
model is then selected according to the value of  R
2 
 or  R
2
Adjusted. 
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6. Results and Discussion 
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6.1.  Development of analytical procedure for concurrent determination of CLA and 
MTZ (for assay and dissolution). 
6.1.1. Selection of suitable HPLC conditions and reagents 
 Selection of suitable wave-length for detection of both CLA and MTZ: 6.1.1.1.
Measuring the absorbance of CLA and MTZ, proceeding exactly as directed in section 
5.1.3.1, gave the following results: 
 The maximum absorbance points for metronidazole were as follow: 
                    330nm                   A=1.246 
                    228nm                    A=0.597 
                     210nm                     A=0.78 
 The maximum absorbance points for clarithromycin were as follow: 
    205nm                   A=0.417 
   210nm                     A=0.343 
So the choice was for λ=210 for HPLC-analysis of both CLA and MTZ, as both substances 
have a maximum absorbance at this wavelength.  
  Selection of HPLC-column (173) (217): 6.1.1.2.
High resolution is typically required when separating samples with many components. 
Column internal diameter is chosen depending on analytical requirements and system 
limitations. Usually 4.6-mm internal diameter columns are used when working with 
traditional HPLC systems. The particle size of the stationary phase affects the efficiency of 
a separation; sure high efficiency is needed especially when separating few components. 
Smaller particle size gives higher efficiency; but flow rate needs to be adjusted downward. 
The most widely used particle size is 5 µm in diameter. Select hydrophobic stationary 
phases (C18, C8) when differences in analyte hydrophobicity are large and can be 
exploited to affect a separation. 
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Depending on the columns in the single monographs of USP, and on the fact that we have 
two different hydrophobicity analytes (CLA and MTZ), and different hydrophobicity 
matrix components, the choice was for C18, 4.6-mm × 15-cm; 5-µm (packing L1). As in 
this column the hydrophilic analyte (MTZ) will be eluted early and away from the 
hydrophobic analyte (CLA) which elution would be later; so better separation will be 
obtained. 
 Selection of suitable mobile phase (program, components and percentages), 6.1.1.3.
and suitable injection volume, column temperature and flow rate: 
Different components were used, taking into consideration to use organic and inorganic 
solvents (buffer), as different polarity analytes have to be separated. 
Different concentrations of the mobile phase components were used, and each time the 
chromatograms were evaluated based on the separation (resolution), shape (almost sharp 
and symmetrical) and purity of peaks resulted. 
Different programs of mobile phase were used, isocratic and gradient. 
In parallel to changing in the mobile phase, changing in injection volume (10, 20 and 
50µm), changing in column temperature (40 and 50ºC) and changing in the flow rate (1000 
to 2000) µl/min took place. 
After many trials and many changes applied to the HPLC conditions, good shape, well 
separated peaks, definite retention times for each substrate in the dosage form (MTZ, CLA 
and EZO) were obtained. Samples of chromatograms obtained during the development and 
after the final approved development for the analytical method are shown in (Figure  6.1)  
and (Figure 6.2)  respectively.  The optimal HPLC conditions are listed below: 
 Selected chromatographic conditions: 
Mode: LC 
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Flow rate:  1 ml/ min (1000µl/min). 
Injection volume:  20µl. 
Temperature: 50ºC. 
Buffer 0.017M, Adjust the pH to 4 by phosphoric acid. 
Mobile phase gradient is described in (Table 6.1): 
Table 6.1: Gradient of the mobile phase in the analytical procedure of CLA and MTZ. 
 
Time 
 
Acetonitrile 
 
Buffer 
Zero 10 90 
3 10 90 
17 65 35 
18 65 35 
19 10 90 
20 10 90 
 
 
Figure 6.1: Sample of chromatogram during development of the analytical method.  
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Figure 6.2: The chromatogram obtained after the final approved development of the 
HPLC method. 
 
6.1.2. Dissolution media: 
Selection of dissolution media was based on: 
1.  Stability of the active ingredients (CLA and MTZ):  
 After comparison the peak response of freshly prepared samples and stability samples 
(stored 3 hours) that were prepared in different dissolution media, the following results 
were observed: 
 MTZ was not stable at low pH media (0.1N HCL), but was more stable at higher pH HCL 
media. Furthermore it was very stable at sodium acetate media, either at pH 4 or pH 5. 
 CLA had poor stability at HCL media with different pH-range (1-5). 
On the other hand, its stability was poor at sodium acetate media with pH 4, but an 
excellent stability at sodium acetate media with pH 5.  
  So the dissolution media selection regarding the stability of the components was (sodium 
acetate media with pH 5 ), due to the high stability of both CLA and MTZ in it. This result 
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was consistent with the aim of incorporating EZO within the tablet, which was for 
increasing the pH of the stomach to 5 inorder to protect CLA from degradation at low pH.  
2.  Solubility of the active ingredients (CLA and MTZ): 
This test was applied to the dissolution media that passes the stability test. After dissolving 
the maximum dose of the drug components in 200ml dissolution media (stock solution), 
and dilute a sample from this stock to have a concentration of 0.25mg/ml CLA and 0.3mg, 
then compared the response of this sample to standard solution having the same 
concentrations (no stock here), we found the following results: 
% Recovery = (Peak response of diluted sample/Peak response of standard) x100% 
% recovery CLA = (215678/222267) X 100%= 97% 
% Recovery MTZ= (8382762/8069070) X 100%=103% 
The percentage of recovery from both diluted solutions indicated their complete dissolution 
in the media. The slight difference in their recovery is due to the higher solubility of MTZ.  
As a result, sodium acetate media with pH 5 has been approved to be the dissolution media 
for the release of MTZ and CLA based on stability and solubility studies. 
Furthermore, the dissolution media could be used as a diluent for the assay and dissolution 
tests, based on the stability and solubility tests, and after comparing the results of standard 
solutions prepared by dissolving in mobile phase, and another dissolved in dissolution 
media, they were very close and the alternative use of both diluents was accepted. 
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6.2. Validation of analytical procedure 
 
The method was validated according to USP-NF 36 and ICH Q2 (R1) guidelines for the 
quantitation of drug substance in dosage forms. The tests were assessed in our work were: 
the linearity, accuracy, precision, range, specificity and selectivity, in order to ensure that 
the method is reliable. 
6.2.1. Linearity 
Linearity was assessed by analyzing seven standard solutions of different concentrations 
covering the range 10% -160% of the nominal standard concentration in the assay and 
dissolution methods. The results are listed in (Tables 6.2 and 6.3). The calibration curves 
were plotted and shown in (Figures 6.3 and 6.4). 
The linearity of the method was established from the correlation coefficient (R
2
) of the best 
fit least squares linear regression  curve, which was obtained by plotting peak areas versus 
known concentrations of MTZ and CLA. For these studies, an R
2
 value of > 0.990 was 
considered appropriate to demonstrate the linearity of the analytical method. 
 Clarithromycin curve: The calibration curve was found to be linear over the concentration 
range stated, with an R
2
 of 0.9998 and the equation for the line was ( y = 964.98x – 
1361.6). 
Metronidazole curve: The calibration curve was found to be linear over the concentration 
range stated, with an R
2
 of 0.9998 and the equation for the line was (y = 25621x—19720). 
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Table 6.2:  Linearity results of HPLC method validation (Clarithromycin).  
Concentration 
          % 
St. Conc. µg/ml 
Clarithromycin 
 
Peak area- 1 
 
Peak area-2 
 
Average 
160% 443.2 423786 424385 424085.5 
120% 332.4 321802 323733 322767.5 
100% 277 266824 266621 266722.5 
80% 221.6 214582 210862 212722 
50% 138.5 129431 128375 128903 
25% 69.25 66239 66249 66244 
10% 27.7 25845 25765 25805 
 
 
Table 6.3: Linearity results of HPLC method validation (Metronidazole). 
Concentration 
% 
St. Conc. µg/ml 
Metronidazole 
 
Peak area-1 
 
Peak area-2 
 
Average 
160% 532.8 13536480 13565188 13550834 
120% 399.6 10307923 10287017 10297470 
100% 333 8591386 8551652 8571519 
80% 266.4 6852399 6794230 6823315 
50% 166.5 4177941 4162606 4170274 
25% 83.25 2110005 2100523 2105264 
10% 33.3 843358 841235 842296.5 
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Figure 6.3: Linearity graph of Clarithromycin for HPLC method validation. 
 
                  
 
 Figure 6.4: Linearity graph of Metronidazole for HPLC method validation. 
 
6.2.2.  Accuracy 
The percentages recovered from spiked samples for five concentrations covering the range 
10%-160% were calculated. 
y = 964.98x - 1361.6 
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 An acceptance criterion for accuracy was considered to have a recovery of 100+2.0% 
(assay) or 100±5% (dissolution). 
The resultant values for recovery complied with the acceptance criteria.  Results are 
illustrated in (Tables 6.4 and 6.5) and shown in (Figures 6.5 and 6.6) with an R
2
 value of 
0.9998 for both CLA and MTZ. 
Table 6.4: Accuracy results of HPLC method validation (Clarithromycin). 
Target 
Conc. (%) 
Theo. Conc. 
(µg / ml) 
Clarithromycin 
Conc. after Spiking 
(µ/ml) 
Clarithromycin 
Name of 
sample 
Spiked Sample 
Response 
Recovery 
(%) 
160 
 
 
443.2 
 
 
425.6 
1.1 
411563 101.1 
1.2 
414819 101.8 
1.3 
413920 101.6 
100 
 
 
277 
 
 
266 
2.1 
257317 100.4 
2.2 
263824 103 
2.3 253014 98.8 
50 
 
 
138.5 
 
 
133 
3.1 127278 102.8 
3.2 
129416 104 
3.3 128991 103 
25 
 
 
69.25 
 
 
66.5 
4.1 
63423 99.7 
4.2 
65204 102.5 
4.3 66165 104 
10 
  
 
26.6 
5.1 
26063 104.8 
27.7 
5.2 
25404 102.5 
 
5.3 
25939 104.6 
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Table 6.5: Accuracy results of HPLC method validation (Metronidazole). 
Target 
Conc. 
(%) 
Theo. Conc.  
(µg / ml) 
Metronidazole 
Conc. after 
Spiking (µ/ml) 
Metronidazole 
Name of 
sample 
Spiked Sample 
Response  
Recovery 
(%) 
160 
 
 
532.8 
 
 
480 
1.1 12225715 99.9 
1.2 12312165 100.8 
1.3 12287052 100.6 
100 
 
 
333 
 
 
300 
2.1 7627495 98.8 
2.2 7810864 101.1 
2.3 7559596 97.9 
50 
 
 
166.5 
 
 
150 
3.1 3878555 103 
3.2 3866475 102.9 
3.3 3866654 102.9 
25 
 
 
83.25 
 
 
75 
4.1 1940494 102 
4.2 1926180 101.2 
4.3 1940620 102 
10 
 
33.3 
 
 
30 
5.1 769989 101.5 
 
5.2 775767 102.2 
 
5.3 757297 99.8 
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Figure 6.5: HPLC method validation accuracy regression line (Clarithromycin). 
 
         
   
 Figure 6.6: HPLC method validation accuracy regression line (Metronidazole). 
 
6.2.3. Precision: 
The precision is the ability of a method to produce precise analytical results from a series 
of measurements of the same homogenous sample under prescribed assay conditions. The 
relative standard deviation (% RSD) of a series of measurements is usually used to assess 
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the precision of an analytical method. The % RSD is calculated using the following 
equation. 
                             
 
  
          
Where, 
σ = Standard deviation around the mean of a set number of samples (calculated using 
nonbiased or n-1 method). 
X = Mean of the peak height ratio responses for a set number of samples 
The precision of our method was assessed by repeatability. The repeatability was 
determined by analysis of 15 determinations at 5 concentrations of the test concentration. 
The repeatability results obtained are shown in (Tables 6.6 and 6.7). The results revealed 
that % RSD values were within the acceptable limits thus the method is repeatable for the 
analysis of CLA and MTZ together. 
Acceptance criteria: 
 A value for % RSD < 2 % was set as an acceptable limit. 
Table 6.6: Precision results of HPLC method validation (Clarithromycin) 
Name  
of sample 
  No.  
of injection 
Conc. 
 µg/ml 
Response Average 
Response 
      SD  
of response 
 
% RSD 
 
Sample-1 
1  
425.6 
411563  
413920 
 
1681 
 
0.4 2 414819 
3 413920 
 
Sample-2 
1  
266 
257317  
258051 
 
5442 
 
2 2 263824 
3 253014 
 
Sample-3 
1  
 
133 
127278  
128561 
 
1131 
 
0.88 2 129416 
3 128991 
 
Sample-4 
1  
 
66.5 
63423  
64930 
 
1391 
 
2 2 65204 
3 66165 
 
Sample-5 
1  
 
26.6 
26063  
25802 
 
350 
 
1.3 2 25404 
3 25939 
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Table 6.7: Precision results of HPLC method validation (Metronidazole) 
Name  
of sample 
  No.  
of injection 
Conc. 
 µg/ml 
Response Average 
Response 
      SD 
of response 
 
% RSD 
 
Sample-1 
1  
 
480 
12225715  
 
12274977 
 
 
 
44471 
 
 
 
0.36 
 
2 12312165 
3 12287052 
 
Sample-2 
1  
 
300 
7627495  
 
7665985 
 
 
 
129980  
 
 
1.69 
 
2 7810864 
3 7559596 
 
Sample-3 
1  
 
150 
3878555  
 
3870561 
 
 
 
6923 
 
 
 
0.17 
 
2 3866475 
3 3866654 
 
Sample-4 
1  
 
75 
1940494  
 
1935764 
 
 
 
8300 
 
 
 
0.48 
 
2 1926180 
3 1940620 
 
Sample-5 
1  
 
30 
769989  
 
767684 
 
 
9448 
 
 
1.23 2 775767 
3 757297 
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6.2.4. Range 
The range is the interval between the upper and lower concentrations of analyte in the 
sample that have been demonstrated to have a suitable level of precision, accuracy, and 
linearity. It confirms that the analytical procedure provides an acceptable degree of 
linearity, accuracy and precision when applied to samples containing amounts of analyte 
within these concentrations (lower and upper limits). 
After applying linearity, precision and accuracy tests to the analytical method, it has been 
approved that the acceptable range the method was from 10%-160% of the nominal 
concentrations, which are (27.7- 443.2  µg/ml) for CLA, and (33.3- 532.8 µg/ml) for MTZ. 
6.2.5. Selectivity Test: 
It measures the degree of interference from materials other than active material, such as 
excipients, impurities, and degradation products and diluents. It should be ensuring that the 
peak response is due to a single component only. To validate for selectivity, the 
interference from excipients and the Interference with degradants were determined.  
 The interference with excipients and diluent was determined by injecting the excipients 
alone (placebo sample), the diluent alone, standard solution of 100% concentration and a 
spiked sample. Then the chromatograms were compared, and the %recovery of the spiked 
sample was calculated. The chromatograms are shown in (Figures 6.7 and 6.8), it is 
observed that there is no interference with the excipients or the diluent.  
                               Peak area sample                          Conc. standard  
% Recovery=   ------------------------------- X        --------------------- 
                              Peak area standard                             Conc. sample          
% Recovery of CLA = (258051/266722) X (277/266) X 100% 
                                  = 100.7 % 
% Recovery of MTZ = (7665985/8571519) X (333/300) X 100% 
                                  = 99.3 % 
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Figure 6.7: Blank (diluent) sample chromatogram/ selectivity. 
 
   
    Figure 6.8: Placebo sample/Selectivity test. 
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6.3. Formulation development: 
6.3.1. Selection of the optimal formula and the optimal manufacturing process 
The primary objectives of the formulation studies were optimization of the separation 
between the two layers, optimization of floating lag time and total floating time and 
optimizing the release of both CLA and MTZ in a synchronous, sustained manner from the 
dosage form. These objectives were achieved by suitable polymers used and by optimizing 
the ratios of the gas generating agents to the polymers. In addition different manufacturing 
procedures were applied in order to achieve the best formula performance. 
The results of different formulations generated are shown and discussed below, based on 
the In-vitro floating performance of the formulations, separation time of the rapidly 
dissolving layer (RDL) and the integrity of the matrix. These tests are critical steps in the 
primary acceptance of the formulations. As mentioned before the acceptance criteria for 
these tests are: Separation time of the rapidly dissolving layer is NMT 2 minutes (187),  
Floating lag time is NMT 2 minutes (218) (188) and Total floating time (without 
disintegration) is NLT 24 h.  
It is important to mention that in our study we followed the formulation by trial method in 
which we tried to optimize the floating characteristics of the different formulas and by 
using the different manufacturing methods ( direct compression, wet-granulation and dry 
granulation). The aim was to obtain a slow synchronous release of both MTZ and CLA. 
We tried first to include the MTZ and CLA in the same position within the matrix in the 
direct compression and the wet granulation procedures, and for those formulas that passed 
the floating test we tested the dissolution. 
We found that the release of MTZ was faster than CLA  in both direct compression and 
wet granulation, due to its high solubility. So we thought to include MTZ inside the 
granules and CLA outside to retard MTZ release. At first we tried the wet granulation 
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method but we didn`t acquire good release. However changing to dry granulation did 
provide the acquired release. This could be justified by the presence of PVP-K30 binder 
within the granules of the wet granulation, which increased the binding between their 
components and decrease the entry of dissolution media and hence delayed MTZ release to 
great extent. On the other side in the formulations of dry-granulation the granules had been 
formulated without using binder solution, and so they decreased the release of MTZ but 
less than that in the wet granulation. 
 Wet granulation formulas: 6.3.1.1.
 
  
  
130 
Table 6.8: Wet granulation results of Floating properties, matrix integrity and separation 
of RDl. 
 
Formula 
Separation of 
RDL 
(NMT 2min) 
     FLT 
(NMT 2min) 
TFT 
NLT 24 h. 
 
Matrix integrity and behavior. 
W1 28 sec. 6.5 min Intermittent  
(floated and 
sank) 
Weak, continue to floated and sank 
then disintegrated after 2 h. 
W2 1 min. 1min+7sec. 20 min Weak, disintegrated (20 min). 
W3 35 sec. 1min+40sec. 10min. Weak, disintegrated (10 min) 
W4 1min. 5 min. 15min. Weak, disintegrated (15 min) 
W5 1min+10sec 4.5 min 2min. Coherent integrity but couldn`t float 
(sank) 
W6 40 sec. 58 sec. ˃ 24h * Fairly swollen and coherent matrix. 
W7 1+ 20sec. 6min. 1min Coherent integrity but couldn`t float 
(sank) 
W8 28sec. 42 sec. ˃ 24h * Good swollen and coherent matrix 
W9 18 sec. 33 sec. 30 min Weak, disintegrated (30 min) 
W10 25 sec. 40 sec. 20 min Weak, disintegrated (20 min) 
W11 22 sec. 30 sec. 5 min Weak, disintegrated (5 min) 
W12 27 34 40 min. Weak, disintegrated (40 min) 
W13 21 26 ˃ 24 h * Good swollen and coherent matrix. 
*: See dissolution (drug release) results and graphs in section 6.4.2.6.  
 
W1-W4: 
 Using HPMC-K4M alone as a matrix forming polymer resulted in rapid disintegration 
of the tablets; this could be explained by failure of the polymer to provide a robust gel 
layer within suitable time, that could entrap the generated CO2 for longer times within its 
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matrix, and hence the gas generated caused erosion and disintegration of the tablet instead 
of floating(205). 
 Distributing the gas forming agent into two portions (W4) within and around the 
granules accelerated the disintegration time, as gas formation was faster due to its easier  
contact with the dissolution media when distributed within the matrix outside the granules. 
W5-W8: 
 Replacement of HPMC-K4M took place with higher viscosity hydrophilic polymer 
(HPMC-K100M) to get better matrix integrity that could entrap the CO2 inside for 
prolonged period and with a hydrophobic polymer (EC) that caused gradual ingress of the 
media to the system and with its low density it decreased the system density and enabled 
its floating (153). Also addition of citric acid in a ratio of 1: 4 of sodium bicarbonate to 
enhance the floating lag time has been done. 
 Incorporating of half of the gas generating agents quantity inside the granules (W5) 
caused failure of the floating of the system , this was because the quantity distributed 
within the matrix couldn`t generate a sufficient quantity of CO2 that  is required for 
decreasing the system density and causing its buoyancy.  
 Increasing the quantity of HPMC-K100M over 300mg/tablet (W7) causing failure of 
floating of the system. This could be justified by the insufficient quantity of CO2 gas 
generation that could attain the required floating force of the system by decreasing its 
density below that of the media. So increasing the amounts of gas generating agents took 
place in W8 in parallel with the hydrophobic polymer EC to prevent tablet disintegration 
by allowing gradual ingress of fluid media to the system. 
 W6 and W8 showed good floating properties. In these formulations immediate generation 
of CO2 from gas generating agents occurred upon interaction with the dissolution media, 
the generated gas entrapped within the swollen polymer matrices. As a result ,expansion of 
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the polymer matrix occurred  causing tablet density to decrease lower than that of the 
dissolution media and leading to rapid floating time and longer total floating time(188). 
 
W9-W10: 
 Additional change was incorporating of lactose within the matrix of the system and  
within the granules, in order to accelerate the release rate of W6 and W8 (results are 
detailed in the next section 6.3.2.2.    
As it is known lactose could be added to the controlled release dosage forms to enhance the 
release. Lactose is water soluble channeling agent, when come in contact with fluid, it will 
dissolve leaving behind channels through which GIT fluid gains access into the tablet 
matrix causing the active drug to dissolve and diffuse out of the system(219).  
 Using lactose with different ratios in the formulas, either 5.5% (W9) or 1.5% (W10) 
gave undesirable effect of the matrix of the system, caused its rapid disintegration. This 
could be explained as follow; the dissolving of lactose within the media was much more 
faster than the gelling forming capacity of the polymers, this cause faster formation of CO2 
inside the matrix that couldn‘t remain entrapped within a gel layer, so it diffused out 
quickly causing its disintegration instead of floating. 
 
W11-W13: 
 Different grades of HPMC polymers (K4M and k15M) have been incorporated beside 
HPMC-K100M to enhance the release. These polymers have different relaxation, swelling 
and gel forming capacities. By suitable tuning for the polymers ratios and grades within the 
formula, floating properties could be maintained and the release could be optimized(220). 
 Using HPMC-K15M to HPMC-K100M in ratio 1: 1 (W11), then using HPMC-K4M   to 
HPMC-K100 in ratio 1:4 (W12), resulted in weak integrity matrices that disintegrated 
rapidly after introduction to dissolution media (W12 was better than W11). This was 
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caused by the rapid gas generation occurred in parallel with the replacement of portion of 
the amount of the high viscosity (and high M.Wt) HPMC-K100M with lower viscosity 
grades that have lower ability to form a coherent gel-framework matrix that could entrap 
the generated CO2 inside, so instead of entrapment of the CO2, diffusion occurred and 
cause disintegration instead of remained afloat. 
 W13: Small modification was applied by decreasing the amounts of gas generating 
agents, gave good floating , this was because the quantity of CO2 generated was enough to 
be entrapped within the swollen matrix leading to decrease the system density and 
consequently its floating.  
 Direct compression formulas: 6.3.1.2.
 
Table 6.9: Direct compression results of Floating properties, matrix integrity and 
separation of RDL. 
 
Formula 
Separation  
of RDL. 
(NMT 2min) 
FLT. 
(NMT 2min) 
TFT. 
(NLT  
24 h) 
 
Matrix integrity and behavior 
D1 40 sec. No floating ------ Weak, disintegrated totally (10 min). 
D2 
1min and 50 
sec. 
5 min. ˃1 h 
Coherent integrity but couldn`t remain floating 
(sank). 
D3 42 sec. 1 min+ 40 sec. 30 min. Weak, disintegrated totally (30 min). 
D4 
2 min+ 40 
min 
10 min 30 min 
Coherent integrity but couldn`t remain floating 
(sank). 
D5 10 min 7.5 min 17 min 
Coherent integrity but couldn`t remain floating 
(sank). 
D6 21 sec 30 sec. 1 h. Weak, disintegrated totally (1h). 
D7 45 sec. 52 sec. ˃ 24 h. * Fairly swollen and coherent matrix. 
 
 D1, D3 and D6: 
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The three formulations failed to remain floating and disintegrated rapidly. Among these the 
faster disintegrating formula was (D1). This was because its matrix involved the low 
viscosity hydrophilic polymer which is HPMC-K4M, this polymer has lower swelling, gel 
forming capacities than higher viscosity polymers, so it couldn‘t form a good matrix gel 
barrier layer that could entrap the generated CO2 inside its framework, and hence the 
generated gas caused rapid disintegration rather than floating. Despite changing the 
polymer to a higher grade one that is HPMC-K100M  in both D3 and D6, and the slight 
increase in the EC to HPMC-K100M ratio in D6; the parallel addition of citric acid to both 
formulas caused a disintegration to this system, this could be justified by the rapid 
formation of CO2 gas upon interaction of the dissolution media in a faster manner than the 
formation of the polymer barrier gel layer, the first quantity generated of the gas cause 
floating to the system, but when this quantity increased before swelling of the polymer, it 
caused  polymer erosion and disintegration to the system.  
 D2, D4 and D5: 
All these formulas failed to remain floating; they floated for some period of time then sank 
again. Their long floating lag time indicated that the generation of CO2 inside the systems 
was slow, this may be caused by the amount of the hydrophobic polymer (EC) that was 
larger than the hydrophilic polymer (HPMC-K100M), this hydrophobic polymer prevents 
enough media to ingress to the systems, and so the slow generation of CO2 inside these 
systems caused the elongation of the floating lag times, but once being afloat, the polymers 
swelled more and more by up taking water, their weights increased but no enough CO2 
inside the matrix to maintain low density of the system that is needed for floating , so they 
sank again after short period of floating time. 
Hint: in D2 formula the problem was in the amount of the gas generating agents, as no 
citric acid was incorporated, in addition to the amount of the hydrophobic polymer. 
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 D7: 
This was the most optimized floating formula with the best floating properties among  
the direct compression formulas; containing 20.5% HPMC-K100M, 16.5% EC, 13.1% 
NaHCO3 and 3.25% citric acid. This formula passed the in-vitro floating testing and the 
rapidly dissolving layer separated quickly. So further in vitro dissolution testing was 
performed, see in-vitro dissolution results. 
 Dry-granulation: 6.3.1.3.
Table 6.10: Dry-granulation results of Floating properties, matrix integrity and separation 
of RDL. 
 
Formula 
Separation time of 
RDL (NMT 2min). 
FLT 
(NMT 
 2 min). 
TFT 
(NLT 24 h). 
 
Matrix integrity and behavior 
DG1 10 sec. 10 sec. ˃ 24 h. Good swollen and coherent matrix 
DG2 12 sec. 15 sec. ˃ 24 h. Good swollen and coherent matrix 
DG3 15 sec. 18 sec. ˃ 24 h. Good swollen and coherent matrix 
 
 DG1-DG3: 
The three formulations have excellent floating properties. Having 23.4%HPMC-K100M, 
16.8% EC, and 12.5% NaHCO3 with NaHCO3: citric acid ratio (4:1) gave the optimized 
matrix formulas with optimized floating properties. Which means that the polymers matrix 
were able to swell in an optimum rate that could entrap the required quantity of the 
generated CO2 at the suitable time, leading to floating instead of disintegration, and the 
gradual swelling in parallel to the gradual CO2 generation maintain the system afloat for 
long period. 
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6.4. Quality control tests of the selected formula (DG2). 
6.4.1. Pre-compression tests / In process control (IPC). 
 Angle of repose (Ѳ): 6.4.1.1.
The angle of response was 25º, which indicates excellent flow properties (211).                              
 Carr’s index( Compressibility Index):  6.4.1.2.
 Compressibility Index =  (0.606-0.487) / 0.606 X 100% 
                                           = 19.64 % 
This value indicates  Fair-flowability. (211),  
6.4.2. Post-compression tests: 
 Description of the tablet: 6.4.2.1.
  The tablet is: 
 White. 
 Round-shaped with flat surfaces. 
 Odorless. 
 Bitter taste. 
 Tablets dimensions: 
 Thickness: 9.3 mm 
 Diameter: 12.96 mm. 
 Hardness: 6.4.2.2.
Hardness results (average for 10 tablets) of DG2 tablets are illustrated in (Table 6.11).                                                  
                         Table 6.11: Hardness results of formula DG2. 
Hardness (N) 71.97 
SD 4.64 
% RSD 6.44% 
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 Weight variation test: 6.4.2.3.
The test was applied to randomly 10selected tablets. 
From the results (Table 6.12), it was found that the tablets complied with the requirements 
for weight variation test of tablets as described in the BP, which recommends that NMT 2 
tablets deviates from the average weight of more than 5%, and none deviates by more than 
twice that percentage.               
                    Table 6.12: Weight variation results of formula DG2.  
Tablet nominal weight 1487 mg 
Average tablets` weight 1494 mg 
% Deviation  
(min-max) 
1.2% 
(0.27 % - 2.28 %) 
 
 Friability test: 6.4.2.4.
The test was performed on 10 tablets selected at random, and preceded as described under 
section 5.2.3.4. 
              % Friability = (Wo-W)/ Wo X 100% 
                                   = (14.962g – 14.847) / 14.962 X 100% 
                                   = 0.77 % 
The result complied with the USP acceptance criteria mentioned for the test (˂ 1%). 
 Assay test. 6.4.2.5.
The assay was calculated using the following equation: 
                             Assay = (RU /RS) × (CS /CU) × 100%                   
As the concentrations of standards and samples were equal, then we can omit CS/CU. 
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 Assay of CLA and MTZ: 6.4.2.5.1.
The assays of both CLA and the MTZ were obtained using the developed HPL method 
using the following equation: 
                             Assay = (RU /RS) × 100%        
 Assay (MTZ) =  (7810864 / 8551652) X 100% 
                       = 91.34 % 
This result complied with the USP-36 acceptance criteria (90 – 110) %. 
 Assay (CLA) = (258051 / 266722) X 100%  
                       = 96.75 % 
The result complied with the USP-36 acceptance criteria (90-110) %. 
 
 Assay of EZO: 6.4.2.5.2.
Omeprazole was used as RS for both tests assay and dissolution of EZO, because both tests 
measure the quantity of EZO and not the chirality of  its structure, and both of omeprazole 
and EZO are isomers having the same chemical structure. 
 
The assay of EZO was according to the USP-method, and the result was as follow: 
 Assay = (1115042 / 1015660) X 100% 
           = 109.78 % 
The result complied with the USP-36 acceptance criteria of the test (90-110)%. 
 
 In-vitro dissolution test 6.4.2.6.
 Dissolution of MTZ and CLA from the SR-floating layer: 6.4.2.6.1.
The drug release rate from floating gastroretentive systems , and from conventional SR 
systems of swellable matrix, is usually controlled by transport of the solvent into the 
polymer matrix, polymer swelling, , drug diffusion through the swollen polymer, the gel-
layer thickness dynamics and polymer (matrix) erosion (187). Dissolution of hydrophilic 
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polymers occurs via two major processes, swelling and erosion. Initially rapid water uptake 
by the surface polymer will lead to dissolution of the surface incorporated drugs, so some 
burst release can take place. Upon gradual entry of the water into the matrix, swelling of 
the hydrophilic polymer and formation of gel layer, through which the drug will be 
released gradually usually by diffusion, will occur. Once the polymer reaches a 
disentanglement threshold, its dissolution occur and the release of the remaining drug will 
be controlled by erosion (another burst release could happen) (221).  
When the swellable matrix system is in the dissolution media, three boundaries (fronts) 
control drug dissolution and release are formed, (Figure 6.9); The swelling boundary in 
which the rate of water uptake is the major factor affecting polymer swelling and drug 
dissolution, the diffusion boundary , in which the rate of drug release depends on diffusion 
from the swollen polymer, and the erosion boundary in which the rate of matrix erosion is 
the release controlling step(222). 
 
         Figure 6.9: Different fronts of a swellable matrix tablet(222) 
 
6.4.2.6.1.1. Drug release from wet-granulation formulas: 
 
 W6: as shown in (Figure 6.10), the release from this formula was almost fast and 
couldn`t match the desired sustained release for both MTA and CLA. This could be 
justified by: (1) insufficient quantity of the high molecular weight HPMC-K100M that 
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forms the gel barrier that controls the drug release by gradual diffusion, (2) or insufficient 
EC quantity incorporated within the matrix; leading to rapid entry of dissolution media to 
the matrix, as a result weak swollen framework formed, with erosion rate faster than 
swelling, as a result the release from the eroded polymer instead of gradual diffusion 
through the swollen polymer controlled the release rate, leading to faster drug release. 
 (Retardation for both MTZ and CLA is required). 
 W8: As shown in (Figure 6.11), the enhancement has been made to the formula again 
didn`t match the desired release. As increasing the quantity of the hydrophobic polymer in 
the matrix, prevented enough quantity of the dissolution media to contact with the MTZ 
inside the granules, and MTZ has to cross two barriers, the hydrophilic gel layer of the 
granules and the hydrophobic layer of the matrix, hence its released has been decreased 
more than desired. 
On the other hand, the parallel increase in the quantity of the gas generating agents  
(NaHCO3 and citric acid) within the matrix increased the neutralization reaction between 
them, and lead to increase in the matrix porosity and pore diameter(223), and so more 
media was in contact with CLA and thus its release was greater than MTZ.   
 (Accelerating for MTZ release is required). 
 W13: As shown in (Figure 6.12), incorporation of the low molecular weight polymer 
HPMC-K4M within the granules has been done, to enhance the release of MTZ. In 
parallel, a small decreasing has been done to the amounts of the gas generating reactants to 
slightly decrease the gas generation, and decrease the porosity formed inside the matrix, 
thus slightly decreasing the entry of dissolution media that would be in contact with CLA; 
and hence we could obtain a sustained-synchronous release of both MTZ and CLA. 
We have noticed that minor enhancement for MTZ release was obtained, and minor 
decrease to CLA release was achieved. 
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(Further enhancement for MTZ release is still required). 
 
Table 6.13: Percentages cumulative release of MTZ and CLA from wet-granulation 
formulations. 
 
Time (h) 
% cumulative drug release 
W6 W8 W13 
%MTZ %CLA %MTZ %CLA %MTZ %CLA 
0.5 40 35 11 13 ----- ---- 
1 51 49 16 32 24 30 
2 73 68 20 46 28 45 
3 80 75 23 55 33 50 
4 ----- ----- 27 61 36 53 
5 ----- ----- 30 65 39 61 
             
 
 
                   Figure 6.10: Dissolution profile of formula W6. 
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                    Figure 6.11: Dissolution profile of formula W8.        
 
 
 
 
            
 
                   Figure 6.12: Dissolution profile of W13. 
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6.4.2.6.1.2.  Drug release from direct compression formula 
 
In our work, many formulas have been manufactured using direct compression technique, 
nearly all of them failed in the in-vitro floating tests and the integrity of matrix, except D7 
which show good floating properties with acceptable matrix integrity.so further in-vitro 
drug release was done to this formula (D7), but the results were bad, as rapid drug release 
of both CLA and MTZ was achieved within the first hour! This could be justified by the 
absence of PVP within the matrix, as it act as a strong binder between matrix components 
and hence decrease the release. 
 On the other hand the release of MTZ was greater than the release of CLA; this could be 
justified by the higher solubility of MTZ, and its incorporation without granulation in the 
matrix together with CLA, so its dissolution upon contact with the dissolution media was 
faster than that of the less soluble CLA, as seen in (Figure 6.13 and Table 6.14). 
We concluded from these trials that the direct compression technique was not suitable for 
designing a single synchronous- SR system for two drugs with different solubility. 
 
                Table 6.14: Percentage accumulative release of   MTZ and CLA from  
                                   Direct compression formula D7.  
 
Time (min) 
% cumulative drug release from D7 
% MTZ %CLA 
15 40 35 
30 65 51 
60 95 64 
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                           Figure: 6.13: Dissolution profile of formula D7. 
 
6.4.2.6.1.3. Drug release from dry-granulation formulas: 
 
The drug release from the three formulas DG1, DG2 and DG3 was almost synchronous for 
both MTZ and CLA; this goal was one of the most difficult goals to be met with such 
difference in the solubility of the drugs. Results are shown in (Table 6.15) and (Figures 
6.14, 6.15 and 6.16). 
Regarding the drug release rate, it was very slow for formula DG1, after the burst effect  
during the first 0.5 h, the rate was nearly 1-2% / h . 
Comparing the % of drug released between DG2 and DG3, it could be noted that DG2 has 
slightly better release rate, so it would be our best selected formula, hence it met all the 
specific objectives in this research. 
The rate of dissolution from formula DG2, exactly matched that of the desired SR systems. 
At the beginning the % released of both drugs have slightly some burst effect due to rapid 
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of time and due to the gradual water uptake and swelling of the hydrophilic polymers, a gel 
layer (boundary) was formed through which the released was mainly controlled by 
diffusion.  Till the end of testing period, there was a balance between surface polymers 
erosion and the swelling of the internal polymers leading to regular and gradual drug 
release rate. 
These results of drug release mechanism from the matrix could be exactly explained by the 
swelling test performed (section 6.4.2.8.), the largest swelling % occurred during the first 
0.5 h, the same thing occurred when talking about the drug release. 
Thereafter, gradual and nearly regular swelling continued till the end of dissolution test, 
this was very correspondent with the results of drug release. 
So, we concluded that the release rate in this system was mainly controlled by the diffusion 
through the swellable polymer.  
This mechanism of drug release was further explained by applying the kinetic models to 
release data obtained (Section 6.5). 
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 Table 6.15: Percentage cumulative release of   MTZ and CLA from dry-granulation 
formulations. 
 
Time (h) 
% cumulative drug release 
DG 1 DG 2 DG 3 
%MTZ %CLA %MTZ %CLA %MTZ %CLA 
0.5 35 38 29 28 27 23 
1 41 45 33 33 30 29 
2 44 47 38 34 35 32 
3 48 49 ---- ----- ----- ------ 
4 51 51 44 38 41 35 
5 54 53 ----- ----- ----- ------ 
6 ------ ------ 47 41 46 38 
8 ------- ------- 55 47 51 43 
10 ------- ------- 60 52 48 47 
20 ------ ------- 85 76 80 69 
 
 
 
               Figure 6.14: Dissolution profile of formula DG1. 
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              Figure 6.15: Dissolution profile of formula DG2. 
 
            Figure 6.16: Dissolution profile of formula DG3. 
 Dissolution of esomeprazole pellets: 6.4.2.6.2.
After proceeding as directed by the USP method for dissolution of esomeprazole, the % of 
drug released from the pellets, taking the overage of (RU) for 6 tablets was as follow: 
% Released= (R U / R S) × (CS /L) × V × 100% 
               = (177952/186644) X (0.02/20) X 1000X100% 
                =95.34% 
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The result is acceptable according to the criteria given by the USP-36 for this test.  
This result has proved that the compression of EZO enteric coated pellets into tablet using 
Avicel as pressure absorping matrix, has preserved the coat from destruction and thus 
protect EZO from acid-degradation. 
 Swelling test (water uptake): 6.4.2.7.
The test was performed for the SR-layer as directed under section 5.4.3.8, and the results 
were shown in (Table 6.16) and (Figure 6.17 and 6.18 )  
Table 6.16: Swelling index (water uptake) results of formula DG2 
 Tablet 
1 2 3 
Initial Wt (Wo) 1.3 1.3 1.3 
Wt after 0.5 h 1.8 1.8 1.82 
Average Wt 1.806 
Swelling index 38.9 % 
Wt after 1 h 1.92 1.82 1.85 
Average Wt 1.863 
Swelling index 43.3% 
Wt after 2 h 1.863 1.95 1.93 
Average Wt 1.913 
Swelling index 47.2% 
Wt after 4 h 2.04 1.97 2.00 
Average Wt 2.003 
Swelling index 54.1% 
Wt after 6 h 2.05 2.3 2.21 
Average Wt 2.12 
Swelling index 63.076% 
Wt after 8 h 2.17 2.21 2.02 
Average Wt 2.133 
Swelling index 64.1% 
Wt after 24 h 2.25 2.25 2.25 
Average Wt 2.25 
Swelling index 73.1% 
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Figure 6.17: Tablet of DG2 formula, before and after swelling test. 
 
Figure 6.18: % Swelling index of formula DG2. 
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release kinetic models, including the Zero order, First order, Higuchi, Korsmeyer-Peppas 
and Hixson-Crowe using DDSOLVER program.  
The selection criterion for the best-fit model was based on the adjusted coefficient of 
determination, R2 adjusted. The R2 adjusted value was used to compare the results of 
fitting data to kinetic models with different numbers of parameters. The results of fitting 
the dissolution data to selected mathematical models are summarized in Table 6.17, and 
shown in Figure 6.19 and Figure 6.20. 
By applying different kinetic models to the release data obtained from the best formula 
(DG2) of both MTZ and CLA, we concluded that the best fit model that could describe the 
release of both of MTZ and CLA was Korsmeyer-Peppas, depending on the values of R
2 
and R
2
- adj. This model used to describe the drug release from different modified release 
dosage forms, and usually the release is controlled by diffusion using swellable polymer 
like HPMC, and to exactly describe the mechanism of release from the system, we depend 
on (n) value as mentioned in part one, Section 1.6. 
Table 6.17: Results of kinetic models parameters obtained following fitting dissolution 
data of MTZ and CLA. 
Kinetic model.                       MTZ                        CLA 
R
2
 R
2
- adj. (n) R
2
 R
2
- adj. (n) 
Zero-order 
0.5984 0.5984 
----- 
0.8751 0.8751 
----- 
First-order 
0.3288 0.3288 
------ 
0.0177 0.0177 
----- 
Higuchi 
0.7626 0.7626 
------ 
0.6282 0.6282 
----- 
Korsmeyer -Peppas 
0.9363 0.9363 
0.325 
0.8696 0.8696 
0.301 
Hixson-Crowell 
0.1819 0.1819 
------- 
0.1930 0.1930 
------ 
 
For our system (n) value was less than 0.5, this may be caused by the burst effect occurred 
during the first 0.5 h. A modification for Korsmeyer –Peppas model was prescribed by  
Kim and Fassihi (170) and by Xiao Huang and Christopher S Brazel (224), when burst 
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effect release is present, for better explanation of the release this modification was applied 
to our system, and the results were summarized in Table 6.18 and Table 6.19, and shown 
in Figure 6.19 and Figure 6.20      According to this modification, the release at each time 
will be modified according to the following equation: 
  
  
        
 Mt & M∞: are the absolute cumulative amounts of drug released at time t and infinity. 
K: is a constant incorporating structural and geometrical characteristics of the device, the k 
value is experimentally determined. 
  n: is the exponent, indicative of the mechanism of drug release. 
b:  the amount of drug released by burst effect.             
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Table 6.18: drug release from formula DG2 after modification according  
                                      to Krosmeyer-Peppas model 
 
Time (h) 
% cumulative drug release    (DG2) 
Actual  Modified   
%MTZ %CLA %MTZ %CLA 
0.5 29 28 0 0 
1 33 33 5.6 6.9 
2 38 34 12.7 8.3 
3 ---- ----- ------ ------ 
4 44 38 21.1 13.9 
5 ----- ----- ------ ------ 
6 47 41 25.4 18.1 
8 55 47 36.6 26.4 
10 60 52 43.7 33.3 
20 85 76 78.9 66.7 
 
 
Table 6.19: Kinetic parameters after modification of release according to Krosmeyer-
Peppas model: 
Kinetic parameter MTZ CLA 
R
2
adj 0.9939 0.9918 
kKp 5.929 3.405 
N 0.864 0.991 
 
 The (n) value for MTZ from Krosmeyer-Peppas kinetic model after modification 
was (0.86), and since our system had a cylindrical geometry, this value explained that the 
mechanism of drug release for MTZ followed Anomalous transport (non-Fickian release), 
which is in between  Case-I (Fickian diffusion) and Case-II transport behaviors. In Case-I 
transport (diffusion-controlled), the time-scale of drug diffusion, is the rate-limiting 
step,while in Case-II transport (swelling-controlled), the time-scale for polymer relaxation 
is the ratelimiting step (225), (226). So, in case of  Non-Fickian behavior (Anomalous 
transport) as MTZ behavior in our system, the release is controlled by both, the diffusion of 
the drug from the swollen region and the relaxation of the polymers in the matrix. This 
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diversity of release mechanisms is consistent with the fact that MTZ was incorporated in 
the formulation in two forms; the free form within the matrix and the granulated form.  
These types of release were briefly described by Chien-Chi Lin and Andrew T. 
Metters(227). 
  The (n) value for CLAwhich is very close to 1  indicated that the release followed 
a zero order release. This type of release usually fits the releaseof  low soluble drugs in 
coated forms and osmotic systems. But in swollen-hydrophilic matrices it was explained 
that the mechanism of release is controlled by diffusion coupled with erosion. This was 
occurred because the rates of swelling front into the glassy polymer (core) and the erosion 
of the rubbery state polymer (gel at tablet periphery) were nearly equal, so that the release 
rate for the drug remains nearly constant. 
This phenomena was described by S.K. Baveja, K.V. Ranga Rao and K. Padmalatha Devi 
(228).  
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- Zero order.                                                        – First line order. 
 
      
              -  Higuchi model.                                           -   Hixson-Crowell model. 
 
           
 
-Krosmeyer-Peppas (before modifying).                    –Krosmeyer –Peppas (after modifying) 
 
               Figure 6.19:  kinetic models of MTZ from DG2 formula. 
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- Zero-order kinetic                                           -  First-order kinetic 
        
 
- Higuchi model.                                                - Hixson-Crowell model. 
 
     
 
-Krosmeyer-Peppas (before modifying).                    -Krosmeyer –Peppas (after modifying) 
 
               Figure 6.20: kinetic models of CLA from DG2 formula. 
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Part Seven: 
7. Conclusion and Future work. 
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7.1. Conclusion. 
We have shown in this study that we have been able to formulate a tablet that would 
combine a triple therapy for the treatment of H. pylori induced ulcer. This tablet had two 
layers. The first layer is a fast disintegrating layer that will provide the enteric  coated 
pellets of EZO upon contact with water. We proved that this layer will rapidly deattach and 
will preserve the enteric coating after compression applied. The second layer containing 
both MTZ and CLA, proved to exhibit excellent floating properties, having short floating 
lag time and long duration of floating (up to 24 h). The tablet exhibited a synchronous 
sustained release of both antibiotics which is advantageous in providing a continuous input 
of the two antibiotics in the vicinity of the bacteria. This is important since a local 
treatment of the bacteria is much more benefitial than the systemic one. The analysis of the 
release kinetics and swelling studies showed that the mechanism of the release was mainly 
controlled by diffusion coupled with erosion.  Moreover, a validated system was developed 
in this study to analyze both MTZ and CLA in the same run of the HPLC. 
So in conclusion, this tablet may potentially a better treatment for H. pylori  induced ulcer. 
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7.2. Future work: 
 
Despite the objectives that have been achieved from this research, further work have to be 
done, this may include: 
 Put the product on stability study program, those include accelerated (40 °C ± 2 °C / 
75% RH ± 5% RH) and long term conditions (30 °C ± 2 °C / 65% RH ± 5% RH or). 
 Change the shape of the tablet to oblonged- biconvex to be more convenient for 
administration and easily swallowed. 
 Coating the tablet with poly vinyl alcohol (PVA) coat, to protect from humidity, and to 
easily swallow such large tablet. 
 Perform in-vivo studies which include: 
 Radiography (X-ray), on healthy volunteers, to evaluate the floating properties. 
 Histological examination for suitable animal model inoculated and infected with H 
.pylori, to assess the actual (in-vivo) efficacy of this dosage form in the clearance 
and eradication of the microorganism. 
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Part Eight 
8. Appendices 
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8.1. Inactive ingredients monographs. 
 
8.1.1. Hydroxypropyl methyl cellulose (HPMC, Hypromellose): 
 
 Description: 
HPMC is an odorless and tasteless, white or creamy-white fibrous or granular powder. 
 
 Chemical Name and CAS Registry Number: 
 Cellulose hydroxypropyl methyl ether, {9004-65-3} 
  
 Empirical Formula: 
HPMC is partly O-methylated and O-(2-hydroxypropylated) cellulose. It is available in 
several grades that vary in viscosity and extent of substitution. Grades may be 
distinguished by appending a number indicative of the apparent viscosity, in mPa s, of a 
2% w/w aqueous solution at 20ºC. 
 
 Structural formula: 
 
 
 Applications in Pharmaceutical Formulation or Technology: 
Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. 
In oral-solid dosage forms, hypromellose is primarily used as a tablet binder, in film-
coating and as a matrix for use in sustained release tablet formulations. 
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Concentrations between (2 -5) % w/w may be used as a binder in either wet- or dry-
granulation processes. High-viscosity grades may be used to retard the release of drugs 
from a matrix at levels of (10–80) % w/w in tablets and capsules. Depending upon the 
viscosity grade (usually low viscosity grades are used), concentrations of (2–20) % 
w/w are used for film-forming solutions. 
 
Incompatibilities: 
Hypromellose is incompatible with some oxidizing agents.  
 
Safety: 
Hypromellose is generally regarded as a nontoxic and nonirritating material, although 
excessive oral consumption may have laxative effect. The WHO has not specified an 
acceptable daily intake for hypromellose since the levels consumed were not 
considered to represent a hazard to health. 
 
8.1.2. Ethyl cellulose (EC). 
 
 Description: 
Ethyl cellulose is a tasteless, free-flowing, and white to light tan-colored powder. 
 
 Chemical Name and CAS Registry Number : 
Cellulose ethyl ether,{9004-57-3}. 
 
 Empirical Formula: 
Ethyl cellulose is partially ethoxylated. Ethyl cellulose with complete ethoxyl 
substitution 
(DS = 3) is: C12H23O6 (C12H22O5)n C12H23O5 where n can vary to provide a wide 
variety of molecular weights.  
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 Structural formula: 
 
 
 Applications in Pharmaceutical Formulation or Technology. 
 
The main use of ethyl cellulose in oral formulations is as a hydrophobic coating agent for 
tablets and granules. Ethyl cellulose coatings are used to modify the release of a drug, to 
mask an unpleasant taste, or to improve the stability of a formulation. Modified-release 
tablet formulations may also be produced using ethyl cellulose as a matrix former. In tablet 
formulations, ethyl cellulose may additionally be employed as a binder. 
 
 Incompatibilities: 
Incompatible with paraffin wax and microcrystalline wax. 
 
 Safety: 
Ethyl cellulose is not metabolized following oral consumption and is therefore a 
non-calorific substance. Because ethyl cellulose is not metabolized it is not recommended 
for parenteral products; parenteral use may be harmful to the kidneys. Ethyl cellulose is 
generally regarded as a nontoxic, non-allergenic, and non-irritating material. As ethyl 
cellulose is not considered to be a health hazard, the WHO has not specified an acceptable 
daily intake. The highest reported level used in an oral product is 308.8 mg in an oral SR 
tablet. 
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8.1.3. Sodium bicarbonate. 
 
 Description: 
 
Sodium bicarbonate occurs as an odorless, white, crystalline powder with a saline, slightly 
alkaline taste. Grades with different particle sizes, from a fine powder to free-flowing 
uniform granules, are commercially available. 
 
 Chemical Name and CAS Registry Number: 
 
Carbonic acid monosodium salt {144-55-8}. 
 
 
 Empirical Formula and Molecular Weight: 
NaHCO3 is 84.01 g / mole. 
 
 Applications in Pharmaceutical Formulation or Technology: 
Sodium bicarbonate is generally used in pharmaceutical formulations as a source of carbon 
dioxide (e.g. in effervescent tablets). It is also widely used to produce or maintain an 
alkaline pH in a preparation. In effervescent tablets and granules, sodium bicarbonate is 
usually formulated with citric and/or tartaric acid. Tablets may also be prepared with 
sodium bicarbonate alone since the acid of gastric fluid is sufficient to cause effervescence.  
Recently, sodium bicarbonate has been used as a gas-forming agent in alginate raft systems 
and in floating, controlled release oral dosage forms.  
 Incompatibility: 
In powder mixtures, atmospheric moisture or water content from another ingredient is 
sufficient for sodium bicarbonate to react with some acids. In liquid mixtures containing 
bismuth subnitrate, sodium bicarbonate reacts with the acid formed by hydrolysis of the 
bismuth salt. In solution, sodium bicarbonate has been reported to be incompatible with 
many drug substances such as ciprofloxacin, amiodarone, nicardipine and levofloxacin. 
 
 Safety: 
Sodium bicarbonate is metabolized to the sodium cation, which is eliminated from the 
body by renal excretion, and the bicarbonate anion, which becomes part of the body‘s 
bicarbonate store. Any carbon dioxide formed is eliminated via the lungs. 
Administration of excessive amounts of sodium bicarbonate may thus disturb the 
body‘s electrolyte balance, leading to metabolic alkalosis. Orally ingested sodium 
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bicarbonate neutralizes gastric acid with the evolution of carbon dioxide and may cause 
stomach cramps and flatulence. 
Sodium bicarbonate is generally regarded as an essentially nontoxic and nonirritant 
material. 
LD50 (mouse, oral): 3.36 g/kg. 
LD50 (rat, oral): 4.22 g/kg. 
 
8.1.4. Citric acid anhydrous: 
 
 Description: 
 
It is white, crystalline powder, colorless crystals or granules, very soluble in water, freely 
soluble in alcohol. It melts at about 153 °C with decomposition. 
 
 Chemical Name and CAS Registry Number: 
 
  2-hydroxypropane-1,2,3-tricarboxylic acid, { 77-92-9} 
 
 Empirical formula and molecular weight: 
 
 C6H8O7,  (192.1 g/mole). 
 
 Chemical structure: 
                                       
 Applications in Pharmaceutical Formulation or Technology: 
Citric acid is widely used in pharmaceutical formulations and food products, primarily to 
adjust the pH of solutions. It has also been used experimentally to adjust the pH of tablet 
matrices in enteric-coated formulations for colon-specific drug delivery. Citric acid 
anhydrous citric acid is widely used in the preparation of effervescent tablets.  
  
 Incompatibilities 
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Citric acid is incompatible with potassium tartrate, alkaline earth carbonates and 
bicarbonates, acetates, and sulfides. Incompatibilities also include oxidizing agents, bases, 
reducing agents, and nitrates. It is potentially explosive in combination with metal nitrates.  
 
 Safety: 
Citric acid is found naturally in the body, mainly in the bones, and is commonly consumed 
as part of a normal diet. Orally ingested citric acid is absorbed and is generally regarded as 
a nontoxic material when used as an excipient. However, excessive or frequent 
consumption of citric acid has been associated with erosion of the teeth. Citric acid and 
citrates also enhance intestinal aluminum absorption in renal patients, which may lead to 
increased, harmful serum aluminum levels. 
 
8.1.5. Microcrystalline cellulose (Avicel-PH102) 
 Description: 
It is white or almost white, fine or granular powder. 
Typical mean particle size is 20–200 mm. Different grades may have a different nominal 
mean particle size and consequently different surface aera. 
 
 Chemical Name and CAS Registry Number: 
 
Cellulose,  {9004-34-6} 
 
 Empirical Formula and Molecular Weight: 
(C6H10O5)n (36 000 g/mole  where n 220). 
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 Chemical structure: 
 
                              
 
 Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent 
in oral tablet and capsule formulations where it is used in both wet-granulation and direct-
compression processes. In addition to its use as a binder/diluent, microcrystalline cellulose 
also has some lubricant and disintegrant properties that make it useful in tableting 
 Incompatibility: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
 Safety: 
Avicel is widely used in oral pharmaceutical formulations and food products and is 
generally regarded as a relatively nontoxic and nonirritant material. Avicel is not absorbed 
systemically following oral administration and thus has little toxic potential. Consumption 
of large quantities of cellulose may have a laxative effect, although this is unlikely to be a 
problem when cellulose is used as an excipient in pharmaceutical formulations. 
 
8.1.6.   Polyvinylpyrrolidone (PVP). 
 Description: 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder 
 
 Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer, (9003-39-8) 
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 Empirical Formula and Molecular Weight: 
(C6H9NO)n , (2500–3 000 000) 
PVP-K30 has M.Wt of 50000 g/mole. 
 Chemical structure: 
                                      
 
 Applications in Pharmaceutical Formulation or Technology: 
Povidone is primarily used in solid-dosage forms. In tableting, povidone solutions are used 
as binders in wet-granulation processes. Povidone is also added to powder blends in the dry 
form and granulated in situ by the addition of water, alcohol, or hydro-alcoholic solutions. 
Povidone solutions may also be used as coating agents or as binders when coating active 
pharmaceutical ingredients on a support such as sugar beads. 
 Incompatibility: 
Povidone is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. It forms molecular adducts in solution with 
sulfathiazole, sodium salicylate, salicylic acid, phenobarbital and tannin. The efficacy of 
some preservatives, e.g. thimerosal, may be adversely affected by the formation of 
complexes with povidone. 
 Safety: 
Povidone is widely used as an excipient, particularly in oral tablets and solutions. When 
consumed orally, povidone may be regarded as essentially nontoxic since it is not absorbed 
from the gastrointestinal tract or mucous membranes. Povidone additionally has no irritant 
effect on the skin and causes no sensitization. 
An acceptable daily intake for povidone has been set by the WHO at up to 25 mg/kg body-
weight. 
LD50 (mouse, IP): 12 g/kg. 
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8.1.7. Magnesium stearate: 
 
 Description: 
It is white, very fine, light powder, greasy to the touch, practically insoluble in 
water and in ethanol. 
 
 Chemical Name and CAS Registry Number: 
Octadecanoic acid- magnesium salt,  (557-04-0). 
 
 Empirical Formula and Molecular Weight: 
C36H70MgO4,  (591.24 g / mole). 
 
 Structural formula: 
(CH3 (CH2)16COO)2 Mg. 
 
 Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is primarily used as a lubricant in capsule and tablet manufacture 
at concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
 
 Incompatibility: 
It is incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, 
some vitamins, and most alkaloidal salts. 
 
 Safety: 
Magnesium stearate is generally regarded as being nontoxic following oral 
administration. However, oral consumption of large quantities may produce a laxative 
effect or mucosal irritation. Toxicity assessments of magnesium stearate in rats have 
indicated that it is not irritating to the skin, and is nontoxic when administered orally or 
inhaled. Magnesium stearate has not been shown to be carcinogenic when implanted 
into the bladder of mice. 
LD50 (rat, inhalation) : >2 mg/L 
LD50 (rat, oral) : >10 g/kg. 
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8.2. Certificates of analysis (C.O.A) for the active and inactive materials 
8.2.1. C.O.A. of Clarithromycin 
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8.2.2. C.O.A. of Metronidazole. 
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8.2.3. C.O.A. of Esomeprazole 
 
 
 
 
 
  
172 
8.2.4. C.O.A of HPMC-K4M 
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8.2.5. C.O.A of HPMC-K15M 
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8.2.6. C.O.A of HPMC-K100M 
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8.2.7. C.O.A. of Ethyl cellulose 
 
 
  
  
176 
8.2.8. C.O.A. of Sodium Bicarbonate 
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8.2.9. C.O.A. of Citric acid 
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8.2.10. C.O.A. of Lactose 
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8.2.11. C.O.A. of PVP-K30 
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8.2.12.  C.O.A. of Avicel PH-102 
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8.2.13. C.O.A. of Silicone dioxide 
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8.2.14. C.O.A. of magnesium stearate: 
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صُذلانٍ جذَذ َحتىٌ علً الاَسومُبرازول والكلارَثروماَسُن  مخبرٌ لمستحضر تطىَر وتقُُم
ي تبقً طافُت والمُترونُذازول معا فٍ حبت واحذة مكىنت من طبقتُن، احذاهما سرَعت التفكك والأخر
  .، لعلاج القرحت الهضمُت الناتجت عن البكتُرَا الملىَت البىابُت فٍ المعذة لفترة طىَلت
 
 عبدالقادرمحمد  : سائدة إعذاد
 : د. طارق الجعبتالمشرف
 الملخص
تعد الاصابة بالبكتيريا البوابية واحدة من أكثر الأمراض المعدية انتشارا والتي تصيب حوالي نصف 
الم.و يبقى القضاء عمى ىذه البكتيريا ىاما في علاج الامراض المصاحبة ليا مثل القرحة سكان الع
 .سرطان المعدة اليضمية، والمضاعفات طويمة المدى مثل
ىو العلاج الثلاثي المكون من  المبكتيريا ومرض القرحة اليضمية المصاحبة لي الصف العلاجي الأول
(مثل  ايسين، ميترونيدازول)  ومثبط لممضخة البروتونيةاثنين من المضادات الحيوية(كلاريثروم
وذلك لقصر ممكن ان يفشل،  لتقميديةعلاج القرحة اليضمية بالأشكال الصيدلانية ا.  ايزوميبرازول)
الوقت الذي يبقى فيو الدواء في المعدة ( المكان الرئيسي لاستعمار البكتيريا) بسبب التفريغ المعدي 
م مساوىء ىذه العلاجات التقميدية ىو الحاجة لجرعات متعددة منيا يوميا، . وواحدة من أىالمستمر
 ممايزيد من عدم انتظام المريض عمى أخذ العلاج و ازدياد احتمالية حدوث الأعراض الجانبية.
من طرق تحسين علاج القرحة اليضمية ىو وجود علاجات بديمة ليا القدرة عمى البقاء لفترات طويمة 
ل دائم وبتركيز عالي في في المعدة بحيث تعمل عمى تحرير الدواء بشكل متاني يضمن بقاءه بشك
بالتالي ، مما يؤدي لتحسين فعالية العلاج وتقميل عدد الجرعات اليومية و البكتيريا مكان استعمار
تحسين انتظام المريض عمى العلاج وتقميل الأعراض الجانبية. المستحضرات الصيدلانية طويمة 
  
 691
الوجود في المعدة لعلاج البكتيريا البوابية لاقت اىتماما كبيرا من قبل  الباحثين حول العالم وذلك 
 لقدرتيا عمى توفير االمزايا المذكورة ّانفا.
يدلاني جديد يحتوي عمى أدوية الصف العلاجي الأول في ىذا البحث تم تطوير شكل ص
(كلاريثرومايسين و ميترونيدازول و ايزوميبرازول) لعلاج القرحة اليضمية. اعتمد تصميم المستحضر 
عمى ان يكون حبة واحدة مكونة من طبقتين، ليا القدرة عمى الانتفاخ والطفو وتحرير الدواء بشكل 
عة التفكك وتحتوي عل حبيبات الايزوميبرازول، والطبقة الثانية واحدة من الطبقات ىي سريمتأني. 
تحتوي عمى المضادات البكتيرية ( الكلاريثرومايسين والميترونيدازول) بحيث تبقى طافية في المعدة 
 وتحرر الأدوية بشكل متأني.
لزوجة اعتمد تشكيل الحبوب عمى استخدام بوليمرات الييدروكسي بروبيل ميثل السميولوز بدرجات 
مختمفة واستخدام بوليمر الايثيل سيميولوز كمواد غير فعالة مسؤولة عن  انتفاخ الحبات ومنظمة 
كمواد مسؤولة عن لتحرير الدواء. كما تم استخدام مادتي بايكربونات الصوديوم وحمض السيتريك 
الضغط المباشر  تكوين غاز ثاني أوكسيد الكربون داخل الحبة. تم استخدام تقنيات تصنيع مختمفة وىي
 لمحبوب والتحبيب الرطب والتحبيب الجاف ، لاختيار الأفضل منو.
خصائص الطفو لمحبات بحيث تم اختيار الحبات فحوصات  اعتمد اختيار افضل تركيبة أولا عمى 
خصائص  فحوصات التي استغرقت أقل وقت لتطفو واستمرت بالطفو لأطول فترة ممكنة، ثانيا عمى
الحبة بحيث تم اختيار الحبات التي تعمل عمى تحرير كلا المضادات الحيوية تحرير الدواء من 
 المستخدمة بشكل متأني ومتزامن.
 تم تحبيب مادة الميترونيدازول . حيثفي التركيبة الأمثل تم استخدام طريقة التصنيع بالتحبيب الجاف
تحبيب مع باقي مكونات الطبقة. في الطبقة متأنية التحرير بينما تم دمج مارة الكلاريثرومايسين دون 
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وفي الطبقة سريعة التفكك تم دمج حبيبات الايزوميبرازول مع باقي المكونات بحيث تنفصل عن الطبقة 
وقد تم فحص الخصائص الفيزيائية والكيميائية  متأنية التحرير بوقت قصير لا يتجاوز الدقيقتين.
وجدت  ، وقداين في الوزن والفحص الكمي الصلابة والتفتيت و التبتشمل فحوصات لمحبوب والتي 
كما تم فحص خصائص الخميط قبل كبسو الى   ،جميعيا مطابقة لمتطمبات دساتير الادوية العالمية
 حبوب
كم تم فحص قدرة الحبة عمى الانتفاخ و تقييم آلية تحرر المواد الفعالة باستخدام نماذج رياضية عدة ، 
 -س مايرر كو نموذج مع  لميترونيدازول والكلاريثرومايسين) يتناسبالمواد الفعالة (اوقد وجد أن تحرر 
ليذا الموذج يتضح ان التحرر كان مختمطا عن طريق الانتشار من  )n(بيباس ، واعتمادا عمى قيمة 
 خلال طبقة الجل المنتفخة وعن طريق تآكل البوليمر عمى سطح الحبة. 
لكلا  في نفس العينة  بشكل متزامن رونيدازولتم احتساب كميات مادتي الكلاريثرومايسين والميت
، وذلك باستخدام طريقة لاجراء الفحوصات من الحبة الفحصين، الفحص الكمي وفحص تحرر الدواء
والتي اعتمدت عمى استخدام جياز الاستشراب  تم تطويرىا والتثبت من صحتيا ودقتيا في ىذا البحث
 .CLPH(السائل عالي الانجاز (
% من 32ل التي تم تصنيعيا باستخدام طريقة التحبيب الجاف احتوت عمى مانسبتو تركيبة الأمثال
% من بوليمر الايثيل 71) و M001-Kبوليمر الييدروكسي بروبيل ميثيل سيميولوز عالي المزوجة (
% من حمض السيتريك في الطبقة المتانية التحرير. في 3% بايكربونات الصوديوم و 21سيميولوز و 
   ثانية 22ة استغرق انفصال الطبقتين سريعة التفكك و متأنية التحرير وقتا لم يتجاوىذه التركيب
 42ثانية، فيما استمرت الحبة بالطفو لمدة تجاوزت  23واستغرق وقت حدوث الطفو وقتا لم يتجاوز 
ل % لمادة المترونيدازو 58ساعة. وبمغت كمية الدواء التي تم تحريرىا من الطبقة المتانية التحرير 
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ىذه النتائج حققت الاىداف من ىذه الدراسة بتصنيع شكل صيدلاني   % لمادة الكلاريثرومايسين.67و
جديد لو القدرة عمى البقاء لوقت طويل في المعدة مع تحرير الدواء بشكل متاني، آممين ان يؤدي ذلك 
 بوابية.لتحسين الفعالية الموضعية ليذه المضادات الحيوية في القضاء عمى البكتيريا ال
   
  
 
 
